Identification of novel atherosclerosis modifiers in mice by Nicolaou, Alexandros
Aus dem Institut für Laboratoriumsmedizin der
Ludwig-Maximilians-Universität München
Direktor: Univ.-Prof. Dr. med. Daniel Teupser
Identification of novel 
atherosclerosis modifiers in mice
Dissertation
zum Erwerb des Doktorgrades der Naturwissenschaften
an der Medizinischen Fakultät
der Ludwig-Maximilians-Universität München
vorgelegt von
Alexandros Nicolaou
aus 
Paphos (Zypern)
2018
Mit Genehmigung der Medizinischen Fakultät 
der Ludwig-Maximilians-Universität München 
Betreuerin: Prof. Dr. med. Dr. rer. nat. Lesca Holdt
Zweitgutachter: Prof. Dr. rer. nat. Jürgen Bernhagen
Dekan: Prof. Dr. med. dent. Reinhard Hickel
Tag der mündlichen Prüfung: 05.09.2019
Meinen Eltern
  1 / 154
 Abstract
Atherosclerosis is a chronic inflammatory condition of the large and medium-sized vasculature. 
It is a complex, progressive disease determined by genetic as well as environmental factors. 
This PhD thesis aims to make a contribution in identifying new determinants of atherosclerosis 
by investigating two recently reported, yet still uncharacterized atherosclerosis susceptibility 
loci on mouse chromosomes 3 and 12, which were identified in an intercross of atherosclerosis- 
susceptible C57BL/6 (B6) and atherosclerosis-resistant FVB mice on the LDL-receptor deficient 
background (Ldlr -/-). 
We genetically dissected the locus on chromosome 3 by quantitative trait locus (QTL) fine-mapping 
and, subsequently, by creating congenic mice that carried the B6 risk genetic interval in 
an otherwise FVB background. To identify candidate effector genes at the locus, we performed 
differential expression analysis in congenics using mRNA microarrays, and expression QTL 
(eQTL) mapping in 227 F2 mice as complementing strategy. We revealed two overlapping, yet in-
dependent subloci for atherosclerosis susceptibility, one associated with increased expression 
of vascular cell adhesion molecule 1 (Vcam1), a well-known atherosclerosis modifier, and the oth-
er associating with down-regulation of the secreted phospholipase Pla2g12a in atherosclerosis- 
susceptible B6.Ldlr -/- mice. Pla2g12a was highly expressed in endothelial cells and PLA2G12A 
protein prevented binding of cultured blood monocytes to these cells. Our data indicate that 
PLA2G12A is a novel atherosclerosis modifier that protects from atherosclerosis, by reducing the 
adhesiveness of vascular cells entering atherosclerotic lesions.
In the same QTL mapping effort, the metalloprotease a disintegrin and metalloprotease 17 (Adam17) 
has emerged as candidate effector of the second atherosclerosis risk locus on chromosome 12. 
ADAM17 is well-known as protease that processes dozens of membrane-resident factors, includ-
ing signaling molecules. To study the effect of Adam17 on atherosclerosis, we crossed Adam17 
hypomorphic mutant mice into an Ldlr -/- background. We found that ADAM17 exhibited an 
atheroprotective effect in vivo, which was unexpected given its presumed pro-inflammatory 
role in other diseases. Using proteomic screening of candidate cleavage products of a range 
of established ADAM17 substrates, we found that shedding of Tumor necrosis factor receptor 2 
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(TNFR2) and of Tumor necrosis factor-α (TNFα) from the cell membrane was impaired in 
Adam17-deficient vascular cells. Impaired cleavage increased membrane-resident TNFR2 and 
TNFα, which remained, however, signaling-active. Consequently, TNFR2 pathway activation 
augmented adhesion and proliferation and impaired apoptosis of macrophages and vascular 
smooth muscle cells. Together, our data indicate that normal levels of ADAM17 are required to 
dampen TNFR2 signaling on vascular membranes in order to protect from atherosclerosis.
Finally, in a third study, we also report that ADAM17 exerted yet another role in vascular biology. 
We revealed arterial dilation and changes in elastin fibers in brachiocephalic arteries of Adam17 
mutant mice. This phenotype was reminiscent of early-phase arterial aneurysm onset. Our data 
indicate a function of ADAM17 in maintaining a proper elastin network in the extracellular matrix 
(ECM) of arteries to protect the integrity of the arterial wall.
Summarizing, we have identified and characterized one novel atherosclerosis modifier, PLA2G12A, 
and have revealed that ADAM17 had a previously unrecognized protective role in vascular disease, 
which was due to TNFR2 signaling and ECM regulation.
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Die Atherosklerose ist eine chronische, entzündliche Erkrankung der großen und mittleren Arterien, 
die sowohl durch genetische als auch durch Umweltfaktoren bestimmt wird. Die vorliegende 
Doktorarbeit beschäftigt sich mit der Identifizierung und funktionellen Charakterisierung neuer 
genetischer Determinanten der Atherosklerose an zwei Genorten der Atherosklerose auf den 
Chromosomen 3 und 12 der Maus. Diese Genorte wurden in Vorabeiten der Arbeitsgruppe 
mit Hilfe eines hypothesenfreien Ansatzes in einer F2-Kreuzung atheroskleroseempfindlicher 
C57BL/6 (B6)- und atheroskleroseresistenter FVB-Mäuse auf dem LDL-Rezeptor defizienten Hinter- 
grund (Ldlr -/-) identifiziert. Welche genetischen Varianten an diesen zwei Loci dem gesteigerten 
Atheroskleroserisiko zugrundelagen war bislang unbekannt. 
Der Chromosom 3 Genort wurde zunächst mit Hilfe von quantitative trait locus (QTL) Analysen 
feinkartiert und kongene Mäuse, die ein definiertes genomisches Intervall des B6-Risiko Lokus 
auf einem ansonsten FVB.Ldlr -/- Hintergrund trugen, hergestellt. Um Kandidaten-Effektorgene 
am Locus zu identifizieren, wurden differentielle Genexpressionsanalysen in kongenen und FVB 
Mäusen unter Verwendung von mRNA-Mikroarrays und eine Expressions-QTL (eQTL)-Kartierung 
als ergänzende Strategie in 227 F2 Mäusen der Kreuzung durchgeführt. Auf diese Weise wurden 
zwei überlappende, jedoch unabhängige Subloci für die Atheroskleroseempfindlichkeit gefunden. 
Ein Lokus war assoziiert mit einer erhöhten Expression des vaskulären Zelladhäsionsmoleküls 1 
(Vcam1), einem bekannten Atherosklerose-Modifikator. Der zweite Lokus war hingegen mit einer 
Herunterregulation der sezernierten Phospholipase Pla2g12a in atheroskleroseempfindlichen 
B6.Ldlr -/- Mäusen assoziiert. Pla2g12a war in Endothelzellen stark exprimiert und PLA2G12A Protein 
verhinderte die Bindung von kultivierten Blutmonozyten an vaskuläre Endothelzellen. Unsere 
Daten zeigen, dass PLA2G12A ein neuer Atherosklerose-Modifikator ist, der vor Atherosklerose 
schützt, indem er die Adhäsion von Gefäßzellen, die in atherosklerotische Läsionen einwandern, 
verringert.
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In der gleichen QTL-Kartierung wurde a disintegrin and metalloprotease 17 (Adam17) als Effek-
torgen des Atherosklerose Risikogenorts auf Chromosom 12 etabliert. ADAM17 ist eine Metallo-
protease, die dutzende membranständige Faktoren, einschließlich Signalmoleküle, spaltet und 
somit freisetzt. Um den Effekt von Adam17 auf die Atherosklerose zu untersuchen, kreuzten wir 
Adam17 hypomorphe Mäuse auf den Ldlr -/- Hintergrund, und konnten zeigen, dass ADAM17 in vivo 
eine atheroprotektive Wirkung besitzt. Dies war unerwartet, da ADAM17 bislang hauptsächlich 
mit der Freisetzung von inflammatorischen Molekülen in Verbindung gebracht worden ist. Durch 
proteomisches Screening etablierter ADAM17-Substrate konnten wir zeigen, dass die Freisetzung 
von Tumor necrosis factor receptor 2 (TNFR2) und Tumor necrosis factor-α (TNFα) von Adam17-
defizienten Gefäßzellen beeinträchtigt war und konsekutiv die Mengen von membranständi-
gem TNFR2 und TNFα erhöht waren. Da TNFR2 und TNFα an der Membran weiterhin aktiv als 
Signaltransduktionsmoleküle blieben, kam es zur Überaktivierung des TNFR2-Signalwegs in 
Adam17-defizienten Zellen, was schlussendlich zu einer gesteigerten Adhäsion und Proliferation 
führte und die Apoptose von Makrophagen und vaskulären glatten Muskelzellen beeinträchtigte. 
Zusammenfassend zeigen unsere Daten, dass ADAM17 durch Kontrolle des TNFR2-Signalwegs vor 
Atherosklerose schützt. 
Schließlich konnten wir in einer dritten Studie zeigen, dass ADAM17 eine weitere Rolle in der vas-
kulären Biologie spielt und Adam17-Defizienz zu arterieller Dilatation und Veränderungen von 
Elastinfasern im hypomorphen Mausmodell führt. Dieser Phänotyp erinnert an die Frühphase 
der Ausbildung eines arteriellen Aneurysmas. Weitere Analysen zeigten, dass ADAM17 für die 
Aufrechterhaltung des Elastin-Netzwerks in der extrazellulären Matrix (ECM) von Arterien und 
somit für den Schutz der Integrität der Arterienwand wichtig zu sein scheint.
Zusammenfassend haben wir PLA2G12A als neuen Regulator der Atherosklerose identifiziert und 
charakterisiert und konnten zeigen, dass die Metalloprotease ADAM17 eine bisher unbekannte 
protektive Rolle bei Gefäßerkrankungen besitzt, die auf die Kontrolle des TNFR2-Signalwegs und 
Regulation der extrazellulären Matrix zurückzuführen ist.
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1 Introduction
1.1 Atherosclerosis and cardiovascular disease
Atherosclerosis is a chronic inflammatory condition of the large and medium-sized vasculature 
and the main cause of cardiovascular disease (CVD). The three major manifestations of CVD are 
peripheral vascular disease (PVD), cerebrovascular disease (CVA) and coronary heart disease 
(CHD). Atherosclerosis is a complex and progressive disease that is affected by genetic (poly-
genic disease) as well as environmental factors [3]. It is a disease that occurs over a lifetime and 
is influenced by numerous factors, including excessive dietary fat, smoking, diabetes, sedentary 
lifestyle and genetic factors [4]. Over the time, locally confined sites in the vascular wall develop 
fibrous, fatty lesions (plaques) characterized by inflammation, and abnormal cell proliferation 
and apoptosis. Plaque progression may lead to rupture and subsequent thrombus formation, 
which is the most important cause of acute cardiovascular events such as myocardial infarction 
and stroke [5].
CVD is the leading cause of morbidity and mortality in Germany as well as worldwide [6]. 
Worldwide, it was estimated that there were 422.7 million cases of CVD and 17.92 million CVD 
deaths, accounting for one-third of all deaths, in the year 2015 [7]. Of these deaths, an estimated 
7.4 million were due to coronary heart disease and 6.7 million were due to stroke [8]. Each year, 
CVD causes over 4 million deaths in Europe and 1.9 million deaths in the European Union (EU) [9]. 
Thus, CVD is responsible for approximately 47 % of all deaths in Europe and 40 % in the EU. About 
60 % of all CVD deaths occur in people over 75 years, 1.4 millions under the age of 75 and about 
700,000 under the age of 65 years [10]. Overall, CVD is estimated to cost the European Union economy 
almost € 210 billion a year [11]. In Germany, CVD are with 38.9 % or 338,056 deaths, the leading 
cause of mortality each year. Of these, 148,538 (43.9 %) account for men and 189,518 (56.1 %) for 
women. Furthermore, myocardial infarction is responsible for the death of 50,104 people or 5.8 % 
of all deaths [12].
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1.2 Pathophysiology of atherosclerosis
Atherosclerosis is a focal disease process that occurs predominantly at sites of disturbed laminar 
flow, notably, arterial branch points and bifurcations of large arteries [13]. Although much pro-
gress has been achieved over the last years, the pathogenesis of the disease is not fully under-
stood. Various models have been proposed for the development of atherosclerosis, of which 
the so-called “Response to Injury” hypothesis is probably the best accepted today. This theory 
states that atherosclerosis occurs as a response to some form of activation of arterial endothelial 
cells. This can be triggered by any number of insults, either alone or in combination [14]. 
Arterial walls are composed of a highly ordered structure of cells and extracellular matrix (ECM) 
and are thicker than that of veins in order to withstand pulsatile flow and higher blood pres-
sures. The normal muscular artery has a trilaminar structure: the tunica intima, the inner coat 
with a monolayer of endothelial cells and resident smooth muscle cells; the tunica media, the 
middle coat containing vascular smooth muscle cells (VSMCs). The media is the thickest layer 
and provides structural support, vasoreactivity and elasticity. The outer coat, the tunica adventitia, 
contains mast cells, fibroblasts, nerve endings and microvessels (Figure 1) [15]. 
FIGURE 1: Layers of the arterial wall [1]. 
The ECM makes up to 60 % of the intimal volume and consists of elastic lamellae, smooth muscle 
cells and three major protein components, including proteoglycans, collagen and multi-adhesive 
matrix proteins [16].
Atherosclerosis starts with an initial damage of the vascular endothelium, which evokes endothe-
lial dysfunction and causes a chronic inflammatory response. Intimal damage due to injury, high 
blood pressure, smoking, in particular of the endothelium, leads to an increased permeability 
and influx of lipoproteins from the blood, resulting in an increased accumulation of low-density 
lipoproteins (LDL) in the intima [17]. Several animal experiments, epidemiological and clinical 
studies established that high concentrations of cholesterol in the circulation promote athero- 
sclerotic cardiovascular disease [18, 19]. Cholesterol is transported in the blood in lipoprotein 
particles, where low-density lipoproteins (LDL) particles contain esterified cholesterol and 
triglycerides surrounded by phospholipids, cholesterol and apolipoprotein B100 (ApoB100). 
Through the subendothelial retention, LDL particles are captured in the intima, the innermost 
layer of the artery, where they are exposed to oxidative modifications by reactive oxygen species or 
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enzymes like myeloperoxidase or lipooxygenases (12/15-lipoxygenase [20]) released from inflam-
matory cells. Otherwise, antioxidants, as α-tocopherol (Vitamin E), γ-tocopherol, α- and β-car-
otene and lycopene support to prevent the oxidation of LDL particles in the circulation [21, 22]. 
One of the first changes to which the endothelium is subjected is a reaction to the hemodynamic 
changes in the lumen. As arterial segments are under high shear stress, typical for normal lam-
inar blood flow, they show a high production of nitric oxide (NO). NO acts by two mechanisms 
antiarteriosclerotic: on the one hand, it acts both vasodilatory and antithrombotic [23], on the 
other hand NO reduces the adhesiveness of the endothelium by inhibiting the expression of the 
vascular cell adhesion molecule (VCAM) in leukocytes. While oxidized lipoproteins inhibit the 
nitric oxide (NO) production in the endothelial cells, endothelial cells themselves are stimulated by 
the oxidized lipoproteins to attract monocytes from the blood. In the arterial segments, where 
the shear stress is diminished, e.g. at the crotch of arterial branches, the NO production is re-
stricted by the endothelial cells. These segments are particularly susceptible to the develop-
ment of arteriosclerotic lesions [24, 25]. Constituents of oxidized LDL can stimulate the expres-
sion of chemoattractant molecules, like monocyte chemoattractant protein-1 (MCP-1), to attract 
the attached leukocyte to migrate through the endothelial monolayer into the arterial intima 
[26]. Moreover, oxidized phospholipids stimulate the expression of adhesion molecules on the 
surface of vascular endothelial cells to mediate leukocyte adherence to the luminal surface of 
these cells. Recruitment of the leukocytes is primarily augmented by the adhesion molecules 
vascular cell adhesion molecule-1 (VCAM1), intercellular cell adhesion molecule-1 (ICAM1) and 
P-selectin on the surface of the arterial endothelial cells [27]. Once leukocytes passed through 
the endothelial monolayer, macrophage colony-stimulating factor (M-CSF) contributes to the 
differentiation of blood monocytes into macrophage foam cells [28]. These macrophage foam 
cells produce cytokines such Tumor Necrosis Factor-α (TNF-α) and Interleukin-1 (IL-1) and induce 
the expression of adhesion molecules (VCAM-1, ICAM-1) on the endothelial surface to attract 
more monocytes and T-lymphocytes [29].
Macrophage foam cell formation is characteristic for atherosclerosis. Under normal conditions 
macrophages are unable to take up circulating LDL because of down regulation of the LDL-receptor 
gene. Monocytes, once resident in the intima and differentiated into macrophages, exhibit 
enhanced expression of scavenger receptors [30, 31]. Scavenger receptors such scavenger- 
receptor A (SR-A), scavenger-receptor B1 (SR-B1) and CD36 bind with high affinity and internalize 
the oxidized LDL (oxLDL) or acetyl-LDL. Since scavenger receptors are not subjected to feed-
back inhibition in contrast to the LDLR, they lead to uncontrolled endocytotic uptake of oxLDL 
in macrophages and ultimately to the formation of foam cells. These lipid-laden macrophages 
(foam cells), characterize the early atherosclerotic lesion. Macrophages engulfing modified 
lipoproteins produce cytokines and growth factors, which in turn cause further recruitment of 
the macrophages and vascular smooth muscle cells (VSMC) from the tunica media through the 
lamina elastica to the intima and consequently to the lesions [27].
The recruitment of macrophages and T cells into the atherosclerotic lesions is guided by endo- 
thelial leukocyte adhesion molecules and chemoattractants. The latter include chemokines, 
which belong to a large group of structurally related and secretable chemotactic cytokines [32]. 
Chemokines can be expressed in different vascular cells like endothelial cells but also inflam-
matory cells. The recruitment of leukocytes involves a sequence of rolling, firm adhesion, lateral 
migration and transendothelial diapedesis, controlled by chemokines [33]. Monocytes that are 
located in the intima are stimulated by colony-stimulating factor (CSF) produced by activated 
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endothelial cells to differentiate into macrophages. In the intima, macrophages upregulate their 
scavenger receptors that can then take up oxLDL. The subsequent cholesterol accumulation 
turns these macrophages into foam cells that are characteristic of the atherosclerotic lesion. 
Smooth muscle cells located in the media change their phenotype after migration. This pheno-
typic transformation can be initiated by oxidized lipoproteins, cellular toxins, and endothelial 
dysfunction. SMCs take on properties that can contribute to the inflammation process. While 
SMCs normally have a contractile function, SMCs found in arteriosclerotic lesions have less myo- 
filaments, but more synthetic cell organelles such as Golgi apparatus and rough endoplasmic 
reticulum. Smooth muscle cells in the intimal lesion are therefore able to react to growth factors 
and have a synthesis function [34, 35]. 
Atherosclerotic plaques maturate in the arterial intima over a period of years, even decades. 
Underneath the formed fibrous cap, many dead or dying macrophages, cellular debris and 
extracellular accumulations build a so-called lipid core. Arterial smooth muscle cells (SMCs) 
located in the media also respond to inflammation- associated mediators. Chemoattractants 
like platelet-derived growth factor (PDGF) produced by activated leukocytes or SMCs them-
selves when stimulated can enter the intimal layer [36]. An important step in the migration and 
proliferation of SMC is the secretion of matrix metalloproteinases (MMP), as MMP-1, MMP-8 and 
MMP-13, which are responsible for the degradation of the internal elastic lamina [37]. Smooth 
muscle cells in the intima express extracellular matrix (ECM) molecules that contribute to lesion 
fibrosis [38, 39]. Fibrosis is the development of a connective tissue layer predominantly collagen 
and the proliferation of muscle cells above the lipid core. Arterial smooth muscle cells produce 
interstitial collagens like type I and III collagen at the beginning and, subsequently, type IV and 
V, elastic fibers, and proteoglycans leading to plaque stabilization and eventually to fibrosis. 
Fibrous (stable) plaques have in comparison to unstable plaque relatively small nuclei and 
relatively thick capsules, which are rich in connective tissue and muscle cells [40]. Underneath 
the fibrous cap, the formed lipid core contains many macrophages, cellular debris including 
apoptotic bodies and extracellular lipid accumulations. Proinflammatory cytokines released 
from activated white cells, endothelial cells and smooth muscle cells can potentiate cells death 
by apoptosis in the advancing lesion. Furthermore, macrophages in the lesions secrete proteinases 
that degrade the macromolecules of the extracellular matrix [26]. Complicated lesions arise when a 
fibrous cap of an unstable plaque ruptures, and the contents with lipids and macrophages come 
in contact with blood. The precipitation of platelets and coagulation factors forms a thrombus. 
In our study we focused on cellular mechanisms associated with the onset of atherosclerosis 
and not with the late thrombotic phase. This means that we focused on phenotypes including 
the adhesion of mononuclear blood cells to endothelial cells, proliferation of vascular SMCs and 
monocytes, the propensity to apoptosis of these cells types and the remodeling of ECM by these 
cells. Molecularly, we applied assays to measure inflammation-regulating cytokines, adhesion 
factors and cytoskeletal features.
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1.3 Genetic factors of atherosclerosis in humans
1.3.1 Heritability of atherosclerosis
Several studies demonstrated that a family history of early coronary artery disease (CAD) is a 
significant risk factor for the development of this disease [41]. The heritability of various risk 
factors of atherosclerosis is in the meanwhile well established by several epidemiological 
prospective studies [42, 43] and can be predicted with increasingly improved validity [44-46]. 
Heritability is used to estimate how much variation in the phenotypic trait in a population is due 
to genetic variation among individuals in that population. In statistical genetics, the heritability 
is determined by comparing the frequency of a trait in interrelated individuals as opposed to 
not related persons. For example, in human medicine comparisons between monozygotic 
twins and dizygotic twins are conducted for evaluating the importance of genetic variation 
in susceptibility to disease. Using such models the influence and significance of environ-
mental effects and the contribution of specific polymorphisms to the total genetic variance 
can be studied [47]. 
The known risk factors of atherosclerosis, which have an inherited component, are mainly factors 
of cholesterol metabolism. For example, the heritability for elevated LDL-cholesterol is 88 % and 
decreased HDL-cholesterol 66 % [48]. A heritability of 41-78 % was found for other classical risk 
factors, such as hypertension [49] and 72 % for diabetes mellitus [50]. 
Lloyd and Colditz have shown that in the determination of the individual risk of atherosclerosis, 
family history plays a decisive role. Also after adjustment for classical risk factors (for example 
overweight, hypercholesterolemia), the risk of atherosclerosis in patients with positive family 
history is higher than in patients without positive family history [51, 52]. These findings indicate 
that atherosclerosis is, in significant parts, a genetically determined disease. This hypothesis was 
studied in numerous twin studies, where clear indications of the genetic influence on athero- 
sclerosis was found: the relative risk to contract disease after the death of a twin from coronary 
heart disease (CHD), is in case of monozygotic twins twice as high compared to dizygotic twins [53]. 
Furthermore, Zdravkovic et al., showed in twin studies, that heritability of fatal myocardial in-
farction in male twins is 57 %, and in female twins 38 % [54]. In the German heart attack family 
study, a heritability of 50 % has also recently been demonstrated for the development of a proximal 
stenosis with existing coronary heart disease [55]. A morphological sign of a subclinical mani-
festation of atherosclerosis is the increased intima-media thickness of the carotid artery. In this 
case, a significant heritability of 38 % was shown [56-58].
1.3.2 Monogenic contributions to atherosclerosis
Atherosclerosis risk can be conferred either by mutations in single genes (monogenic type of 
atherogenesis) or be due to variation in multiple genes (polygenic model). First candidate genes 
of atherosclerosis were identified through their possible role in atherosclerosis development 
particularly in signal or metabolic pathways. Most of these genes have an influence on fat meta- 
bolism, coagulation, inflammation, endothelial dysfunction or even blood pressure regulation. 
In the following, monogenetic defects that lead to atherosclerosis and in consequence to a cardio- 
vascular disease will be reviewed.
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The Familial Hypercholesterolemia (FH), first identified by Brown and Goldstein, was the first 
monogenic disorder that was shown to cause elevated plasma cholesterol levels and especially 
high levels of low-density lipoprotein cholesterol (LDL-C) [59]. The frequency of heterozygous FH 
is 1 : 500, while homozygous FH is reported to be 1 : 1,000,000. Responsible for FH are mutations in 
the low-density lipoprotein receptor (LDLR), apolipoporotein B (APOB) or the protein convertase 
subtilisin/kexin type 9 (PCSK9) genes. LDLR is located on chromosome 19 and in the meanwhile 
more than 800 allelic variations are described [60]. Due to the mutations, the LDL receptor loses its 
ability to mediate the binding, internalization, or degradation of LDL [61]. This leads to extreme 
high cholesterol levels (> 600 mg/dl) in homozygous patients and little lower in heterozygous 
patients (~400 mg/dl). Human APOB is located on chromosome 2 and codes for the main apo-
lipoprotein of chylomicrons and LDL. Cholesterol levels of these patients are lower than those 
of FH, but still highly elevated. PCSK9 is an enzyme encoded by the PCSK9 gene in humans on 
chromosome 1. PCSK9 plays a key role in regulating cholesterol homeostasis. It reduces hepatic 
low-density lipoprotein receptors (LDLRs) thereby increasing LDL-cholesterol. Furthermore, 
the autosomal recessive hypercholesterolemia (ARH), a disorder with similar characteristics to 
individuals carrying LDLR mutations have two defective copies of the LDLRAP1 (low	 density	 
lipoprotein receptor adaptor protein 1) gene [62]. Sitosterolemia shows a similar clinical picture 
like Familial Hypercholesterolemia. It is a rare autosomal recessive disorder of the plant sterol 
metabolism, based on mutations in ABCG5 and ABCG8 [63, 64]. In a linkage analysis Mani et al. 
identified LRP6 (LDL receptor-related protein 6) as the putative causal gene in a family study 
with apparent autosomal dominant inheritance of premature CAD/MI and metabolic syndrome 
[65, 66]. Through genome-wide linkage analysis the myocyte enhancer factor-2 (MEF2A), arachi-
donate 5-lipoxygenase-activating protein (ALOX5AP) and leukotriene A4 hydrolase (LTA4H) were 
also detected to be associated with CAD [67-69]. ApoE is another key protein of the lipid trans-
porting system which regulates serum cholesterol and participates in the formation of high den-
sity lipoproteins (HDL). Furthermore, ATP Binding Cassette Transporter 1 Gene (ABCA1) functions 
as a cholesterol efflux pump in the apolipoprotein mediated cellular lipid removal pathway [60]. 
Mutations of the ABCA1 gene have been described in the case of Tangier disease and the hereditary 
HDL deficiency [70]. Another gene involved in cholesterol metabolism is the CYP7A1 gene.	CYP7A1 
plays a role in the conversion of cholesterol into bile acids. Genetic variations in the CYP7A1 gene 
were associated in some studies with hypercholesterolemia [60].
1.3.3 Genome-wide association studies (GWAS)
The identification of genetic variants that contribute to atherosclerosis risk via polygenic effects 
was made possible by the complete sequencing of the human genome by the Human Genome 
Project and the development of high throughput genotyping technology as a prerequisite of 
genome-wide association studies (GWAS). 
The international Human Genome Project (HGP) was founded 1990 and was completed 2003 with 
the near-complete sequencing of the approximately 3 billion base pairs of the human genome. 
To this end, the international HapMap project also contributed a key role. This research project 
aimed to develop a haplotype map of the human genome, the HapMap, which describes the 
common patterns of human DNA sequence variation [71]. Due to how genetic material is inherited 
by recombination between homologous chromosomes in the process of meiosis [72] and given that 
humans have a confined common ancestry, genetic variants are seen to be inherited together 
  17 / 154
Introduction
in longer segments of DNA that are called haplotype blocks (a set of associated SNP alleles in a 
region of a chromosome). These haplotype blocks gain limited variation across generations and 
are shared by most of the human population. Therefore they can be used to associate genetic 
differences in human DNA sequences with diseases. A major type of sequence variation in the 
haplotype blocks is called single nucleotide polymorphisms (SNPs). In the meanwhile, more 
than 80 million SNPs exist in human populations [73]. Some SNPs in the haplotype blocks are 
redundant, so that only few SNPs are needed to indicate that there is genetic diversity of the 
entire block. These few “tag” SNPs can provide information on the pattern of genetic variation 
in larger genomic region. This haplotype structure of the human genome makes it possible, by 
genotyping approximately 500,000 SNPs, to associate genetic loci with the risk of a disease [74].
A number of high-throughput genotyping technologies have been developed that allow parallel 
genotyping of a high number of genetic markers in DNA. Using DNA microarrays it is possible to 
genotype multiple genomic markers in patients – up to 500,000 SNPs at a time [75]. The evaluation 
of these markers in combination with the meta-analysis of case-control samples leads to the 
identification of genetic variants which are highly and reproducibly associated with the risk for 
CAD and MI [77]. 
Genome-wide association studies (GWAS) are applied to associate genetic polymorphisms with 
phenotypes or certain diseases. Representing a hypothesis-free approach, a typical GWAS analyses 
a large number of genetic loci spread over the whole genome with the aim of identifying new, 
and possibly unanticipated genetic variants in a large unrelated population associated with a 
given trait of interest.
For widespread diseases, such as cancer, diabetes, or coronary heart disease, GWAS provided 
hundreds of genetic markers. The first large-scale, case-control association study to myocardial 
infarction (MI) was performed in 2002 in a Japanese population showing that the homozygosity 
in two SNPs in lymphotoxin A (LTA) at 6p21 was significantly associated with increased risk (odds 
ratio [OR] = 1.78)  [76] (See Chapter 1.5 for details on the calculation of OR). In the meanwhile, 
several genome-wide association studies have been performed with relation to coronary artery 
disease (CAD) and myocardial infarction (MI) and more than 66 genetic variants were identified 
at ‘genome-wide significance’ (P < 5 x 10−8)  [77-80]. The chromosome 9p21 (Chr9p21) locus, emerging 
from multiple GWAS, is the strongest genetic risk factor of atherosclerosis known today [85].
This locus has been replicated in several studies [81-83] and can be considered the most robust 
genetic marker of atherosclerotic cardiovascular disease. Investigating this locus in more depth, 
the first studies identified two genes located at this locus, CDKN2A and CDKN2B. Subsequent 
studies identified that the risk/non-risk alleles at the 9p21 locus are related to different iso-
forms of ANRIL, a long non-coding RNA. ANRIL is thought to affect not only the expression of 
CDKN2A and CDKN2B but also of many other genes, causing effects on cell proliferation and 
apoptosis and inflammation [84, 85]. Table 1 shows an overview of the replicated CAD-linked 
loci in European populations, the closest genes in the neighbourhood of the lead SNP, putative 
functions of these genes and possible relevance to CAD, the name of the lead SNPs, the effect allele 
frequency and the odds ratio that were detected during the past years through genome-wide 
association studies [86]:
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TABLE 1: Replicated genome-wide significant loci for CAD [86].
Chr Closest Gene(s) Putative Functions of Possible Relevance to CAD Lead SNP EAF OR
1 PPAP2B Regulation of cell-cell interactions rs17114036 0.92 1.13
1 PCSK9 Regulation of LDL receptor recycling rs11206510 0.85 1.08
1 SORT1 Regulate apoB secretion and LDL catabolism rs599839 0.78 1.11
1 IL6R IL-6 receptor, immune response rs4845625 0.46 1.05
1 MIA3 Collagen secretion rs17465637 0.73 1.08
2 LINC00954 LncRNA of unknown function rs16986953 0.07 1.09
2 APOB Major apolipoprotein of LDL rs515135 0.78 1.07
2 ABCG5/G8 Cholesterol absorption and secretion rs6544713 0.29 1.05
2 VAMP5/8-GGCX Intracellular vesicle trafficking rs1561198 0.47 1.06
2 ZEB2-AC074093.1 ZEB2-transcriptional repressor rs2252641 0.44 1.03
2 WDR12 Component of nucleolar protein complex rs6725887 0.14 1.14
3 MRAS Cell growth and differentiation rs9818870 0.15 1.07
4 EDNRA Receptor for endothelin-vasoconstriction rs1878406 0.16 1.06
4 GUCY1A3 Nitric oxide signaling rs7692387 0.80 1.07
4 REST-NOA1 REST maintains VSMCs in a quiescent state rs17087335 0.21 1.06
5 SLC22A4/A5 Organic cation transporter rs273909 0.14 1.06
6 ANKS1A May inhibit PDGF-induced mitogenesis rs17609940 0.82 1.03
6 PHACTR1 Regulates protein phosphatase 1 activity rs12526453 0.71 1.10
6 KCNK5 Potassium channel protein rs10947789 0.78 1.05
6 TCF21 Transcriptional regulator rs12190287 0.64 1.06
6 SLC22A3-LPAL2-LPA Lipoprotein(a) rs2048327 0.35 1.06
rs3789220 0.02 1.42
6 PLG Fibrinolysis rs4252120 0.74 1.03
7 NOS3 Production of nitric oxide rs3918226 0.06 1.14
7 HDAC9 Represses MEF2 activity/beige adipogenesis rs2023938 0.10 1.08
7 ZC3HC1 Encodes NIPA, regulator of cell proliferation rs11556924 0.69 1.08
8 LPL Lipolysis of TG-rich lipoproteins rs264 0.85 1.06
8 TRIB1 TG, MAPK signaling, SMC proliferation rs2954069 0.55 1.04
9 CDKN2BAS Cellular proliferation, platelet function rs10757274 0.48 1.21
9 ABO IL-6, E-selectin, LDL-C levels rs579459 0.21 1.08
10 KIAA1462 Component of endothelial cell-cell junctions rs2505083 0.40 1.07
10 CXCL12 Endothelial regeneration; neutrophil migration rs501120 0.81 1.08
rs2047009 0.48 1.06
10 LIPA Intracellular hydrolysis of cholesteryl esters rs1412444 0.37 1.07
rs11203042 0.45 1.04
10 CYP17A1-CNNM2-NT5C2 steroidogenic pathway rs12413409 0.89 1.08
11 PDGFD Role in SMC proliferation rs974819 0.33 1.07
11 SWAP70 Leukocyte and VSMC migration and adhesion rs10840293 0.55 1.06
11 ZNF259 APOA5 APOC3 TG-rich lipoprotein metabolism rs964184 0.18 1.05
12 SH2B3 Negative regulator of cytokine signaling rs3184504 0.42 1.07
12 ATP2B1 Intracellular calcium homeostasis rs7136259 0.43 1.04
12 KSR2 Suppressor of Ras2 – cell proliferation; obesity rs11830157 0.36 1.12
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Chr Closest Gene(s) Putative Functions of Possible Relevance to CAD Lead SNP EAF OR
13 FLT1 VEGFR family; angiogenesis rs9319428 0.31 1.04
13 COL4A1/A2 Type IV collagen chain of basement membrane rs4773144 0.43 1.05
rs9515203 0.76 1.07
14 HHIPL1 Unknown rs2895811 0.41 1.04
15 ADAMTS7 Proliferative response to vascular injury rs7173743 0.56 1.08
15 SMAD3 Downstream mediator of TGF-β signaling rs56062135 0.79 1.07
15 ATP2B1 MFGE8: lactadherin–VEGF neovascularization rs8042271 0.90 1.10
15 FURIN Endoprotease-TGF-β1 precursor and type I MMP rs17514846 0.44 1.05
17 BCAS3 Rudhira-EC polarity and angiogenesis rs7212798 0.15 1.08
17 RAI1-PEMT-RASD1 PEMT encoded protein converts PE to PC rs12936587 0.61 1.03
17 SMG6 Role in nonsense mediated RNA decay rs216172 0.35 1.05
17 UBE2Z Protein ubiquination; apoptosis rs46522 0.51 1.04
18 PMAIP1-MC4R PMAIP1: HIF1A-induced proapoptotic gene; MC4R: leptin signaling-obesity rs663129 0.26 1.06
19 LDLR LDL clearance rs1122608 0.77 1.08
19 APOE LDL and VLDL clearance rs4420638 0.17 1.10
19 ZNF507 Unknown rs12976411 0.09 0.67
21 KCNE2 Maintains cardiac electric stability rs9982601 0.13 1.12
22 POM121L9P-ADORA2A Adenosine A2a receptor: infarct-sparing effects rs180803 0.97 1.20
EAF, effect allele frequency; OR, odds ratio
The identified loci explain only around 10 % of the heritability of coronary artery disease and 
most genome-wide significant hits were not related to traditional risk factors [87]. The main 
traditional risk factors that show some evidence for association with CAD-associated single- 
nucleotide polymorphisms (SNPs) are lipid and blood pressure traits [87]. 
The two atherosclerosis risk loci that we have investigated in our study do not overlap with 
known hits from GWAS for CAD (see above) nor with hits from GWAS for CAD risk factors.
1.4 Mouse models in atherosclerosis
Currently, the mouse is the most frequently and widely used model for atherosclerosis studies. 
Atherosclerosis studies in mice are important for both, identification of novel candidate genes 
of the disease using hypothesis-free approaches, as well as for hypothesis-driven validations 
of candidate genes in vivo. 75 % of mouse genes have an equivalent orthologous gene class in 
humans, making mice ideal for studying different diseases. 
Genetic analysis in isogenic (inbred) mice provides an excellent example of a viable strategy 
to gene discovery for complex human diseases like atherosceloris. Inbred strains are produced 
using not less than 20 consecutive generations of brother x sister or offspring x parent mating. 
At least 98.6 % of the loci in each mouse are homozygous and therefore the individual animals 
are considered as being genetically identical (isogenic) [88]. Many inbred strains are well 
characterized and crossing of phenotypically different inbred strains enables mapping of quan-
titative or qualitative trait loci [89]. 
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Wild-type mice are actually resistant to spontaneous atherosclerotic lesion formation. Compared 
to other vertebrate species, mice have an antiatherogenic lipoprotein profile with high levels of 
High-density lipoproteins (HDL) and low levels of Low-density lipoproteins (LDL) in blood [90]. 
However, through induced mutations it was possible to develop mouse strains that are sus- 
ceptible to atherosclerosis. Three different atherosclerosis mouse models are used to induce 
and examine atherosclerosis. A diet-induced model, secondly the apolipoprotein E-deficient 
model, and third, LDL receptor-deficient mice. Paigen developed a cholesterol-cholate diet 
(“Paigen diet”) consisting of 15 % high-fat, 1.25 % high-cholesterol and 0.5 % cholic acid to induce 
atherosclerosis in wild-type mice [91]. Nonetheless, atherosclerotic lesion formation remained 
small, therefore this mouse model was not extensively used [92]. In the year 1992, two inde-
pendent research groups created hyperlipidemic apolipoprotein E-deficient mice using gene 
targeting through homologous recombination in embryonic stem cells [93, 94]. ApoE is a major 
apoprotein of chylomicrons and intermediate-density lipoproteins (IDLs). ApoE K0 mice lack the 
primary lipoprotein required for the uptake of the lipoproteins through the hepatic receptors. 
In the year 1993, gene targeting in embryonic stem cells was also used to create LDL receptor 
knockout (LDLR-KO) mice, a model of familial hypercholesterolemia. These mice lack the pri-
mary receptor for LDL cholesterol uptake. LDL receptor deficient mice have a more modest lipo-
protein abnormality than the apolipoprotein E deficient mice, with increased levels of LDL- and 
VLDL-cholesterol leading to a total plasma cholesterol of about 250 mg/dl on a chow diet [95]. 
Apolipoprotein E deficient mice are characterized by the plasma accumulation of plasma VLDL 
particles and spontaneously develop atherosclerotic lesions on a low-fat diet. LDL receptor 
deficient mice accumulate plasma LDL and develop higher levels of atherosclerosis when fed a 
high-cholesterol diet [90]. Furthermore, in 1994, ApoE and LDL-receptor (LDLr) double knockout 
(ApoE/LDLr-DKO) mice were generated [96], representing a new mouse model that develops 
severe hyperlipidemia and atherosclerosis [97]. The following figure shows the progression of 
atherosclerosis in the above-described mouse models [98]. 
FIGURE 2: Atherosclerosis phenotyping in mice and corresponding mouse models [98].
Teupser et al. succeeded to induce hypercholesterolemia in mice for atherosclerosis develop-
ment using a semisynthetic diet by adding cholesterol at different concentrations (0.02 %-0.15 %). 
The aim was to establish a diet that would achieve hypercholesterolemia and atherosclerosis in 
LDLR -/- mice without toxicity from very high cholesterol and cholic acid components and without 
the weight gain induced by high-fat feeding [99]. This semisynthetic diet consisted of standard-
ized components: 19 % protein (mainly casein), 67 % carbohydrates (corn starch, maltodextrin, 
sucrose) and 4.3 % fat (soybean oil, cocoa butter). The rest is made up of vitamins, fiber and 
trace elements. In semisynthetic diets with 0.00 % and 0.02 % cholesterol, the plasma cholesterol 
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level was similar (10 mmol/l) and significantly lower compared to diets with higher cholesterol. 
While in the two diets with the lowest cholesterol shares no steatosis was observed, the animals 
showed a significant steatosis of the liver on diets with 0.15 % to 0.50 % cholesterol. The semi- 
synthetic diet containing 0.02 % cholesterol did not induce hepatic impairment. Therefore 
we triggered atherosclerosis by feeding a semisynthetic diet to Ldlr -/- mutant mice for all our 
atherosclerosis studies. 
1.5 Quantitative trait locus (QTL) mapping for atherosclerosis susceptibility
Quantitative trait locus (QTL) analysis is a method that is applied to identify loci making a signifi- 
cant impact on a phenotype, for example identifying genetic factors of atherosclerosis in mice. 
Mouse genetic mapping methods rely on the presence of inbred mouse models. For a QTL analysis, 
two or more inbred mouse strains are needed that differ genetically with regard to the trait 
of interest. Furthermore, genetic markers are required that distinguish between the parental 
F0 strains. Various markers are used for genotyping, as single nucleotide polymorphisms (SNP), 
simple sequence repeats (SSRs), restriction fragment length polymorphisms (RFLPs) and trans-
posable elements [100-102]. There are several variants in QTL mapping methods: the F2 generation 
can either be generated by crossing the littermates of the F1 generation or by backcrossing the 
F1 generation with the parental F0 strains (N2 generation). Inbred F0 mice are genetically identical 
and homozygous at all loci and, consequently, the F1 generation is heterozygous. The resulted 
F2 mice are genetically distinct from each other, since the paternally and maternally derived 
chromosomes recombine before segregating into gametes.
In this regard, genetic linkage analysis is used for mapping heritable trait genes to defined chro-
mosomal regions. The frequency of recombination between two genetic markers is greater, the 
further apart they are. Accordingly, the smaller the distance between to genes, the more unlikely 
it is that these genes will be separated by meiotic crossing-over. Analyzing the separation of 
distinguishing genetic variants over several generations in genetic crosses, the relative distance 
between two genes can be determined via the recombination frequency. Disease candidate 
genes are identified by using genetic markers, whose position is known in the genome. These 
markers, though representing genetic variants are use solely for mapping, and have nothing to 
do with the disease per se. Therefore, if some disease is passed to offsprings along with specific 
marker-genes, then it can be concluded that the gene(s) which are responsible for the disease 
are located close on the chromosomal location of these markers. In the classical parametric 
linkage analysis, the probability that a gene important for a disease is linked to a genetic marker 
is studied through the log of the odds ratio (LOD) score. This score assesses the probability that 
a given pedigree, where the disease and the marker are cosegregating, is due to the existence of 
genetic linkage (with a given linkage value) as opposed to segregation by chance [103].
Mouse models using inbred strains have been proven useful for identifying candidate genes 
of atherosclerosis. All mice of the F2 generation are analyzed genome-wide with polymorphic 
microsatellite markers to define the genotype at each locus. Three different genotypes occur 
in an intercross of AxB mice: Either homozygous (AA or BB) or heterozygous (AB). QTL software 
is then used to define the correlations between genotype and phenotype, and the output is 
given as likelihood ratio statistic or as a log of the LOD score [90]. The LOD score ratio is used 
as a measure of a linkage analysis. The ratio (odds ratio) is calculated from the probability that 
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the observed data are linked and the probability that they are not linked. The logarithm of this 
quotient, the LOD score (logarithm of the odds), serves as a measure of linkage probability. 
For monogenic features or diseases, a LOD score of 3.0 is considered to be evidence of linkage 
(i.e., the probability that linkage is present, would be 1000 times greater than the likelihood of 
no linkage). In our studies, linkage analyses in mice were used to identify novel candidate genes 
for atherosclerosis susceptibility. Therefore, atherosclerosis-susceptible inbred C57BL/6 (B6) 
and atherosclerosis-resistant FVB mice on the LDL receptor-deficient (Ldlr -/-) background were 
intercrossed to generate a heterozygous F1 generation [104]. F1 mice were then mated by brother- 
sister mating to generate F2 mice. Recombination in F2 was assessed with a genome-wide scan 
involving 192 microsatellite markers [104]. Subsequently, a correlation of the genotype of the 
F2 generation with the phenotype was performed to generate a LOD score (logarithm of odds) of 
each genetic marker. 
FIGURE 3: Atherosclerosis-susceptible C57BL/6 and atherosclerosis-resistant FVB mice on the Ldlr -/- back-
ground were intercrossed to generate F1 mice. Heterozygous F1 mice were mated by brother-sister 
mating to generate 459 F2. Recombination in the F2 was assessed with a complete genome scan 
involving 192 microsatellite markers [104].
In principle, QTL analysis in mouse models investigates phenotypes, which differ between the 
two parental strains. In preliminary works, the size of atherosclerotic lesions as well as HDL- and 
LDL-cholesterin levels had been determined. Figure 4 shows the lesion sizes as the phenotype of 
a QTL experiment of an atherosclerosis-susceptible C57BL/6.Ldlr -/- and atherosclerosis-resistant 
FVB.Ldlr -/- cross-breeding and subsequent generations. The F1 generation has a heterozygous 
phenotype and intermediate atherosclerotic lesions, formed by crossing of the parental inbred 
strains (atherosclerosis-susceptible C57BL/6 [B6] and atherosclerosis resistant FVB). The F2 
generation differs in its characteristic expression with respect to the phenotype, according to 
the proportion of the genes from the grandparental generations (Figure 4).
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FIGURE 4: Atherosclerotic lesion size (phenotype) in female mice of an intercross of atherosclerosis-sus- 
ceptible C57BL/6 and atherosclerosis-resistant FVB mice on the Ldlr -/- background [104].
A correlation of the genotypes of the F2 generation with the phenotype (atherosclerotic lesion 
sizes) was performed to generate a LOD score (logarithm of odds) of each genetic marker. For the 
areas between the markers the LOD score is being estimated. 
FIGURE 5: Atherosclerosis LOD score on chromosome 10 [104].
Here, a significant LOD score for atherosclerosis was identified on chromosome 10.
1.6 Atherosclerosis loci in mice
Through quantitative trait locus mapping analysis of mice on the ApoE -/-, Ldlr deficient back-
ground or the Paigen diet, a variety of novel atherosclerosis loci were identified. The following 
table gives an overview of the identified atherosclerosis loci [98]. The chromosome, peak location, 
mouse model, QTL name (if available) and potential identified candidate gene are given.
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TABLE 2: Quantitative trait loci of atherosclerosis in different mouse models [98].
Chromosome Peak Location or Interval Mouse Model QTL Name Proven Gene
1 Paigen diet Ath1 Tnfsf4
1 ApoE -/- Ath30
1 105.4 ApoE -/- QTL-#
1 166.3 ApoE -/- QTL-#
1 176.6 ApoE -/- Ath9
2 Paigen diet Ath2
2 ApoE -/- Ath28
2 148.5 Ldlr -/- Athla1
3 ApoE -/- Ath23
3 115.5 Ldlr -/- Ascla4
3 147.8 Ldlr -/- Ascla3
4 137.4-150.9 Ldlr -/- Athsq1
4 45.-105 Paigen	diet,	ApoE -/- Ath8
5 ApoE -/- Ath24
6 Ldlr -/- Artles Alox5
6 Ldlr -/- Ath38
6 Ldlr -/- Athsq2
6 116.6-128.5 Ldlr -/- Ath37
7 57 Paigen diet Aorls2
7 Paigen diet Ath3
7 ApoE -/- Ath31
9 65.3 ApoE -/- Ath29
10 82.1 Paigen diet Aorls1
10 ApoE -/- Ath11
10 20.1 Paigen diet Ath20
10 67.7 Paigen diet Ath17
10 18.5 Ldlr -/- Ascla2
10 21.4 Ldlr -/- Ascla1
11 108.6 Paigen diet Ath19
12 Paigen diet Ath21
12 Paigen diet Ath6
12 35.9 Paigen diet Ath18
12 14.3 Ldlr -/- Ascla5 Adam17
12 55.1 Ldlr -/- Ascla6
12 ApoE -/- Cath1
13 ApoE -/- Ath25
13 ApoE -/- Ath32
14 51.9-165.9 ApoE -/- Ath13
15 ApoE -/- Ath22
15 ApoE -/- Ath33
17 ApoE -/- Ath26
18 ApoE -/- Ath27
19 38.5 ApoE -/- Ath16
  25 / 154
Introduction
1.7 Atherosclerosis susceptibility loci on mouse chromosome 3 and 12
In preliminary work to this thesis, quantitative trait locus (QTL) mapping in atherosclerosis- 
susceptible C57BL/6 (B6) and atherosclerosis-resistant FVB mice on the Ldl-receptor-deficient 
background (Ldlr -/-) led to the identification of three novel significant atherosclerosis susceptibility 
loci on chromosomes 3, 10, and 12 [104]. In this work we focused on the identified atherosclerosis 
loci on chromosomes 3 and 12 (Figure 6).
FIGURE 6: LOD scores for atherosclerosis on mouse chromosome (A) 3 and (B) 12, respectively [104, 105]. 
The Chr3 locus was gender-dependent and only present in female F2 mice [104]. Different LOD 
score maxima were observed in different female crosses according to the breeding scheme of 
the F0 generation (Figure 6 A). In cross A, male B6 mouse was mated with female FVB (F0 = male 
B6xfemale FVB), the maximum LOD score of atherosclerosis was 3.3 at marker d3mit45. In cross B, 
a male FVB mouse was mated with a female B6 mouse (F0 = male FVBxfemale B6), with a maximum 
atherosclerosis LOD score of 4.1 at marker d3mit57 [104]. Lineage-dependency of loci at chromo-
some 3 suggested that different molecular mechanisms might underlie the two distinct female 
atherosclerosis loci.
On the atherosclerosis locus on mouse chromosome 12, the Adam17 gene was previously identified 
as the candidate gene underlying this atherosclerosis locus through eQTL mapping (Figure 6 B) 
[105]. In that study, however, no further functional validations in vitro or in vivo were performed 
to investigate whether Adam17’s role in atherogenesis was causal [105]. On the following an 
overview will be given of the family of metalloproteases and especially the ADAM17 structure 
and functions. 
1.8 Adam17 as a candidate gene of atherosclerosis and the family of 
metalloproteases
Based on common structural features, motifs and folding patterns in their protein sequence, 
metalloproteases are classified in five major superfamilies [106]. These superfamilies are the 
gluzincins, inuzincins, metzincins, carboxypeptidases and DD carboxypeptidases [107]. The super- 
family of metzincins is characterized by a protease domain with a HEXXHXXGXXH zinc-binding 
motif at the active site and a methionine-containing Met-turn [108]. The family of metzincins 
includes four subfamilies: the astacins, serralysins, matrixins and the adamalysins [Figure 7]) [107, 109]. 
  26 / 154
Introduction
The matrixins comprise the matrix metalloproteases (MMPs). These enzymes are responsible for 
extracellular matrix degradation and remodeling and play substantial roles in development and 
the pathology of diseases such as arthritis and cancer [110]. Members of the astacin family are 
induced in embryonic stages of development, and are implicated in processes like dorsal-ventral 
patterning, hatching, and eggshell matrix degradation [111]. Serralysins are bacterial Zn-endo-
peptidases that act as a virulence factor to cause tissue damage and anaphylactic response 
[112].
FIGURE 7: Protein family of Zn2+ dependent metalloproteases.
Due to structural homologies, the adamalysin family is further divided into three protein families: 
ADAM (A disintegrin And Metalloprotease), ADAM-TS (thrombospondin motif) and SVMPs (Snake 
Venom Metalloprotease). 
ADAM enzymes are structurally closely related to other metalloenzymes such as ADAM-TSs 
(ADAMs with thrombospondin domains), matrix metalloproteinases (MMPs) and snake venom 
metalloproteinases (SVMP) [121]. ADAMs and the membrane-type matrix metalloproteases 
(MT-MMP) are membrane-bound enzymes that are capable of shedding a multitude of proteins 
from the cell surface. All proteases have a signal sequence, a pro-domain and a catalytic domain. 
The structure of ADAMs is closely related to the family of snake venom metalloproteases, which 
are responsible for the hemorrhage effects and massive tissue necrosis seen after snake bites. 
SVMP are soluble proteins in contrast to ADAMs since they have no transmembrane and cyto-
plasmic domain [113]. ADAMs have also a similar domain structure as the matrix metalloproteases 
with two distinct differences. They do not contain the characteristic hemopexin-like domain but 
instead have three additional domains, the cysteine-rich domain, the Epidermal Growth Factor 
(EGF)-like repeat domain and the disintegrin domain [114]. Other subclasses of MMPs have an 
additional fibronectin type II-like sequence. ADAM-TSs are all secreted, extracellular enzymes 
that have diverse roles in tissue morphogenesis and pathophysiological remodeling, in inflam-
mation and vascular biology [115]. Like ADAMs, all ADAM-TS enzymes share a signal peptide, a 
prodomain, a catalytic domain, a disintegrin-like domain and possess further a central throm-
bospondin (TS) repeat, a cysteine-rich- and a spacer domain.
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FIGURE 8: Schematic representation of the domain structure of metzincin proteases, modified after [116].
As mentioned in 1.6 (Atherosclerosis Loci in mice), several quantitative trait loci (QTL) for athero- 
sclerosis were identified in different mouse crosses. A QTL mapping in atherosclerosis-resistant 
FVB and atherosclerosis-susceptible C57BL/6 (B6) mice on the Ldl-receptor deficient (Ldlr -/-) 
background [104] led to the identification of a novel atherosclerosis locus on chromosome 12 
and subsequently to the identification of metalloproteinase a disintegrin and metalloprotease 17 
(Adam17) as a candidate gene of atherosclerosis [105]. 
ADAM17 belongs to one of 34 members of the ADAM family that have been described so far in a 
variety of species [117]. ADAM proteins are structurally similar but only few of them are proteo- 
lytically active [118]. ADAM17 is a type I transmembrane protein [119] and it was first identified as 
an enzyme that convertes membrane-bound tumor necrosis factor (TNF)-α precursor to a soluble 
form [120]. It is a multi-domain protein starting with a signal sequence (1-17 aa), followed by 
a prodomain (18-214 aa), a metalloproteinase or catalytic domain (215-473 aa) with the typical 
HEXXHXXGXXH sequence, a disintegrin domain (474-572 aa), a cysteine-rich domain (603-671 aa), 
followed by a transmembrane domain (672-694 aa) and a intracellular tail (695-824 aa). ADAM17 
has very little sequence similarities with other ADAMs; its closest relative is ADAM10 [121].
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FIGURE 9: ADAM17 domains and structure, modified after [122].
The enzymatic activity of ADAM17 is inhibited through its prodomain during translation [123]. 
The prodomain of ADAM17 is cleaved by furin, a proprotein convertase, in the trans-Golgi at the 
last 4 amino acids (RVKR) before the catalytic domain [124]. Latest reports show that iRhom2, 
a proteolytically inactive member of the rhomboid family, binds ADAM17 and promotes its 
exits from the endoplasmic reticulum [125]. The catalytic (metalloproteinase) domain of ADAM17 
contains the Zn2+ chelating sequence HEXXHXXGXXH (X being any amino acid residue) and is 
responsible for shedding membrane-bound proteins. ADAM17 substrates such as adhesion 
molecules VCAM1, ICAM1, L-selectin and JAM-A as well as cytokines and receptors TNFα, TNFR1, 
TNFR2, IL-6R and CX3CL1 play an important role in cell-cell adhesion, intra- and extracellular 
signaling, inflammation and cell proliferation [121, 122, 126]. So far, 76 ADAM17 substrates were 
identified. Table 3 gives an overview of some of the most important ADAM17 substrates.
TABLE 3: Substrates of ADAM17 [122].
Cytokines, Growth factors Receptors Adhesion molecules
TNFα SEMAD4D TNFR1 SORT1 ICAM1
TGFα LAG-3 TNFR2 Notch1 VCAM1
AREG DLL1 IL-6R LOX-1 NCAM
HB-EGF MICA IL1-R2 ErbB4 ALCAM
EPGN MICB NTRK1 TNFRSF5 EpCAM
Fractalkine/CX3CL1 LTA CSF1R TNFRSF8 CD62L
CSF-1 FLT-3L SORL1 VEGFR2 JAM-A
Jagged TMEFF2 EPCR IGF2-R CD44
Other molecules
MUC-1 CAS9 PRNP LYPD3 CD163
APP GP KL VASN PMEL17
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The disintegrin domain of ADAM17 can, in some cases, interact with integrins to influence cell 
adhesion and cell-cell interactions [127]. Furthermore, the disintegrin and the EGF-like domains 
are thought to be involved in substrate recognition and dimerization [128]. Furthermore, ADAM17 
is acting as a sheddase for epidermal growth factor ligands [129]. In line with this, ADAM17 
has been established in the pathogenesis of several types of inflammatory diseases, such as 
rheumatoid arthritis, inflammatory bowel disease, psoriasis and pulmonary inflammation [121]. 
Since inflammatory components play a crucial role in the pathogenesis of atherosclerosis [33], 
these findings support the hypothesis that ADAM17 might be involved in this frequent disease [130].
Studies of ADAM17 in mice have been hampered by the fact that Adam17 knockout mice 
(Adam17ΔZn/ΔZn) are not viable. These animals die within several hours after birth and show severe 
epithelial abnormalities [131]. Only recently, hypomorphic Adam17 mice (Adam17 ex/ex) have been 
generated, which are partially deficient for Adam17 and have barely detectable levels of Adam17 
in all tissues [132]. Until now, conditional knockout mice with Adam17-deletions in myeloid cells 
[133], in thymic epithelial cells [134], in osteochondroprogenitor cells [135], leucocytes [136] and 
endothelial cells [137, 138] were used to study inflammation (rheumatoid arthritis) and cancer. 
A mouse model overexpressing Adam17 showed no enhanced shedding activity in vivo despite 
higher Adam17 mRNA and protein expression [139]. To date, none of these mouse models was 
used to study the effect of ADAM17 on atherosclerosis [130].
1.9 Goal of this thesis
Atherosclerotic cardiovascular disease has a strong heritable component. Over the last decade, 
several atherosclerosis susceptibility loci were identified across the entire mouse genome 
through quantitative trait locus mapping in different crosses from atherosclerosis-susceptible 
and atherosclerosis resistant mice. About 50 % of the risk for developing atherosclerosis is 
genetically determined, but only a fraction of this percentage genetically annotated. Thus, the 
identification of novel candidate genes for atherosclerosis susceptibility remains important. 
Through quantitative trait locus (QTL) mapping in atherosclerosis-susceptible C57BL/6 (B6) and 
atherosclerosis-resistant FVB mice on the Ldl-receptor-deficient background (Ldlr -/-), two novel 
atherosclerosis susceptibility loci were identified [104], an atherosclerosis locus on chromo-
some 3 and a separate risk locus on chromosome 12. It was the goal of this thesis was to identify 
and characterize the underlying effector genes at these loci.
This PhD thesis is divided in three major projects with the following aims:
1. Chromosome 3 atherosclerosis locus:
The identified chromosome 3 atherosclerosis locus was gender-dependent and only presented 
in the female F2 generation in crosses of atherosclerosis-susceptible C57BL/6 (B6) and athero- 
sclerosis-resistant FVB mice. Interestingly, risk differed depending on whether risk alleles were 
transmitted from grandfathers or from grandmothers suggesting that more than one single 
molecular mechanisms or several distinct subloci might underlie this locus. The aim was to 
identify the genes affecting risk through this locus by establishing a congenic mouse model 
and to unravel their potential molecular role in atherogenesis by investigating their function in 
pathophysiologically relevant vascular cells in cell culture models.
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2. Chromosome 12 atherosclerosis locus:
On the atherosclerosis locus on mouse chromosome 12, the Adam17 gene had been previously 
identified as the candidate gene underlying this atherosclerosis locus [105]. This study had 
revealed that an allele that led to higher Adam17 mRNA expression associated with reduced 
susceptibility to atherosclerosis, indicating an unexpected antiatherogenic role of ADAM17, but 
leaving open the mode of ADAM17’s molecular action in atheroprotection [105]. Since mice with 
complete Adam17-deficiency are not viable, it was the aim of the current study to study Adam17 
function in adult mice in situ taking advantage of the fact that hypomorphic Adam17 mutants, 
with strongly reduced Adam17 mRNA and protein expression, survive (Adam17 ex/ex) [132]. For this, 
Adam17 hypomorphic mice should be crossed onto the low-density lipoprotein receptor (Ldlr)- 
deficient background to be able to induce atherosclerosis and to histologically test for the 
function of Adam17. Finally, the role of ADAM17 should be investigated related to cellular functions 
known to be involved in the etiology of atherogenesis, like apoptosis, proliferation, and adhesion 
in atherosclerosis-relevant cell lines of macrophages, vascular smooth muscle cells and endo- 
thelial cells. 
3. Chromosome 12 atherosclerosis locus (elastic stability):
Adam17 has also been studied in other vascular diseases, such as aneurysms. Its role therein 
remained controversial, with one study reporting reduced ADAM17 expression in aneurysms [140], 
and other studies showing a positive correlation between expression and aneurysm risk or 
occurrence [141-143]. The aim of project 3 was to specifically address whether and how Adam17 
functionally regulated aneurysm onset by taking advantage of the Adam17 hypomorphic mouse 
model established in project 2. In aneurysms the integrity of the arterial wall is compromised 
by inflammatory processes and other extracellular matrix (ECM)-degrading factors, impairing 
elastin lamellae that support and transmit mechanical load to the cellular cytoskeleton [144, 145]. 
Therefore we wanted to quantify whether ADAM17 affected arterial wall elasticity and ECM 
properties in different arteries [146].
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2.1 Mouse models
2.1.1 Generation of F2 intercross-mice linkage analysis (C57BL/6-FVB)
This PhD thesis is based on the F2 intercross from atherosclerosis-susceptible C57BL/6 (B6) 
and atherosclerosis resistant FVB mice on the Ldl receptor-deficient background generated by 
Prof. Teupser in the year 2006 [104]. B6 mice on the Ldlr -/- background were obtained from The 
Jackson Laboratory (B6.129S7-Ldlrtm1HerJ, stock no.002207, henceforth called B6.Ldlr -/-). FVB mice 
on the Ldlr -/- background (henceforth called FVB.LDLR -/-) were generated in the laboratory [99]. 
Mice of the F1 and F2 generation were generated in two ways: In cross A “mB6xfFVB,” male B6.Ldlr -/- 
mice were crossed to female FVB.Ldlr -/- mice and the resulting F1 generation, was intercrossed 
by brother-sister mating to generate 107 female and 112 male F2 mice. In cross B “mFVBxfB6,” 
male FVB.Ldlr -/- mice were crossed to female B6.Ldlr -/- mice and the resulting F1 generation was 
intercrossed to generate 120 female and 120 male F2 mice [104]. Working material of all 459 mice 
from this intercross was at our disposal for further experiments.
2.1.2 Genetic analysis of the F2 generation
By cross-breeding the inbred parental strains B6 and FVB, a heterozygous F1 generation is 
formed. Mating heterozygous F1 mice by brother-sister, an F2 generation is formed with a genetic 
recombination. During recombination, pieces of DNA are broken and recombined to produce new 
combinations of alleles. This recombination process creates genetic diversity at the level of genes 
that reflects differences in the DNA sequences of different organisms [147]. A complete genome 
scan with genetic markers from each of the 459 animals of the F2 generation is available. Genetic 
recombination in the F2 generation was assessed with 192 microsatellite markers. Genomic DNA 
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was isolated from mouse tissues (liver, tail) by digestion with proteinase K and precipitation with 
ethanol. Genotyping was performed with microsatellite markers with known polymorphisms 
between B6 and FVB mice. The genome scan was first performed with 154 markers in approximately 
10 cM intervals and with an additional set of 54 markers to allow a finer mapping, or to repeat 
marker, where the analysis was unclear [104].
2.1.3 Generation of chromosome 3 congenic mice
Congenic strains are produced by transferring a mutation from one genetic background to a 
specific inbred strain through repeated backcrossing. Congenic mice are strains of mice that 
differ only in restricted regions of the genome. They are generated by mating two inbred strains 
and backcrossing the descendants 5-10 generations with one of the original strains, known as 
recipient strain. 
Chromosome 3 congenic mice were generated by crossing B6 and FVB mice and backcrossing 
the resulting heterozygous Chr3FVB/B6 F1 mice onto the FVB.Ldlr -/- background for 10 generations. 
Heterozygous FVB.Chr3FVB/B6 (carrying an interval from megabases [Mb] 80 to 160 from Chr3 of B6 
mice in an otherwise FVB background) were intercrossed to generate FVB.Chr3B6/B6, FVB.Chr3FVB/B6 
and wild-type FVB.Chr3FVB/FVB control mice [148]. To allow identification of the respective congenic 
and subcongenic mice SNP assays were designed across the chromosome 3 interval from 80 to 
160 Mb. All SNPs used for the genotyping are listed in Table 30 of the appendix.
2.1.4 Generation of hypomorphic Adam17 ex/ex.Ldlr -/- mice
Hypomorphic Adam17 ex/ex mice were obtained from the laboratory of Prof. Rose-John from the 
Institute of Biochemistry, University of Kiel [132]. Chalaris et al. developed a novel strategy to 
generate mice with barely detectable levels of ADAM17 in all tissues. The strategy is based on the 
generation of a new exon within the Adam17 gene, which starts with an in-frame translational 
stop codon and which was flanked by splice donor/acceptor sites, which slightly deviated from 
the canonical consensus sequence. Homozygous mice used the new exon for about 95 % of the 
Adam17 mRNAs, resulting in a dramatic loss of ADAM17 protein in all cell types. The hypomorphic 
Adam17 ex/ex mice on the C57BL/6 (B6) background were backcrossed onto the Ldl receptor deficient 
background with C57BL/6 LDLR -/- mice for 6 generations and B6.Ldlr -/-Adam17 wt/wt (Adam17 wt/wt.Ldlr -/-), 
B6.Ldlr -/-Adam17 wt/ex (Adam17 wt/ex.Ldlr -/-) and B6.Ldlr -/-Adam17 ex/ex (Adam17 ex/ex.Ldlr -/-) mice were 
generated for further atherosclerosis studies.
  33 / 154
Material and Methods
2.1.5 Atherosclerotic studies in mice
In all atherosclerosis studies, mice were weaned at 28 days of age and fed a semisynthetic diet 
containing 0.02 % cholesterol until they were killed at 20 weeks of age [99]. Whole blood samples, 
plasma and tissues were collected from all mice. The aortic root and the brachiocephalic artery 
were embedded in mounting medium (OCT compound, Tissue-Tek) as described below.
FIGURE 10: Study design of atherosclerosis experiments.
2.2 Mouse section
2.2.1 Removal of organs and vessels
Mice were euthanized by intraperitoneal anesthesia using 0.2 ml Rompun + 0.6 ml Ketamine. 
Blood was collected from the right ventricle with 1 ml syringe containing EDTA and subsequently 
the mouse heart was rinsed with 10 ml PBS containing Heparin. 40 µl of the whole blood was 
used for determination of the blood parameters and the remaining blood was centrifuged by 
8000 rpm for 10 min to collect plasma. Tissues (liver, spleen, kidney, lung, gut, muscle, brain, 
parametrial/subcutaneous/perirenal fat) were collected from all mice and immediately put into 
liquid nitrogen and stored at -80 °C. Plasma supernatant was collected for clinical chemistry 
analyses and determination of lipoprotein subfractions. For atherosclerotic studies, the aortic 
root (AoR) and the brachiocephalic artery (BCA) were embedded in mounting medium (OCT com-
pound, Tissue-Tek) as described below. Bone marrow was isolated from both femurs and tibias 
using 10 ml heparinized PBS. The bone marrow was homogenized and the collected cell sus-
pension was drained through a cell strainer (40 µm, Nylon, BD) and centrifuged for 5 minutes at 
1000 rpm. The supernatant was discarded and the cell pellet was resuspended in 1.5 ml DMEM 
(10 % FCS, 1 % Pen-Strep) and split into 3 tubes à 500 μl. 400 μl fetal calf serum (FCS) and 100 μl 
Dimethyl Sulfoxide (DMSO) were added. After gradual freezing at -80 °C for 24h, cells were trans-
ferred into liquid nitrogen as cryopreservation for further studies.
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2.2.2 Laboratory analysis
Clinical chemistry parameters (alanine transaminase [ALT], aspartate transaminase [AST], 
cholinesterase [ChE], glutamate dehydrogenase [GLDH], Glucose, Urea, Cholesterol [Chol], 
Triglycerides [TG]) were measured on automated analyzers (Modular PPE, Roche). For determi-
nation of blood cell parameters (white blood cells) an automated hematology analyzer (Sysmex) 
was used. Lipoproteins were determined quantitative by sequential ultracentrifugation (Beckman 
Coulter, Optima LE-80K Ultracetrifuge, Rotor Ti42.2) from plasma at densities (d) < 1.006 g/ml 
(very low-density lipoprotein [VLDL]), 1.006 ≤ d ≤ 1.063 g/ml (intermediate-density lipoprotein 
[ILDL] and low-density lipoprotein [LDL]), and d > 1.063 g/ml (high-density lipoprotein [HDL]) [149]. 
60 µl mouse plasma were overlayed with 60 µl PBS in a Thickwall Cellulose Propionate Tube 
(7x20 mm) (Beckman Coulter) and centrifuged at 4 °C and 40,000 U/min for 3 hours. 60 µl of the 
lower and the upper phase were transfered to two separate ultracentrifuge tubes, respectively. 
60 µl potassium bromide (KBr) (d=1.12 g/ml) were added to the lower phase and centrifuged 
again for 18 hours at 4 °C and 40,000 U/min. 60 µl of the resulting fractions containing LDL (lower 
phase) and HDL (upper phase) were transferred to 1.5 ml Eppendorf tubes each. Subsequently, 
60 µl of the upper phase, obtained from the first centrifugation step, were mixed with the same 
volume of PBS and centrifuged for 18 hours at 4 °C and 40,000 U/min. The resulting lower phase 
contained LDL, whereas VLDL was received from the upper phase. Both fractions were transfered 
to 1.5 ml Eppendorf tubes as well. Enzymatic colorimetric assays (Roche) were used to determine 
the cholesterol (cholesterol oxidase-phenol-aminophenazone: CHOD-PAP [150]) and triglyceride 
(glycerol phosphate oxidase-p-aminophenazone: GPO-PAP) concentration in the lipoprotein 
fractions (LDL, HDL, VLDL). The measurement was performed with a fluorescence and absorbance 
reader (SpectraMax Paradigm Multi-Mode Microplate Reader, Molecular Devices) at 500 nm.
2.3 Histological, histochemical and immunohistochemical methods
2.3.1 Quantitative analysis of atherosclerotic lesions
Atherosclerosis was quantified at the aortic root and the brachiocephalic artery (BCA) as described 
by [99, 151]. All cryosections were performed with the cryostat LEICA CM1850 from Leica Bio- 
systems.
2.3.1.1	 Brachiocephalic artery (BCA) section
For quantification of atherosclerosis in the OCT-compound-embedded brachiocephalic artery 
(BCA), transverse cryosections of 10 µm were prepared in a proximal direction from the bifurcation 
with the right common carotid artery and right subclavian artery to the aortic arch. Two sections 
were prepared per slide. At a distance of 200, 400, and 600 µm (Figure 11) proximal from the bifur- 
cation of the BCA the sections (1A, 2A, 3A) were mounted on glass slides and used for oil red O 
staining and subsequent lesion quantification. The remaining sections (B, C, D) were cryopre-
served and used for immunohistochemical stainings.
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FIGURE 11: Scheme for the preparation of cryosections of the BCA for atherosclerotic and immunohisto-
chemical studies [99].
2.3.1.2	 Aortic root (AoR) preparation
Determination of atherosclerotic lesions at the aortic root was performed according to a method 
described by Paigen et al. [151, 152]. Embedded hearts were cut parallel to the valvular level at 
10 µm thickness. Preparation of cryosections of the aortic root started when two out of three 
aortic valves were completely visible, until no aortic valves were observable. 2 sections were 
preserved per slide (Figure 12).
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FIGURE 12: Scheme for preparation of cryosections of the aortic root (modified from Healthwise, Incoporated 
[https://myhealth.alberta.ca]).
All (a) sections were used for oil-red O staining while (b) and (c) sections were used for immuno- 
histochemical stainings. All cryosections were stored at -80 °C for further usage.
2.3.1.3	 Oil red O staining (atherosclerosis staining)
Quantitative and qualitative analysis of the aortic roots and the brachiocephalic arteries was 
performed using oil red O (Sigma-Aldrich) for staining neutral triglycerides and lipids, Light 
Green SF yellowish (Merck) for collagen and Haematoxylin (Sigma-Aldrich) for cell nuclei. Before 
staining, the cryosections were fixed in formalin solution overnight at 4 °C. The staining was 
performed with an automatic slide stainer (Bavimed).
TABLE 4: Protocol used for oil red O staining:
Solution Time
H2O 1´
H2O 1´
60 % Isopropanol 30´´
oil red O 0.24 % 10´
60 % Isopropanol 2´´
H2O 1´
H2O 1´
Haematoxylin Solution 2´
Bluing Solution 1´
H2O 1´
Light Green 0.25 % 30´´
H2O
Upon oil red oil staining, all sections were mounted with warmed (55 °C) glycerol gelatine (Sigma- 
Aldrich) and coverslips (VWR).
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2.3.1.4	 Quantification of atherosclerotic lesions
The quantification of atherosclerotic lesions was performed on oil red O-stained sections using 
a Leitz DMRD fluorescent phase contrast microscope and the Leica Application Suite 4.4 (LAS) 
software (Leica). All (a) sections of the BCA (5 x magnification) and the aortic root (5 x magnification) 
were imaged and lesions were manually quantified with the LAS software (Leica). Only intraluminal 
lesions were quantified. Atherosclerotic lesions at the BCA were determined as mean value of 
lesion quantification of the 1 A, 2 A, and 3 A sections. At the aortic root, atherosclerotic lesions 
were determined as mean value of five sequenced (a)-sections. Aortic root quantification started 
when 2 of the 3 aortic valves leaflets were no longer visible and then counted back the last five 
sections (8a-4a or 10a-6a) [153].
2.3.2 Immunohistochemical staining
Immunohistochemical staining of serial sections (10 µm) of the aortic root and the brachioce-
phalic artery was performed using primary antibodies. Frozen sections were fixed in ice-cold 
methanol-acetone (1 : 1) solution for 10 min, dried at room temperature for 5 min and washed 
3 times with PBS. Peroxidases were quenched with 3 % H2O2 for 3 min at RT. Sections were washed 
and blocked with 2.5 % normal horse (Vector Laboratories) or goat serum for 30 min. The primary 
antibodies were incubated overnight at 4 °C and then washed with Tween PBS (0.125 % Tween20) 
and incubated with horseradish peroxidase (HRP-) conjugated secondary antibody for 30 min. 
After washing, peroxidase was visualized by incubating with Nova Red (Vector Laboratories) and 
counterstained with hematoxylin. Sections were dried and permanently mounted with Vecta-
Mount mounting medium (Vector Laboratories) and photographed with a Leitz DMRD fluorescent 
phase contrast microscope (Leica). All antibodies and their dilutions used for the immunohisto-
chemical stainings are presented in Table 28 of the appendix.
2.3.3 Immunofluorescence staining
Immunofluorescence stainings of PLA2G12A (sc-1043029, Santa Cruz Biotechnology) and ADAM17 
(ab39163) and co-staining with CD68 positive macrophages (MCA1957, Serotec), Mac2 positive 
macrophages (CL8942AP, Cedarlane), α-SMA-positive smooth muscle cells (ab5694; Abcam), von 
Willebrand Factor (vWF) positive endothelial cells (ab11713, Abcam) and Ki67 proliferating cells 
(ab15580) was performed on serial cryosections (10 µm) of the aortic root. Cryosections were 
dried at 50 °C for 10 min and subsequently fixed with 4 % PFA for 15 min. After repeated washing 
with PBS and PBST (PBS, 0.2 % Triton X-100) cryosections were blocked with 5 % donkey normal 
serum (X0907, Dako) for 1 h. Samples were incubated with first antibodies overnight at 4 °C in 
a humidified chamber and afterwards with fluorescently labeled secondary antibodies (Alexa 
Fluor 594 Donkey anti Rabbit F(ab´)2, Dianova; Alexa Fluor 488 Donkey anti Sheep F(ab´)2, Dianova; 
Alexa Fluor 488 Donkey anti Rat F(ab´)2, Dianova; Alexa Fluor 488 Donkey anti Goat F(ab´)2, Dianova) 
for 1 h. After washing in PBS, sections were mounted in Fluorescence Mounting Medium (Dako) 
and photographed with a Leitz DMRD microscope (Leica). Immunostaining results for Ki67, a-SMA 
and Mac-2 were analyzed by counting the number of Ki67+, a-SMA+ and Mac-2+ in the lesions, 
relative to the number of DAPI-stained nuclei and are expressed as the percentage of the total 
number of lesional cells [130].
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2.3.4 TUNEL staining
TUNEL staining for apoptosis detection of serial cryosections (10 µm) of the aortic root was per-
formed using the DeadEnd™ Fluorometric TUNEL System from Promega. Sections were washed 
by immersion in 0.9 % NaCl and PBS for 5 min, respectively. Subsequently, sections were fixed 
in 4 % PFA for 15 min and washed twice with PBS for 5 min. Permeabilization was performed by 
adding 20 µg/ml Proteinase K solution and incubation for 10 min at RT. Sections were washed in 
PBS and fixed with 4 % PFA. After washing with PBS the sections were incubated for 10 min with 
equilibration buffer. Labelling of the fragmented DNA of apoptotic cells was accomplished by 
adding the Terminal Deoxynucleotidyl Transferase (TdT) mix for 1h at 37 °C in a humidified chamber. 
The reaction was stopped by immersion in 2xSCC solution for 15 min. After repeated washing 
in PBS sections were mounted in VECTASHIELD Antifade Mounting Medium with DAPI (Vector 
Laboratories) for staining nuclei. Sections were analyzed by fluorescence microscopy, detecting 
green fluorescence of apoptotic tissue (520 ± 20 nm) and DAPI stained nuclei in blue (460 nm). To 
analyze TUNEL staining, the number of TUNEL+ cells in the lesions was counted, relative to the 
number of DAPI-stained nuclei and plague area [130].
2.3.5 Collagen and elastin-fiber staining
Arterial extracellular matrix (ECM) properties were determined by assessing elastic fibers with 
Verhoeff-Van Gieson staining and by quantifying total collagen fiber content by PicroSirius Red 
imaging using polarized light. 
To study the collagen properties of brachiocephalic arteries (BCA) of wild-type Adam17 wt/wt.Ldlr -/- 
and homozygous Adam17 ex/ex.Ldlr -/- mice, cryosections of 10 µm were stained by PicroSirius Red 
(1.2 % Sirius Red F3 [w/v] [CI 35780, Direct Red, Sigma Aldrich] in saturated picric acid [0.5 % 
acetic acid]) for 1 h. Cryosections were washed twice with acidified water, dehydrated in three 
changes of 100 % ethanol and mounted with DPX Mounting medium (Sigma-Aldrich). Images 
were shot using polarization microscope (Axio Imager.M2, Carl Zeiss Microimaging GmbH, Jena, 
Germany) and converted to greyscale images. The collagen density was analyzed using the imaging 
software KS400 (AxioVision KS400, Zeiss). 
Staining of elastic fibers was performed by Verhoeff-Van Gieson method. Cryosections were 
hydrated to distilled water and stained in Verhoeff’s solution (5 % alcoholic hematoxylin, 10 % 
ferric chloride, Weigert’s iodine solution) for 1 hour. The slides were rinsed in tap water for 
3 times and differentiated in 2 % ferric chloride for 2 minutes. The differentiation was stopped 
with several changes of tap water and subsequently treated with 5 % sodium thiosulfate for 
1 minute. The slides were washed in running tap water for 5 minutes and counterstained in Van 
Gieson’s solution for 5 minutes. The slides were dehydrated through 95 % Ethanol and 2 changes 
of 100 % Ethanol, cleared in 2 changes of xylene for 3  minutes each and mounted with DPX 
Mounting medium (Sigma-Aldrich). To quantify the fiber length, we determined the length of 
individual elastic fibers within sub-segments of identical length (20 µm).
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2.3.6 Labelling of cell surface proteins by biotin
Cell-membrane proteins of BMDM of mice were labeled using the EZ-Link Sulfo-NHS-SS-Biotin 
(1 mg/ml in PBS) from Thermo Scientific. EZ-Link Sulfo-NHS-SS-Biotin is a water-soluble, NHS-ester 
biotinylation reagent with a spacer arm which includes a cleavable disulfide bond for reversible 
labeling of proteins. It is a negatively charged reagent that does not permeate cell membranes. 
Cells were incubated with the labeling reagent at 4 °C under gentle agitation for 30 min. The 
biotin solution was removed by decanting and cells were washed three times with ice-cold 
PBS. The cells were incubated with 50 mM glycine in PBS solution for 15 min at 4 °C with gentle 
rocking to block unbound biotin. After repeated washing with PBS, the cells were scraped with 
RIPA lysis buffer (50 mM Tris pH8, 150 mM NaCl, 1 % Igepal CA-630, 1 % sodium deoxycholate, 0.1 % 
SDS) supplemented with cOmplete™ Protease Inhibitor Cocktail (Roche); 0.1 mM phenymethyl- 
sulfonylfluorid (PMSF); 20 µM metalloproteinase inhibitor BB-2519 (Tocris Bioscience); 10 mM 
1,10-phenathroline (Sigma-Aldrich) and 1 mM sodium orthovanadate (NEB). Cells were incubated 
for 1 hour on ice to swell and homogenized with 25 strokes in a loose-fitting Dounce homoge-
nizer. The whole cell lysate was incubated with Dynabeads MyOne Streptavidin C1 Beads (Invi- 
trogen) overnight at 4 °C to bind the biotin-labeled membrane proteins. The beads were washed 
three times with PBS buffer and eluted with 1x Laemmli buffer (2 % SDS; 10 % glycerol; 62.5 mM 
Tris-HCl pH 6.8; 5 % β-mercaptoethanol; 50 mM DTT; bromophenol blue) [130].
2.4 Cell culture
2.4.1 Cultivation of cells
Cell culture experiments were performed in murine RAW264.7 macrophages, vascular smooth 
muscle cells MOVAS, mouse cardiac endothelial cells (MCEC) cells and bone marrow-derived 
macrophages (BMDM). RAW264.7 cells are a macrophage-like cell line derived from Balb/c mice. 
RAW264.7 cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies) 
with 10 % fetal bovine serum (FBS, Millipore) and 1 % penicillin/streptomycin (Pen/Strep, Gibco- 
Life Technologies) as additive. MOVAS (immortalized with SV40 large T antigen smooth muscle 
cells derived from a C57/BL/6 mouse) were purchased from ATCC (CRL-2797) and cultivated in 
DMEM (Cat.# 30-2002, ATCC) medium with 10 % FCS and 0.2 mg/ml G-418. Mouse cardiac endothe-
lial cells (MCEC) were purchased from Cedarlane (Cat.# CLU510) and cultivated in DMEM (D5796, 
Sigma Aldrich) medium with 10 mM penicillin/streptomycin, 10 mmol/L HEPES (Gibco) and 
5 % FCS. L929 mouse fibroblasts were cultivated to obtain cell culture supernatant (= L-cell- 
conditioned medium), containing the macrophage colony-stimulating factor (M-CSF) as an im-
portant growth factor for bone marrow cells [154]. Fibroblasts were incubated with DMEM, 10 % 
FCS and 1 % Pen/Strep for 48h; the supernatant (L-cell-conditioned medium) was separated, 
filtered and stored at -80 °C thereafter. 
Cryo-preserved bone marrow cells were thawed and differentiated into macrophages (BMDM) in 
the presence of L-cell-conditioned medium for 14 days. BMDM were cultivated in DMEM with the 
presence of 20 % L-cell-conditioned medium, 10 % FCS, 1 % Pen/Strep and 1 % Partricin as anti-
mycotic. For functional studies, BMDM were incubated with 100 nmol/L Phorbol-12-myristate-
13-acetate (PMA, Sigma Aldrich) for 1 h. All cell types were cultured at 37 °C and 5 % CO2 (Binder 
incubator).
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2.4.2 Cell culture functional assays
Cell proliferation, apoptosis and adhesion are all cellular processes which are key regulators in 
the development of atherogenesis [1]. 
Cell proliferation was performed in a 96- or 384-well plate with a clear bottom using quadru-
plicates and was determined by CellTiter-Glo® Luminescent Cell Viability Assay (Promega). The 
assay is a homogeneous method to determine the number of viable cells based on quantitation 
of the ATP present, which signals the presence of metabolically active cells (Promega). Upon 
cell seeding, the single reagent (CellTiter-Glo® Reagent) is given directly to the cultured cells, 
incubated for 10 minutes and subsequently the luminescence is measured. 
Cell apoptosis was performed in a 96-well white flat bottom plate using quadruplicates. 
Apoptosis was induced for 24 hours with cycloheximide (CHX, Sigma Aldrich), an inhibitor of protein 
biosynthesis, in concentrations of 10 µg/ml and 50 µg/ml and staurosporine (Merck-Millipore), a 
protein kinase inhibitor that prevents ATP of binding to the kinase, in concentrations of 0.125 mM 
and 0.25 mM. The Caspase-Glo® 3/7 Assay (Promega) is a luminescent assay that measures 
caspase-3 and -7 activities in cultured cells. The reagent is optimized for caspase activity, luciferase 
activity and cell lysis. Adding the single Caspase-Glo® 3/7 reagent to the cells results in cell lysis, 
followed by caspase cleavage of the substrate and generation of a luminescent signal. After 
1 hour of incubation, protected from light, the luminescence was measured. 
Cell adhesion experiments of RAW264.7 macrophages were performed in a 96-well white flat 
bottom plate using quadruplicates. Initially, the 96-well plate was coated with matrigel and 
collagen in different dilutions to allow cells to adhere. Treated cells were given to the precoated 
wells and left 1 hour to allow adhesion. Subsequently, the 96-wells were washed and the number 
of adherent cells was determined using the CellTiter-Blue® Cell Viability Assay (Promega) in 
relation to standard curves of the respective cell line. The CellTiter-Blue® assay is a fluorometric 
method for estimating the number of viable cells present in multiwell plates. It is based on the 
ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin). 
Viable cells retain the ability to reduce resazurin into resorufin. For quantifying adhesion of 
bone marrow-derived BMDMs to endothelial cells, two different experimental setups were 
investigated: first, siRNA-treated ECs were preplated on uncoated 96-well plates at 28,000 cells 
per well 24 hours before the adhesion experiments. BMDMs were seeded on top of preplated 
MCECs, incubated for 45 min, washed twice with cell culture medium and BMDMs’ adhesion was 
measured with an IncuCyte Live Cell Analysis System (Essen Bioscience). The IncuCyte Live Cell 
Analysis System allows quantitative live cell imaging and analysis while cells remain within the 
controlled environment of a standard cell incubator. Adhesion is determined by quantifying 
the number of macrophages attached on endothelial cells using phase contrast imaging to 
differentiate between the respective cell types. Quadruplicate measurements per condition were 
performed. Independently, BMDM were treated with siRNA for 24 hours and subsequently were 
allowed to adhere to non-treated preplated ECs. Adherent cells were quantified as described 
above. Cell adhesion assays of RAW264.7 macrophages were performed in 96-well plates coated 
with Matrigel (BD Biosciences) or on uncoated dishes. Cells were allowed to adhere for 40 min in 
both conditions. Numbers of adherent cells were determined in relation to standard curves using 
CellTiter-Glo (Promega). All fluorescence and luminescence measurements were performed with 
the SpectraMax Paradigm Multi-Mode Microplate Reader from Molecular Devices [130, 148].
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2.4.3 RNAi (small interfering RNA)
Small interfering RNA (siRNA) consist of approximately 20 (deoxy)ribonucleotides or chemically 
modified analogs. siRNAs are applied to suppress gene expression in a specific manner [155, 156]. 
Once the oligonucleotide crosses the cell membrane, it has the ability to bind with high affinity 
to the target messenger RNA sequence through Watson-Crick base pairing and therefore blocks 
the protein translation process. siRNA knock-down was performed in murine RAW 264.7 cells, 
MOVAS, MCEC and Bone Marrow-Derived Macrophages (BMDM) using Lipofectamine2000 (Cat. 
# 11668030, Life Technologies) and the Amaxa Nucleofector Technology (4D-Nucleofector System, 
Lonza). Lipofectamine is a cationic liposome formulation that forms complexes with negatively 
charged nucleic acid. These complexes are then taken up by the cell through endocytosis and 
then released in the cytoplasm (Thermo Fisher Scientific). The Amaxa Nucleofector is basically 
a electroporation, where cell membranes are made permeable exposing them to short pulses 
of an intense electric field. For the BMDMs we used the P2 Primary Cell 4D-Nucleofector X Kit L 
(Catalog # V4XP-2024), for the MCECs the P5 Primary Cell 4D-Nucleofector X Kit L (Catalog # V4XP-
5024) and for the RAW264.7 macrophages the SF Cell Line 4D-Nucleofector X Kit L (Catalog # V4XC-
2024). Knock-down efficiency was determined by quantitative RT-PCR after 48 h of incubation. 
siRNAs used for transfection studies are listed below in Table 5.
TABLE 5: siRNAs used for transfection studies.
siRNA Product No. Supplier
Adam17 SASI_Mm01_00083937 Sigma Aldrich
Tnfr2 SASI_Mm01_00134452 Sigma Aldrich
Pla2g12a Cat# s83067 Ambion
Gapdh Cat#: 4390849 Ambion
SCR Cat#: 4390843 Ambion
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2.5 Molecular biological methods
2.5.1 RNA isolation
RNA isolation from cells and tissues was performed with the monophasic phenol and guanidine 
isothiocyanate solution (TRIzol, Life Technologies) according to the manufacturer’s protocol. 
Mouse tissue (50 mg) homogenization was performed in a Precellys24 homogenizer (PeqLab) using 
CK24 ceramic beads and 900 µl TRIzol. Subsequently, 600 µl TRIzol was added to the homogenized 
tissue, which was incubated for 5 min at room temperature (RT). The mixture was centrifuged at 
4 °C and 12,000 g for 10 min and the supernatant was transfered to a new Eppendorf tube. After 
300 µl chloroform was added, shaken (15 s) and incubated for 2 min at RT, the tube was centrifuged 
for 20 min at 4 °C. The upper aqueous phase was taken over, mixed with 750 µl isopropanol and 
precipitated for 10 min at RT, followed by a centrifugation step (10 min, 12,000 g, 4 °C) to pellet the 
RNA. The RNA pellet was washed twice with 1 ml 75 % ethanol, dried and finally dissolved in Diethyl- 
pyrocarbonate (DEPC) water (55 °C, 10 min). RNA was stored at -80 °C. RNA isolation from RAW267.4 
cells, MOVAS smooth muscle cells, mouse cardiac endothelial cells (MCEC) and bone-marrow- 
derived macrophages was conducted by lysis of the respective cells with 750 µl TRIzol and addition 
of 150 µl chloroform. Precipitation was performed using 375 µl isopropanol. The following steps 
were performed as described before.
2.5.2 RNA isolation of the aortic arch (RNAqueous-Micro Kit)
For isolation of total RNA from the aortic arch of mice the RNAqueous®-Micro Kit (Life Technologies) 
was applied, which is made for micro-sized samples using a guanidinium-based lysis/denaturant 
and a glass fiber filter separation technology.
150 µl lysis buffer were given in 2 ml screw-cap tubes prefilled with ceramic beads and the aortic 
arch. The samples were homogenized with the Precellys24 homogenizer for 2 x 20 sec at 5,000 rpm. 
The lysate was mixed with 75 µl ethanol and centrifuged at RT at 15,000 g for 1 min. 150 µl of the 
mixture was applied to a silica-based filter that selectively binds RNA. The filter was washed 
with 180 µl Wash Solution 1 and twice with Wash Solution 2/3. The flow-through was discarded 
and the filter was centrifuged for 1 min at maximum speed. The RNA was eluted into a new micro 
elution tube with 20 µl preheated (75 °C) Elution Solution. To remove remaining genomic DNA the 
sample was subsequently treated with DNase I. 2 µl 10xDNase I Buffer and 1 µl DNase I were added 
to the sample and mixed gently. After incubation for 20 min at 37 °C, 2 µl of DNase Inactivation 
Reagent were added, mixed well and left at room temperature for 2 min. The reaction was centri-
fuged at maximum speed to pellet the DNase Inactivation Reagent and the RNA was transferred 
to a new RNase-free tube.
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2.5.3 Determination of concentration and purity of nucleic acids
Nucleic acids and proteins have absorbance maxima at 260 and 280 nm, respectively. To 
determine the purity and concentration of nucleic acids, we measured the absorbance with the 
NanoDrop System (Thermo Scientific). The absorbance ratio at these wavelengths has been used 
as a measure of purity in both nucleic acid and protein extractions. The ratio E260/E280 should be 
1.8 for DNA and 2.0 for RNA in 1 x TE buffer. Furthermore, the absorbance at 238 nm is accepted 
as being the result of other contamination. Therefore the ratio of A260/A230 was also calculated. 
The ratio E260/E230 for “pure” nucleic acid is commonly in the range of 2.0-2.2.
2.5.4 Complementary DNA (cDNA) synthesis by reverse transcription (RT)
Reverse transcription (RT reaction) is a process in which single-stranded RNA is reverse tran-
scribed into a stable complementary DNA (cDNA) for PCR amplification. RNA from mouse tissue, 
RAW264.7 cells, MCECs, MOVAS and bone marrow-derived macrophages was reversed transcribed 
into cDNA using Superscript II reverse transcriptase (Invitrogen) and random hexamer primers. 
100 ng-2 μg dissolved RNA was diluted with DEPC-H2O to a final volume of 10 μl. 1 µl random 
hexamer primers (500 µg/ml, Roche) was added and incubated for 10 min at 68 °C, followed by 
the addition of 9 µl master mix and the incubation for 60 minutes at 42 °C. 
TABLE 6: Master mix composition for the reverse transcription.
1 μl Recombinant RNAsin Ribonuclease (10,000 U, Promega)
1 μl dNTPs (10 mM, Invitrogen)
2 μl DTT (0.1 M, Invitrogen)
4 μl 5 x First Strand Buffer (FSB, Invitrogen)
1 μl Superscript II Reverse Transcriptase (200 U/μl, Invitrogen)
The samples were diluted with 1xTE buffer at a ratio of 1 : 15. Aortic arches were diluted at a ratio 
of 1 : 5. cDNA samples were stored at -20 °C until further use. 
2.5.5 Whole genome mRNA expression analysis
Whole genome expression analysis was performed in liver RNA from congenic FVB.Chr3B6/B6 
(n = 4) and FVB (n = 4) mice, as well as in the aortic arch and bone marrow-derived macrophages 
(with and without PMA stimulation) from wild-type Adam17 wt/wt.Ldlr -/- (n = 4) and homozygous 
Adam17 ex/ex.Ldlr -/- (n = 4) mice. The total RNA was labeled and hybridized to Illumina Ref8V2 Bead-
Chips and imaged using the iScan System at the Interdisciplinary Center for Clinical Research 
Leipzig (PD Dr. Knut Krohn, Faculty of Medicine, University of Leipzig). Bead level data pre- 
processing was done in Illumina Genome Studio, the integrated data analysis software platform. 
Upstream regulator analysis was performed using transcripts with expression changes of < 0.7 
and > 1.3 using the Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com). 
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FIGURE 13: Whole genome expression analysis in mice.
2.5.6 Isolation of genomic DNA from mice
DNA from tails or ear tags of mice was isolated using lysis buffer (50 mM Tris, pH8; 100 mM 
EDTA; 100 mM NaCl; 1 % SDS), proteinase K and 100 % isopropanol for precipitation. A tail- or ear-
tag biopsy was incubated in a thermomixer at 55 °C overnight with 500 μl lysis buffer and 50 μl 
proteinase K (Roche, 10 mg/ml). After incubation, the samples were centrifuged at maximum 
speed for 10  minutes. The supernatant was transferred to a new tube and an equal volume 
of 100 % isopropanol was added. The solution was mixed by inversion several times and sub- 
sequently centrifuged at 10,000 xg for 10 minutes. The supernatant was carefully removed and 
the DNA pellet was washed with 500 µl of 70 % ice-cold ethanol. After centrifugation for 10 min at 
4 °C and maximum speed, EtOH was removed and the tubes were turned upside down to air-dry. 
The dried DNA pellets were dissolved to a concentration of 30-50 ng/µl with 0.1xTE (10 mM Tris, 
pH 8.0; 1 mM EDTA). DNA was stored at 4 °C until further analyses.
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2.5.7 Genotyping
Genotyping is used for the determination of differences in the DNA sequence of an individual 
compared to that of another individual or a reference sequence. Single nucleotide poly- 
morphisms (SNPs) have emerged as genetic markers of choice because of their high-density and 
relatively even distribution in the human genomes [157-159]. SNPs typically have three geno- 
types, denoted generically as homozygous for AA, heterozygous for Aa or homozygous for aa. 
Genotyping was performed in Adam17 hypomorphic mice and in chromosome 3 congenic mice 
via melting curve analysis as described below.
2.5.7.1	 Adam17 genoytping (hypomorphic Adam17 mice)
Genotyping of hypomorphic Adam17 mice was performed by polymerase chain reaction (PCR) as 
described by Chalaris et al. [132]. To construct a targeting vector for the Adam17 gene, Chalaris 
et. al inserted a loxP sequence followed by a noncanonical donor splice site downstream of a 
cryptic acceptor splice site within intron11. This manipulation generated a new exon between 
exons 11 and 12, which started with an in-frame translational stop codon. Whereas in wild-type 
animals only a band of 380 bp (wt/wt) was detected, heterozygous ADAM17 wt/ex mice showed an 
additional band of 550 bp (wt/ext) corresponding to the insertion of the new exon. Homozygous 
Adam17 mice showed only a band at 550 bp (ex/ex) (Agarose gel Figure 14). Adam17 genotyping was 
performed in a FlashGel™ System (LONZA) with the FlashGel™ DNA marker 50 bp - 1.5 kb (LONZA).
TABLE 7: Adam17 genotyping by PCR (Master mix and cycle parameter).
DNA Template 2.0 µl
AmpliTaq Gold 360 Mastermix 6.25 µl
360 GC Enhancer 1.25 µl
ADAM17_DNA_Fwd 0.625 µl
ADAM17_DNA_Rev 0.625 µl
Dest. H2O 1.75 µl
Total 12.5 µl
Cycle – Parameter:
95 °C 5´
95 °C 1´
 
 43 x52 °C 1´
72 °C 1´
72 °C 5´
4 °C ∞
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FIGURE 14: Agarose gel of Adam17 genotyping. 
2.5.7.2	 SNP genotyping via melting curve analysis (chromosome 3)
The chromosome 3 genotyping was performed using known single nucleotide polymorphisms 
(SNP) between the two parental strains B6 and FVB. To find known SNPs across the required 
interval (80-160 Mb) on chromosome 3 we used Phenome Jax (www.phenomejax.de), a mouse 
database, were SNPs of different mouse strains are listed. 
SNP genotyping was performed using melting curve analysis with a single dual-label probe, at 
the end of a classic PCR-reaction amplifying the DNA region in which the mutation of interest 
lies. In contrast to a standard qRT-PCR-protocol, the probe is not hydrolyzed through the 5´-exo- 
nuclease activity of the Taq-polymerase. To avoid hydrolysis of the probe during the PCR-reaction, 
the melting point of the probe was chosen 10 °C below the annealing temperature of the PCR 
primers. Melting curve analysis was performed by stepwise increase of the temperature and 
continuous detection of the fluorescence signal. The probe dissociates from the DNA with the 
mutated allele at a lower temperature than from the DNA with the homozygote wild-type allele 
(Figure 14). The here described method is based on the decrease of the FRET (Förster resonance 
energy transfer) phenomenon, when the probe is released from the target sequence and achieves 
a random single-stranded conformation. The distance between the reporter and the quencher 
molecules of the melted probe becomes shorter resulting in a FRET effect, which is inversely 
proportional to the sixth power of this distance. Therefore, a difference in the fluorescence 
emission between the hybridized and the melted configurations of the probe is detectable [160]. 
Primers were designed using the Primer Express software (Life Technologies) and probes with 
the freeware MELT-CALC (www.meltcalc.de) purchased by Eurofins Genomics. Primers hat a final 
concentration of 100 and 900 nM respectively, whereas the primer with the lower concentration 
is located on the strand where the probe has its binding site. The probe had a final concentration 
of 100 nM. 
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All reactions were performed in 384-well plates in the LightCycler480 II (Roche) under the following 
conditions:
TABLE 8: Master mix, cycle parameter and melting curve analysis parameter for SNP genotyping via melting 
curve analysis.
Reagent Stock Final 1 x Reaction [µl]
MgCl2 [mM] – Solis Biodyne 25 mM 4 2.00
10 x Buffer – Solis Biodyne 10 x 1 1.25
dNTP Mix [mM] – Promega 2.5 mM 0.25 1.25
FIREPol DNA Polymerase I [U/µl] – Solis Biodyne 5 U/µl 0.05 0.13
Probe [µM] – MWG 10 µM 0.1 0.13
Primer Fwd [µM] – MWG 20 µM 0.1 0.06
Primer Rev [µM] – MWG 20 µM 0.9 0.56
BSA [mg/ml] – NEB 10 mg/ml 0.5 0.63
H20-Lichrosolv 4.00
+ DNA-Template 2.50
Total 12.50
Cycle – Parameter:
95 °C 5´
95 °C 1´
 
 43 x62.5 °C 1´
72 °C 1´
72 °C 5´
4 °C ∞
Subsequently a melting curve analysis was performed, using the following parameters:
95 °C 3´
20 °C 2.5´
20 °C to 95 °C ramp rate of 5 °C/min 
95 °C 15´´
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FIGURE 14: Using melting curve analysis of Real-Time PCR we can detect single-nucleotide polymorphisms 
(SNP) and can distinguish between homozygous wildtype (red), heterozygous (green) and homo-
zygous (blue) mutant alleles.
2.5.8 Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) is used for the amplification of specific DNA or cDNA 
sequences. The method relies on repeated cycles of three temperature-dependent steps: 
denaturation of the double-stranded DNA into single-stranded DNA; annealing of the specific 
primers to the single-stranded template DNA; elongation of the primers by Taq-Polymerase 
and therefore duplication of the DNA-fragment between the primers. Specific primers for the 
amplification of genes were designed with the Primer Express 2.0 software (Applied Biosystems). 
Primer pairs annealed at two sequenced exons of the cDNA of the candidate genes. The synthesis 
of primers used was carried out at MWG Biotech (Ebersberg). Tables 9 and 10 show the PCR 
protocol and the cycling conditions.
TABLE 9: Standard-protocol for PCR.
DNA- or cDNA-Template 2.5 µl
10 x PCR-Puffer (Roche) 2.5 µl
MgCl2 (25 mM, Solis Biodyne) 5.0 µl
dNTPs	(1250	μM) 2.5 µl
Forward-Primer (20 pmol/μl) 0.5 µl
Reverse-Primer (20 pmol/μl) 0.5 µl
Ampli	Taq	Gold	DNA-Polymerase	(Roche) 0.25 µl
H20 13.75 µl
Total 25.00 µl
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TABLE 10: Cycling conditions for the PCR.
T [°C] t [min] Cycles
Initial Denaturation 95 °C 10:00
Denaturation 95 °C 0:10
  
40 x
Annealing/Elongation 60 °C 1:00
Final Elongation 60 °C 2:00
4 °C ∞
2.5.9 Agarose gel electrophoresis
Agarose gel electrophoresis is used for separating DNA fragments of varying sizes. The phos-
phate backbone of the DNA (or the RNA) molecule is negatively charged, therefore when placed 
in an electric field, DNA (and RNA) will move to the positively charged anode. Fragments of DNA 
migrate through the pores of the gel at a rate which is inversely proportional to the log of their 
molecular weight.
DNA and RNA were separated using TAE-gels with different concentrations of agarose (0.8-3 %), 
dependent on the expected fragment size. The molecular-weight size marker X (Roche Diag-
nostics) was used as standard to identify the approximate size of the respective fragments. The 
electrophoresis buffer consisted of 2 M Tris-acetate and 5 mM Na2EDTA (pH 8.0). After running the 
gel for 30-90 min at 80 Volt, it was stained with ethidium bromide (1 ng/ml) for 5 min, destained 
for 5 min in distilled water and the visualization of bands was performed an UV transilluminator 
(Fusion X, PeqLab).
2.5.10 Subcloning of PCR fragments into PCR® II-TOPO
Cloning of PCR-products was performed with the TOPO TA Cloning Kit (Invitrogen) according to 
the manufacturer’s instructions. 10-20 ng of PCR-product were ligated into the 3950 bp pCR® 
II-TOPO vector (TOPOTM TA Cloning Kit, Invitrogen) and then transformed into Escherichia coli 
cells (Top10 One Shot, Invitrogen). Successfully transformed bacteria are selected based on their 
ampicillin resistance. Furthermore, the blue-white selection allows the identification of successful 
products of cloning reactions through the colour of the bacterial colony. The LB agar plates 
contain apart from ampicillin, IPTG and X-Gal. The multiple cloning site (MCS) of the pCR® 
II-TOPO vector is flanked by the lacZ sequence. After a successful incorporation of a PCR-product 
a functional β-galactosidase enzyme is not produced. If β-galactosidase is produced, X-Gal is 
hydrolyzed, which spontaneously dimerizes to produce an insoluble blue pigment. The colonies 
therefore appear blue while the recombinant ones appear white. The white recombinant colonies 
are picked and cultured.
LB-Medium and LB-Agar were prepared as follows and autoclaved overnight.
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TABLE 11: LB-Medium and LB-Agar.
LB-Medium LB-Agar
5 g Tryptone (BD) 5 g Tryptone (BD)
2.5 g Yeast extract (BD) 2.5 g Yeast extract (BD)
5 g NaCl (Roth) 5 g NaCl (Roth)
ad 500 ml H20 dest 7.5 g Bacto Agar (BD)
ad 500 ml H20 dest
FIGURE 15: pCR 2.1-TOPO vector.
2.5.11 Preparation of plasmid-DNA (plasmid-mini preparation)
Mini-preparation of plasmid DNA was performed using the Fast Plasmid Mini Kit (5Prime). This 
Kit uses a single solution for cell resuspension, lysis and DNA trapping. This single solution con-
tains a mixture of enzymes and detergents that lyse bacterial cells, denatures and solubilizes 
cellular components, degrades RNA and traps DNA on a matrix, all in one step (5Prime).
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In brief, 1.5 ml of fresh bacterial culture were pellet at maximum speed. The medium was removed 
by decanting. 400 µl of ice-cold Complete Lysis Solution were added and mixed thoroughly by 
constant vortexing for 30 seconds. The lysate was incubated at room temperature for 3 minutes 
and transferred to a Spin Column Assembly by decanting. The Spin Column Assembly was centri-
fuged for 60 seconds at maximum speed. 400 µl of DILUTED Wash Buffer were added to the Spin 
Column Assembly and centrifuged for 60 seconds at maximum speed. Subsequently the Spin 
Column was centrifuged again at maximum speed for 1 minute to dry the Spin Column. The Spin 
Column was then transferred into a Collection Tube. 50 µl Elution Buffer were directly added to 
the center of the Spin Column membrane and centrifuged at maximum speed 60 seconds.
The plasmids were analyzed by restriction analysis to confirm the presence of the insert. The 
insertion site of the pCR® II-TOPO vector is flanked by EcoRI restriction sites. 1 µl Plasmid was 
incubated for 2h at 37 °C with 20 U EcoRI (New England Biolab, Frankfurt/Main), the respective 
reaction buffer and 0.5 µl RNAse (0.5 µg/µl; Boehringer, Mannheim) in a final volume of 10 µl. The 
size of the resulting fragments was checked on an agarose gel.
2.5.12 DNA-sequencing
Sequencing was performed to confirm that the fragment is cloned into the plasmid in the correct 
orientation. Primers M13 fwd and M13 rev (Invitrogen) were used, which hybridize on both sides 
of the pCR® II-TOPO insertion site.
TABLE 12: Master mix for the sequencing reaction.
Reagent 1x Reaction
Big Dye 5x Dilution Buffer (Applied Biosystems) 2.0 µl
Big Dye 3.1 Reaction Mix (Applied Biosystems) 1.5 µl
M13-Primer forward or reverse (5 µM) 1.0 µl
Plasmid (m ~ 1.0 µg)
H2O ad 10.0 µl
TABLE 13: Cycling conditions.
T [°C] t [min] Cylcles
96 °C 1:00
96 °C 0:10
 
 25 x50 °C 0:05
60 °C 2:00
After cycle sequencing, reactions were cleaned up by ethanol precipitation to remove unin- 
corporated dye nucleotides. The samples were mixed with 10 µl H20, 2 µl 3 M Na-Acetate (pH 5.2) 
and 55 µl 100 % Ethanol, centrifuged for 20 min at 14,000 xg and 4 °C and the supernatant was 
discarded. The pellet was washed with 250 µl 70 % Ethanol and centrifuged again. The final pellet 
was dried for 10 min at 68 °C. Sanger sequencing of the respective samples was performed at 
MWG Eurofins. 
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2.5.13 Standard curve preparation for qRT-PCR (TaqMan)
Plasmids containing cloned target sequences were used as standards in quantitative RT-PCR. 
Initially the plasmid standard was linearized with a restriction endonuclease, which cuts the 
vector (not the insert) at a single restriction site.
3 µg Plasmid-DNA, 4 µl 10x Restriction-Buffer, 40 U HindIII (or XhoI) (New England Biolabs) and 
DEPC.H2O to a final volume of 40 µl were incubated at 37 °C overnight. The restriction enzyme was 
inactivated for 20 min at 65 °C. The result of the restriction was initially checked on an agarose gel 
and the concentration of the linearized plasmid-DNA was measured with the NanoDrop System 
(Thermo Scientific).
The clone picked as standard was diluted to 109 single-strand molecules/μl with 1xTE buffer. 
Dilution to the required copy number of the standard curve was performed with 1xTE buffer 
containing 0.06 % 5 x First Strand Buffer. 
2.5.14 Quantitative real-time PCR (TaqMan)
FIGURE 16: Principle of TaqMan probe-based assays [2].
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Real-time quantitative PCR allows the specific detection of PCR-products generated during each 
PCR-cycle, which are directly proportional to the amount of template prior to the start of the 
PCR process. TaqMan probes are labeled on the 5` end with a fluorescent dye reporter (FAM) 
and a quencher dye which is attached to the 3 ́ end (TAMRA). TaqMan probes spann the exon/
exon junction to avoid significant amplification of contaminative genomic DNA. The TaqMan 
probe anneals downstream from one of the primer sites and as long as the probe is intact FRET 
(fluorescence resonance energy transfer) occurs and the fluorescence emission of the reporter 
dye is absorbed by the quenching dye. The probe is cleaved by the 5 ́ nuclease activity of the 
Taq polymerase enzyme during the extension phase of the PCR. Cleavage of the probe separates 
the reporter and quencher dyes, thereby increasing the fluorescence from the reporter dye. The 
increase in the intensity of fluorescence is proportional to the formation of PCR products.
2.5.14.1	Quantification of candidate genes
Quantification of gene expression was performed on ViiA 7 Real-Time PCR-System (Life Technol-
ogies). All primers and probes used for the candidate genes quantification are listed in Table 29 
of the appendix. Cloned cDNA fragments of the template were used as standards in serial dilu-
tions and Beta	actin (Ba) was used as housekeeping gene. Quantification of candidate genes was 
performed in quadruplicates in a 384-well plate. 
The following protocol was used for all qRT PCRs: 
TABLE 14: PCR conditions.
Reagent 1 X Reaction
H2O 4.56 µl
MgCl2 (25 mM Stock) 2.5 µl
10xPCR Buffer 1.25 µl
dNTPs 1 µl
Forward primer (300 nM) 0.1875 µl
Reverse primer (300 nM) 0.1875 µl
Probe (10 µM Stock) 0.25 µl
Ampli TaqGold Polymerase (Thermo Fisher) 0.0625 µl
Total ad 10.0 µl
+ cDNA/Standard 2.5 µl
Reaction volume 12.5 µl
TABLE 15: Cycling conditions.
T [°C] t [min] Cycles
Initial Denaturation 95 °C 10:00
Denaturation 95 °C 0:10
  
40 x
Annealing/Elongation 60 °C 1:00
Final Elongation 60 °C 2:00
4 °C ∞
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2.6 Functional analysis
2.6.1 Western blotting
Proteins are separated using gel electrophoresis followed by the transfer of proteins to a mem-
brane. Now the proteins can be detected with specific antibodies.
Western blots were performed with mice tissues, whole cell lysates (RAW264.7, MOVAS, MCEC and 
BMDM) and isolated cell membrane proteins of BMDM (3.1.) of mice. Cells were scraped with RIPA 
lysis buffer (50 mM Tris pH8, 150 mM NaCl, 1 % Igepal CA-630, 1 % sodium deoxycholate, 0.1 % SDS) 
supplemented with cOmplete™ Protease Inhibitor Cocktail (Roche); 0.1 mM phenymethylsulfonyl- 
fluorid (PMSF); 20 µM metalloproteinase inhibitor BB-2519 (Tocris Bioscience); 10 mM 1,10- 
phenanthroline (Sigma-Aldrich) and 1 mM sodium orthovanadate (NEB). Mouse tissue was homo- 
genized in a Precellys24 homogenizer (PeqLab) using CK24 ceramic beads using 300 µl RIPA lysis 
buffer. Cells and tissues were incubated for 1 hour on ice to swell and subsequently centrifuged 
at 13,000 xg for 30 min and 4 °C. The supernatant was removed and the protein concentration 
was measured using the PierceTM BCA Protein Assay (Thermo Scientific). The bicinchoninic acid 
assay (BCA assay) is a biochemical assay for determining the total concentration of protein in a 
solution (0.5 μg/mL to 1.5 m/mL). The principle of this method is that proteins can reduce Cu+2 
to Cu+1 in an alkaline solution (biuret reaction) and result in a purple color formation by bi- 
cinchoninic acid. The absorbance was detected at 562 nm on a plate reader (SpectraMax Paradigm 
Multi-Mode Microplate Reader, Molecular Devices) and the concentration was determined using 
a standard curve (Diluted Albumin [BSA] Standards). 
Equal amounts of protein (20 µg per sample) were loaded on 10 % NuPAGE Bis-Tris Mini or Midi 
gels (Invitrogen). Subsequently proteins were blotted to nitrocellulose or PVDF (Polyvinylidene 
fluoride) membranes for 1h by 135 mA. Membranes were blocked for 1 hour using PBS, 0.3 % 
Tween 20, 0.05 % Triton X-100 and 5 % skim milk powder, followed by incubation with the primary 
antibody overnight at 4 °C. Dilutions of primary and secondary antibodies are given in Table 28 
of the appendix. Protein bands were visualized by chemiluminescence (AceGlow-Solution [PeqLab]) 
and detected with the Fusion FX image system (PeqLab). The densitometric analysis of proteins 
on western blots was performed using the ImageJ Software (NIH).
2.6.2 Multiplex immunoassay
The Luminex technology enables up to 100 proteins or genes to be detected simultaneously in 
each well of a 96 or 384-well plate, using very small sample volumes. Biomolecules (such as an 
oligo or antibody) are conjugated to the surface of beads, allowing the capture and detection of 
specific analytes from a sample. Furthermore, the beads are internally dyed with red and infra-
red fluorophores, marking each bead with a unique spectral signal and therefore representing a 
particular assay. A dual detection flow cytometer is used to sort out the different assays by bead 
colors in one channel and to determine the concentration of the specific analyte by measuring 
the reporter dye fluorescence in another channel. Common applications include the detection 
of cytokines, metabolic markers and phosphorylated proteins. The concentrations of released 
ADAM17 substrates, like receptors, cytokines, chemokines and adhesion molecules were detected 
in the plasma and the supernatant of BMDM of wild-type Adam17 wt/wt.Ldlr -/- (n = 12), heterozygous 
  55 / 154
Material and Methods
Adam17 wt/ex.Ldlr -/- (n = 10) and hypomorphic Adam17 ex/ex.Ldlr -/- (n = 12) mice. The assays were per-
formed using the bead-based Milliplex xMAP multiplex technology (Millipore) according to the 
manufacturer’s instructions on the Luminex 100 instrument (Biorad). In the following table are 
the assays and the parameters listed that were measured. 
TABLE 16: Multiplex assays and parameters mesaured in wild-type Adam17 wt/wt.Ldlr -/- (n = 12), heterozygous 
Adam17 wt/ex.Ldlr -/- (n = 10) and hypomorphic Adam17 ex/ex.Ldlr -/- (n = 12) mice.
Assays Cytokines/Receptors
Milliplex Map Mouse Cytokine/Chemokine
(Cat.# MCYTOMAG-70K – Millipore) GM-CSF, IL-10, KC, MCP-1, TNF-α
Milliplex Map Mouse Cytokine/Chemokine Magnetic Bead Panel II  
(Cat.# MCYP2MAG-73K – Millipore) Fractalkine
Milliplex Map Mouse Cardiovascular Disease (CVD) Panel I  
(Cat.# MCVD1-77AK – Millipore) VCAM-1, ICAM1
Milliplex Map Mouse Soluble Cytokine Receptor Magnetic Bead Panel 
(Cat.# MSCRMAG-42K – Millipore)
sCD30, sgp130, sIL-6R, sVEGFR2,  
sIL-1R2, sTNFR1, sTNFR2
Bio-Plex Pro™ Mouse Cytokine Group I assay 
(Biorad)
sIFNγ, sIL-1b, sIL-10, sIL-6, sMIP-1α, 
sMIP-1β, sRANTES, sMCP-1, sEotaxin
Using standard curves, analyte concentrations were determined using the Bio-plex software.
2.7 Statistics
For statistical analysis of data the GraphPad Prism Software (Version 6.0) was used. All data are 
given as mean ± SEM unless otherwise indicated. Normality of distribution was assessed using 
the Kolmogorov-Smirnov test. Comparison of multiple groups was done using ANOVA and Tukey 
was performed as a post-test. Comparison of 2 groups of normally distributed samples was 
done using the t-test.
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Quantitative trait locus mapping in mice identifies  
phospholipase Pla2g12a as novel atherosclerosis modifier
 
 
This work has been published in [148].
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3.1 Quantitative trait locus mapping (QTL) of atherosclerosis on mouse 
chromosome 3
In a previous study, a novel atherosclerosis susceptibility locus on mouse chromosome (Chr) 3 
was identified by quantitative trait locus (QTL) mapping in atherosclerosis-susceptible C57BL/6 
(B6) and atherosclerosis-resistant FVB mice on the low density lipoprotein (LDL)-receptor- 
deficient background (Ldlr -/-) [104]. For the initial QTL mapping, F1 animals from reciprocal crosses 
of male and female B6 and FVB mice were intercrossed and atherosclerosis lesion sizes were 
quantified in the F2 generation. The Chr3 locus was gender-dependent and only present in 
female F2 mice [104]. Furthermore, different LOD score maxima were observed in different 
female crosses according to the breeding scheme of the F0 generation (Figure 17 A, B). In cross A, 
male B6 mouse was mated with female FVB (F0 = male B6xfemale FVB), the maximum LOD score 
at 78.5 cM at marker d3mit45 was 3.3. In cross B, a male FVB mouse was mated with a female B6 
mouse (F0 = male FVBxfemale B6), with a maximum LOD score of 4.1 at 55 cM at marker d3mit57.
FIGURE 17: Atherosclerosis LOD scores on mouse chromosome 3. The Chr3 locus was gender-dependent and 
only present in female F2 mice. (A) LOD score in cross A was generated from male B6 and female 
FVB and (B) cross B from male FVB with a female B6 mouse.
Lineage-dependency of loci at Chr3 suggested that different molecular mechanisms might underlie 
the two distinct female atherosclerosis loci. This indicated that potentially independent candidate 
genes on the Chr3 risk QTL predisposed for atherosclerosis susceptibility in females. To vali-
date the Chr3 atherosclerosis locus and to identify the causal genes in both subcrosses we first 
generated chromosome 3 congenic mice and performed expression studies in congenic and 
F0 mice as well as in mice of the F2 generation.
3.1.1 Fine-mapping of Chr3 subloci in female F2 mice in cross A and cross B
To fine-map the two previously identified female-specific atherosclerosis risk subloci and to 
reduce the number of potential candidate genes within the Chr3 QTL [104], we genotyped 107 
female mice of cross A and 120 female mice of cross B with 6 additional single nucleotide poly- 
morphisms (SNPs). The 6 additional SNPs were evenly spaced along the genome on chromo-
some 3 (Table 17) [148].
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TABLE 17: SNPs used for fine-mapping and their chromosomal position.
Number SNP # Position [Mb]
1 rs4224041 87.174.360
2 rs3683384 110.052.310
3 rs36523879 122.019.140
4 rs30359806 140.072.342
5 rs30102565 150.234.187
6 rs31598641 159.008.817
QTL analysis revealed LOD score maxima for atherosclerosis at the initially identified markers 
d3mit45 (LOD 3.3, cross A) and marker d3mit57 (LOD 4.1, cross B), where the homozygous B6 
alleles correlated with 2.3-fold and 2.2-fold more atherosclerosis [104]. Dupuis and Siegmund 
found that 1.5-LOD support intervals provide around 95 % coverage in the case of a dense marker 
Map [161]. Applying this conservative cutoff of 1.5 LOD when defining the confidence intervals, we 
were able to narrow down the genetic regions potentially containing candidate genes of athero- 
sclerosis risk from 44 to 36 Mb in cross A and 54 to 44 Mb in cross B, respectively (Table 18) [148]. 
TABLE 18: Old and new confidence intervals (CI) in female crosses A and B [148].
Start (Marker) Base pairs End (Marker) Base pairs Length [bp]
Cross	A	(old	CI) d3mit57 115.433.310 End Chr3 159.599.783 44.166.473
Cross	A	(new	CI) rs36523879 122.018.890 rs31598641 159.008.567 36.989.677
Start (Marker) Base pairs End (Marker) Base pairs Length [bp]
Cross	B	(old	CI) d3mit51 76.802.932 d3mit254 131.611.739 54.808.807
Cross	B	(new	CI) rs4224041 87.174.110 d3mit254 131.611.739 44.437.629
The confidence interval (CI, green area) of cross A now spanned from SNP rs36523879 to rs31598641 
(Figure 18), had a length of 36.989.677 base pairs and contained 221 genes, the previous confidence 
interval contained 406 annotated RefSeq transcripts [148].
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FIGURE 18: Confidence interval in cross A of mouse chromosome 3. The black lines indicate the microsatellite 
markers used initialy for genotyping the F2-generation mice and the blue lines the additional 
SNPs used to narrow the confidence intervals [148].
The confidence interval (blue area) of cross B now spanned from SNP rs4224041 to d3mit254 
(Figure 19), had a length of 44.437.629 base pairs and contains 593 genes. The previous confidence 
interval contained 788 genes.
FIGURE 19: Confidence interval in cross B of mouse chromosome 3. The black lines indicate the microsatellite 
markers used initialy for genotyping the F2-generation mice and the blue lines the additional 
SNPs used to narrow the confidence intervals [148].
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3.1.2 Generation and characterization of chromosome 3 congenic mice 
To validate that the B6 allele on chromosome 3 was causal for promoting atherosclerosis, we 
first generated chromosome 3 congenic mice by introducing an 80 Mb long genomic stretch 
of Chr3 from atherosclerosis-susceptible B6 into the FVB.Ldlr -/- background. These mice were 
generated by crossing atherosclerosis-susceptible C57BL/6 (B6) and atherosclerosis resistant 
FVB mice and backcrossing the resulting heterozygous Chr3FVB/B6 mice onto the FVB.Ldlr -/- back-
ground for 10 generations [148].
FIGURE 20: Chromosome 3 congenic mice. Chromosome 3 congenic mice carry an 80-160 Mb interval of Chr3 
from B6 on the FVB background.
The identified loci on mouse chromosome 3 were female specific, thus only female mice were 
generated. Heterozygous FVB.Chr3FVB/B6 mice (carrying an 80-160 Mb interval of Chr3 from B6 on 
the FVB background) were intercrossed to generate female homozygous FVB.Chr3B6/B6 (n = 20), 
female heterozygous FVB.Chr3FVB/B6 (n = 20) and female wild-type FVB.Chr3FVB/FVB (n = 20) control 
mice. Neither heterozygous FVB.Chr3B6/FVB nor homozygous FVB.Chr3B6/B6 or wild-type FVB mice on 
the Ldlr-deficient background showed any great abnormalities and proved healthy and fertile 
when maintained under specific pathogen-free conditions. Mice were weaned at 4 weeks and 
were fed a semisynthetic diet containing 0.02 % cholesterol for 16 weeks which was previously 
shown to promote hypercholesterolemia and atherosclerosis and at the same time avoiding 
obesity with all of the attendant metabolic complications [99]. Subsequently they were sacrificed 
at 20 weeks of age by a standardized protocol (see Methods 3.3.1.2). 
Plasma parameters were analyzed on an automated analyzer (Modular PPE, Roche) and lipo- 
proteins were isolated by sequential ultracentrifugation. Total body weight and biochemical and 
clinical chemical characteristics of all mice are indicated in Table 19. Clinical chemistry parame-
ters and plasma lipid levels showed no differences between FVB.Chr3B6/B6, FVB.Chr3B6/FVB and FVB.
Chr3FVB/FVB mice.
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TABLE 19: Total body weight, biochemical characteristics and chemical clinical parameters of female FVB, 
FVB.Chr3B6/FVB and FVB.Chr3B6/B6 mice [148].
Measurement FVB FVB.Chr3B6/FVB FVB.Chr3B6/B6 p-Value
n = 20 n = 20 n = 20 FVB/ FVB.Chr3B6/B6
FVB/ FVB.
Chr3B6/FVB
FVB.Chr3B6/FVB/ 
FVB.Chr3B6/B6
Weight [g] 22.1 ± 2.1 23.6 ± 2.5 24.5 ± 2.7 0.003 n.s. n.s.
ALT [ukat/l] 0.65 ± 0.33 0.54 ± 0.14 0.76 ± 0.43 0.003 n.s. n.s.
AST [ukat/l] 2.2 ± 1.14 2.06 ± 0.88 2.22 ± 1.32 n.s. n.s. n.s.
ChE [ukat/l] 109.3 ± 15.2 125.7 ± 19.7 136.8 ± 14.8 n.s. n.s. n.s.
Urea [mmol/l] 8.06 ± 2.02 9.1 ± 1.55 9.42 ± 3.71 n.s. n.s. n.s.
Total Protein [g/dl] 48.3 ± 3.29 50.3 ± 3.72 48.4 ± 3.8 n.s. n.s. n.s.
Triglyceride [mg/dl] 31.71 ± 14.59 38.55 ± 15.49 29.36 ± 8.28 n.s. n.s. n.s.
Cholesterol [mg/dl] 163.78 ± 26.84 191 ± 42.7 168.28 ± 37.11 n.s. n.s. n.s.
Creatinine [µmol/l] 12.32 ± 2.35 12.82 ± 3.5 11.88 ± 2.91 n.s. n.s. n.s.
VLDL-Cholesterol [mg/dl] 30.43 ± 16.58 47.61 ± 28.39 32.08 ± 15.45 n.s. n.s. n.s.
LDL-Cholesterol [mg/dl] 259.6 ± 60.6 307 ± 96.5 261 ± 69.3 n.s. n.s. n.s.
HDL-Cholesterol [mg/dl] 89.46 ± 10.67 91.36 ± 17.9 87.64 ± 11.58 n.s. n.s. n.s.
VLDL-TG [mg/dl] 106.8 ± 81.9 131.2 ± 77.2 92.4 ± 34.4 n.s. n.s. n.s.
LDL-TG [mg/dl] 63.87 ± 23.88 64.78 ± 23.36 61.8 ± 24.9 n.s. n.s. n.s.
HDL-TG [mg/dl] 22.85 ± 23.93 17.46 ± 14.09 24.44 ± 18.99 n.s. n.s. n.s.
Data are given as mean ± SD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ChE, cholinesterase;  
GLDH, Glutamate dehydrogenase; VLDL, very low- density lipoproteins; LDL, low-density lipoproteins; HDL, high-
density lipoproteins. Comparison of multiple groups was done using ANOVA and Tukey was performed as a post-
test. n.s. = not significant.
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3.1.3 Increased atherosclerosis in Chr3 congenic female mice
Atherosclerotic lesion areas were quantified at the aortic root of female wild-type FVB (n = 20), 
heterozygous congenic FVB.Chr3B6/FVB (n = 20) and homozygous congenic FVB.Chr3B6/B6 (n = 20) mice 
on the Ldlr-deficient background using oil red O staining. Oil red O is used for staining neutral 
triglycerides and lipids, Light Green SF yellowish for staining collagen and hematoxylin for staining 
cell nuclei. In Figure 21, representative oil red O stainings of chr3 congenic FVB.Chr3B6/B6 and FVB 
mice are shown as well as the atherosclerosis quantification [148].
FIGURE 21: (A) Representative oil red O stainings of chr3 congenic FVB.Chr3B6/B6 and FVB mice and (B) Athero-
sclerosis quantification in FVB.Chr3B6/B6 (B/B), heterozygous FVB.Chr3B6/FVB (B/F) and wild-type FVB 
(F/F) mice. Data are given as mean ± SEM. * p	<	0.05 [148].
Homozygous congenic FVB.Chr3B6/B6 mice showed significantly 2.5 fold greater atherosclerotic 
lesion areas compared to heterozygous FVB.Chr3B6/FVB and wild-type FVB mice. These data con-
firmed that genetic factors contained within the 80 Mb at chromosome 3 conferred atheroscle-
rosis susceptibility, and that atherogenesis was likely triggered independent of cholesterol and 
triglyceride metabolism as no differences were observed among all mice (Table 19) [148].
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3.1.4 Identification of novel atherosclerosis modifier genes on mouse chromosome 3
To identify and functional characterize candidate genes for subsequent functional character- 
ization at the atherosclerosis susceptibility locus at Chr3 we applied the following strategy 
(Figure 22).
FIGURE 22: Strategy for identifying novel atherosclerosis modifier genes on mouse chr3 for subsequent 
functional studies. (A) Genome-wide expression analyses were performed in livers of congenic 
FVB.Chr3B6/B6 (n = 4) and FVB	(n = 4) mice using Illumina Ref8 arrays and technical validated in livers 
of congenic FVB.Chr3B6/B6 (n = 9) and FVB	(n = 8) mice using RT-qPCR (TaqMan) assays. (B) A biological 
validation of differentially expressed candidate genes was performed in livers (n = 5/5), aortas 
(n = 6/6) and bone marrow-derived macrophages (BMDM) (n = 6/6) of the parental B6 and FVB 
strains using RT-qPCR (TaqMan) assays. (C) Candidate genes that passed through the technical 
and biological validation were then measured in eQTL analyses in female mice of the F2-generation. 
(D) Identified genes were subsequently characterized in cellular expression and functional exper-
iments [148].
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In a first step, we performed transcriptome-wide expression analyses in RNA from livers of female 
congenic FVB.Chr3B6/B6 (n = 4) mice and in FVB (n = 4) control mice to identify differentially regulated 
transcripts within the interval. Here, we found that 19 genes were differentially expressed with 
a fold change (FC) ratio > 1.4 and < 0.7, which we chose as a biologically relevant arbitrary cutoff 
(Table 20). 9 of these genes were located in the confidence interval of cross A, 13 genes in the 
interval of cross B, and 3 of these genes were in the overlap of the two intervals (Figure 23 and 
Table 20). 
Using qPCRs we validated the differential expression of these genes by comparing their mRNA 
abundance firstly in preparations of livers from congenic FVB.Chr3B6/B6 (n = 8) and FVB (n = 9) mice, 
and secondly by analyzing the parental F0 B6 (n = 5) and FVB (n = 5) female mice (Table 20). To 
examine whether the identified candidates were also differentially expressed in vascular tissue 
or cells known to contribute to atherosclerotic plaque formation (endothelial cells, macrophages), 
we next quantified candidate gene expression in parental F0 aortas (n = 6/6) and, secondly, in 
bone marrow-derived macrophages (BMDM, n = 6/6) (Table 20). In total, 7 genes passed the first 
two validation stages of expression analysis in the liver, out of which 5 were also expressed in 
aortic tissue and/or BMDMs: tropomodulin-4 (Tmod4), vascular cell adhesion molecule 1 (Vcam1), 
fatty	acid	elongase	6 (Elovl6), the group	XIIA	secretory	phospholipase	A2	(Pla2g12a) and cystathio- 
nine gamma-lyase (Cth)	(Table 20). 
Of these, Vcam1, Elovl6	and Cth were induced, and Tmod4 and Pla2g12a were repressed in mice 
carrying the B6 allele in the Chr3 interval (Table 20) [148]. 
FIGURE 23: Chromosome 3 congenic mice (FVB.Chr3B6/B6) are carrying an 80-160 Mb interval of Chr3 from B6 on 
the FVB background. On the 80 Mb long confidence interval are all genes listed that are differentially 
expressed in congenic FVB.Chr3B6/B6 and FVB mice [148].
To remain conservative in our gene prioritization strategy we took all 7 candidates to further 
analyses stages [148].
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TABLE 20: Identification of candidate genes through transcriptome-wide expression arrays and qPCRs [148].
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Fdps 88.8 X 1.86 1.14 n.f. n.f. n.f. n.f.
Pklr 88.9 X 1.52 2.16** 2.22** not expr. not expr. 4.4*
Pmvk 89.2 X 1.59 1.24 n.f. n.f. n.f. n.f.
Them4 94.1 X 1.47* 1.13 n.f. n.f. n.f. n.f.
Tuft1 94.1 X 0.65** 0.67 n.f. n.f. n.f. n.f.
Selen-
bp2 94.4 X 1.64 0.72	↑↓ n.f. n.f. n.f. n.f.
Tmod4 94.9 X 0.58*** 0.25*** 0.23*** 0.17*** 0.32*** 0.7
Gm129 95.6 X 1.85* 1.59 n.f. n.f. n.f. n.f.
Vcam1 115.8 X 1.46* 1.73* 2.14** 1.6** not expr. 4.4*
Abcd3 121.4 X 1.41* 1.14 n.f. n.f. n.f. n.f.
Elovl6 129.2 X X 1.73* 2.53* 3.09* 2.2*** 1.02 0.95A; 2.4B
Pla-
2g12a 129.5 X X 0.49*** 0.77* 0.53*** 0.46** 0.71* 3.6*
A, 2.4B
Agxt2l1 130.3 X X 2.1* 3.31*** 2.01* not expr. not expr. 0.13A; 0.5B
Adh7 137.8 X 3.51*** 0.62	↑↓ n.f. n.f. n.f. n.f.
Adh4 138.1 X 0.69** 0.83 n.f. n.f. n.f. n.f.
Gbp3 142.2 X 1.45 1.01 n.f. n.f. n.f. n.f.
Ccbl2 142.3 X 4.85*** 1.48 * 1.08 n.f. n.f. n.f.
Acadm 153.5 X 0.68* 0.78 n.f. n.f. n.f. n.f.
Cth 157.5 X 1.83* 2.76*** 2.6*** 0.85 3.1*** 5.6*
Differentially expressed candidate genes identified by genome-wide expression arrays in homozygous chromosome 
3 congenic FVB.Chr3B6/B6 and FVB.Chr3FVB/FVB mice in the confidence intervals of cross A and B, respectively. As a cut off 
value a fold change (FC) of congenic FVB.Chr3B6/B6 to FVB.Chr3FVB/FVB mice greater than 1.4 and less 0.7 was chosen. All 
fold changes of the validation stages are given. CI = Confidence Interval; n.f. = not followed; not expr. = not expressed; 
BMDM = bone marrow-derived macrophages; A Cross A; B Cross B.
Fdps	=	farnesyl	pyrophosphate	 synthase;	 Pklr	=	pyruvate	kinase,	 liver	and	RBC;	Pmvk	=	phosphomevalonate	kinase;	
Them4	=	thioesterase	superfamily	member	4;	Tuft1	=	tuftelin	1;	Selenbp2	=	selenium	binding	protein	2;	Tmod4	=	tropo- 
modulin-4;	Gm129	=	hypothetical	protein	LOC229599;	Vcam1	=	vascular	cell	adhesion	molecule	1;	Abcd3	=	ATP-binding	
cassette	 sub-family	D	member	3;	 Elovl6	=	fatty	acid	elongase	6;	Pla2g12a	=	group	XIIA	 secretory	phospholipase	A2;	
Agxt2l1	=	alanine-glyoxylate	 aminotransferase	 2-like	 1;	 Adh7	=	alcohol	 dehydrogenase	 class	 4	 mu/sigma	 chain;	
Adh4	=	alcohol	dehydrogenase	4;	Gbp3	=	guanylate-binding	protein	4;	Ccbl2	=	kynurenine-oxoglutarate	transaminase	3;	 
Acadm	=	medium-chain	 specific	 acyl-CoA	 dehydrogenase;	 Cth	=	cystathionine	 gamma-lyase.	 * p	<	0.05; ** p	<	0.01; 
*** p	<	0.001;	* LOD > 3.3 (corresponding to a genome-wide significance level of 0.05 [162])
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3.1.5 Identity by descent analysis (IBD)
eQTLs can principally arise due to genetic variants contained either gene-proximally (within the 
transcribed RNA or the promoter/promoter-proximal regions, changing the transcription, stability 
or degradation kinetics of the mRNA by various mechanisms) [163], or in more distant regulatory 
regions [164]. We thus performed an identity by descent analysis (IBD) of chromosome 3 in C57BL/6 
and FVB mice to explore if any genomic regions in the candidate gene interval could be excluded 
due to sharing of haplotypes (Figure 24, Table 21). Black regions indicate identical segments of 
C57BL/6 and FVB mice and white segments indicate segments that are inherited independently 
[148].
FIGURE 24: Identity by descent (IBD) analysis in the interval of 80-160 Mb of chromosome 3 in C57BL/6 and 
FVB mice. Presented are the 7 candidate genes that passed through the validation stages [148].
TABLE 21: Regions of identity by descent (IBD) in the confidence interval of 80-160 Mb of Chr3 in C57BL/6 and 
FVB mice [148].
No. Start Position End Position No. Start Position End Position
1 80.188.361 80.227.607 54 129.973.800 129.974.021
2 80.536.900 80.594.470 55 130.258.613 130.275.265
3 80.690.601 80.829.263 56 130.961.839 130.965.944
4 81.419.232 83.180.615 57 131.263.933 131.327.493
5 83.695.103 83.697.639 58 132.024.501 133.389.556
6 83.910.647 83.970.081 59 134.979.859 135.039.822
7 84.108.613 84.109.902 60 135274.890 135.290.731
8 84.178.368 84.232.881 61 135.490.845 135.490.845
9 84.420.466 86.840.354 62 135.586.445 135.586.445
10 87.942.214 88.394.992 63 135.700.534 135.730.210
11 88.726.672 88.726.672 64 136.848.780 136.857.802
12 89.089.629 89.089.629 65 136.999.580 136.999.580
13 89.165.033 93.071.701 66 137.069.054 137.090.397
14 94.207.865 94.207.865 67 137.559.532 137.559.816
15 94.985.990 95.747.548 68 137.674.541 137.674.541
16 96.736.639 96.740.089 69 138.119.505 138.216.740
17 96.767.593 96.767.742 70 138.429.420 138.431.027
18 96.810.034 96.811.406 71 138.578.932 138.625.427
19 97.386.657 97.402.858 72 139.082.389 139.082.389
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No. Start Position End Position No. Start Position End Position
20 97.641.765 97.641.912 73 139.312.208 139.312208
21 97.731.201 97.737.430 74 139.901.711 139.901.711
22 98.090.360 98.181.483 75 140.783.381 140.886.545
23 99.040.115 101.508.142 76 141.256.960 141.256.960
24 101.563.427 101.563.427 77 141.630.571 141.631.086
25 102.893.521 102.912.926 78 141.864.016 141.947.400
26 103.434.925 103.435.289 79 142.103.827 142.123.983
27 104.862.464 105.894.207 80 142.425.542 142.425.542
28 106.251.616 107.271.160 81 142.588.681 142.588.681
29 107.324.647 108.706.370 82 143.230.029 143.232.983
30 109.004.747 109.335.491 83 143.313.362 143.352.391
31 109.492.017 109.551.155 84 143.414.498 143.416.205
32 109.693.328 109.731.513 85 143.892.533 143.907.260
33 110.457.786 110.458.378 86 144.398.993 146.266.204
34 112.984.364 112.984.364 87 147.746.587 147.746.688
35 115.294.141 115.294.599 88 148.339.778 148.382.587
36 115.355.523 115.355.761 89 148.484.699 148.484.699
37 115.442.491 115.442.491 90 148.513.159 148.580.347
38 116.078.713 116.239.710 91 148.631.065 148.631.065
39 116.323.774 116.354.251 92 148.728.333 148.728.333
40 117.643.991 117.777.467 93 149.434.141 149.434.141
41 117.894.669 118.045.948 94 149.476.617 149.502.384
42 119.571.115 119.647.899 95 150.477.760 150.477.760
43 120.092.503 120.121.442 96 151.609.744 152.891.138
44 120.838.527 120.838.527 97 152.924.161 152.924.161
45 120.993.033 120.993.033 98 153.109.774 153.316.575
46 121.197.396 121.218.386 99 153.728.658 153.828.179
47 121.288.737 121.414.004 100 153.886.960 154.038.227
48 121.692.915 121.694.285 101 154.333.765 154.390.758
49 121.837.443 121.837.443 102 156.682.833 156.838.748
50 121.917.655 122.039.421 103 157.002.851 157.062.314
51 122.101.525 129.200.388 104 157.308.021 157.316.520
52 129.442.386 129.471.180 105 157.413.336 157.413.336
53 129.556.279 129.556.279 106 157.417.299 157.417.299
The IBD analysis revealed that all 7 candidate genes indeed resided in regions that were inherited 
independently in both strains, and thus none of these candidates could be excluded [148]. 
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3.1.6 Non-synonymous protein-sequence-changing (nsSNPs)
Furthermore, to investigate whether the 7 identified candidate genes contained any nucleotide 
mutations that would alter the amino acid sequence of the protein, we Identified the non- 
synonymous SNPs in the confidence intervals of cross A and cross B (Table 22). Subsequently, 
we determined the SIFT (sorts intolerant from tolerant amino acid substitutions) score, which 
predicts whether an amino acid substitution affects protein function, using the PolyPhen-2 Soft-
ware [165]. The SIFT score ranges from 0.0 (deleterious) to 1.0 (tolerated) and can be interpreted 
as follows: 
 0.0 to 0.05 – Variants with scores in this range are likelly deleterious. Variants with scores 
closer to 0.0 are more confidently predicted to be deleterious.
 0.05 to 1.0 – Variants with scores in this range are predicted to be tolerated (benign). Variants 
with scores very close to 1.0 are more confidently predicted to be tolerated.
TABLE 22: Identified nonsynonymous SNPs in the confidence intervals of cross A (122.019.140 bp-159.008.817 bp) 
and cross B (87.174.110 bp-131.711.739 bp) [148].
SNP ID Coordinate (GRCm38) Gene Symbol C57BL/6J FVB/NJ SIFT Score
rs30016755 87.536.471 Etv3 T C 1
rs30054575 87.556.061 Etv3l A G -
rs31624766 87.728.530 Arhgef11 T C 0.6
rs31085609 87.847.667 Sh2d2a A G 1
rs30756513 87.976.039 Nes T A 1
rs30081012 87.976.065 Nes G A 0.04
rs30699602 87.976.195 Nes T C 0.09
rs31201125 87.976.454 Nes G A 0.11
rs30011971 88.055.415 Gpatch4 C T 0.82
rs13477249 88.247.513 Rhbg A G 0.63
rs13477251 88.854.680 Gon4l C T 0.01
rs30809262 88.912.751 Msto1 A T 1
rs13468134 89.170.304 Clk2 A G 0.95
rs30987263 89.230.775 Muc1 T A 0.78
rs31327584 93.331.614 Hrnr T C -
rs30076287 93.332.617 Hrnr T A -
rs30991551 93.332.685 Hrnr C T -
rs33037297 93.471.541 Tchhl1 G T 0.03
rs30700506 94.317.417 Them4 C T 0.21
rs31054855 94.770.626 Cgn T C 1
rs13459184 95.122.411 Vps72 C T 0.32
rs13459184 95.122.411 Tmod4 C T 0.32
rs30207972 96.442.058 BC107364 A T -
rs13477282 98.713.577 Hsd3b2 A T 0.02
rs3653450 101.860.984 Slc22a15 T G 0.64
rs30608634 102.934.877 Sycp1 G A 0.15
rs13459070 104.804.630 Mov10 A G 0.63
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SNP ID Coordinate (GRCm38) Gene Symbol C57BL/6J FVB/NJ SIFT Score
rs31489662 113.054.049 Gm5548 T A -
rs13466303 116.111.020 Vcam1 A G 1
rs31253294 116.582.921 Trmt13 C G 1
rs30057851 116.589.588 Trmt13 G C 0.19
rs30359775 116.891.876 Frrs1 A G 1
rs30628512 129.810.533 Rrh G T 1
rs30629454 129.810.593 Rrh T C 0.45
rs16790997 129.912.163 Casp6 A G 0.5
rs31379347 134.829.672 Tacr3 G C 0.86
rs13477425 134.932.375 Tacr3 T C 1
rs30358046 138.065.960 1110002E22Rik T G 0.35
rs30406544 138.069.232 1110002E22Rik G A 0.07
rs30256098 138.069.604 1110002E22Rik G A 0.09
rs30902098 138.173.534 4930579F01Rik C A 0.68
rs30980112 139.193.642 Gm4862 G A -
rs30357439 142.352.761 Pdlim5 G A 0
rs30423887 142.507.947 Gbp5 G A 0.19
rs31062787 142.567.699 Gbp3 A G 1
rs31036665 142.569.244 Gbp3 T C 1
rs30720420 154.763.824 Erich3 A C 0
rs30712233 154.872.125 Tnni3k G A 0
rs30203847 155.086.840 Fpgt A G 1
We identified 49 gene transcripts with a SIFT score from 0.0 to 0.05. However, none of the 7 identified 
candidate genes contained non-synonymous protein-sequence-changing SNPs. Thus, it is likely, 
that SNPs within regulatory regions are causal for the differential expression.
3.1.7 Identification of cis-regulated candidate genes by expression QTL (eQTL) 
mapping
To investigate if the B6-derived genetic variants that promoted atherosclerosis also regulated 
gene expression of our candidate genes in cis, we obtained mRNA preparations from livers of 
female F2 mice from cross A (n = 107) or from cross B (n = 120), and performed expression quantitative 
trait locus (eQTL) mapping for Pklr, Vcam1, Elovl6, Agxt2l1, Cth, Tmod4 and Pla2g12a (Figures 25 
and 26) [148].
In cross A, we observed significant LOD scores for Pla2g12a and Cth. These two genes were 
located in the defined confidence interval of cross A. Agxt2l1 and Elovl6 showed no significant 
LOD scores. 
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FIGURE 25: Identification of cis-regulated candidate genes by expression QTL (eQTL) mapping in cross A. 
Black lines- microsatellite markers [104]; blue lines- SNPs used for fine-mapping; green highlighted: 
confidence interval of cross A [148].
We observed a LOD score maximum of 3.6 at SNP rs36523879 for Pla2g12a expression in F2 females 
of cross A, which is 7.4 Mb 5’ to the Pla2g12a gene and the top atherosclerosis marker d3mit45 in 
this subcross (Figure 25). In the same subcross, we observed a significant LOD score for Cth ex-
pression at marker d3mit19, which is located 9.8 Mb distal to marker d3mit45 and only 88.7 kb 3’ 
of the Cth gene. Applying the same conservative cutoff of 1.5 LOD when defining the confi-
dence interval for the Cth cis eQTL [161], Cth’s spans from rs30102565 to rs31598641 (150.234.187 - 
159.008.817 Mb). Thus, there is no overlap between the Cth cis eQTL and the maximum LOD score 
for atherosclerosis in this subcross making Cth an unlikely, candidate gene [148]. 
In cross B, a LOD score maximum of 4.4 for Vcam1 was detected and overlapped most closely 
the location of atherosclerosis-susceptibility at marker d3mit57. We also observed a significant 
eQTL for Pklr at marker d3mit63, however, as with Cth in subcross A, no overlap of the confidence 
interval of the Pklr cis eQTL (d3mit203 to rs3683384; 26.8-110 Mb) with the maximum athero-
sclerosis LOD score was detected. Tmod4, Elovl6, Agxt2l1 and Pla2g12a LOD scores showed no 
significance [148].
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FIGURE 26: Identification of cis-regulated candidate genes by expression QTL (eQTL) mapping in cross B. 
Black lines- microsatellite markers [104]; blue lines- SNPs used for fine-mapping. blue highlighted: 
confidence interval of cross A [148].
Since no eQTLs for Elovl6, Agxt2l1 and Tmod4 were detected, and Cth and Pklr did not overlapped 
with the atherosclerosis LOD score, it is unlikely that genetic variants at Chr3 is causal for their 
differential expression and therefore were not further considered as candidate genes.
In addition, we examined the correlation of Cth in cross A and Pklr in cross B with atherosclerosis 
in mice of the F2 generation. Neither of the two genes revealed a correlation with atherosclerosis 
and therefore were both excluded as candidate genes as previously mentioned.
FIGURE 27: Correlation of (A) Cth and (B) Pklr with atherosclerosis in female F2 progeny from cross A and cross B, 
respectively [148].
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Subsequently, we determined the genotypic effects of the lesion area and the Vcam1 mRNA ex-
pression at marker d3mit57 in the female mice of cross B. There are three different genotypes, 
homozygous for the B6 allele (B/B), heterozygous (B/F) or homozygous for the FVB allele (F/F).
FIGURE 28: Genotypic effects for (A) lesion area and (B) Vcam1 mRNA expression at marker d3mit57 in female 
mice of cross B. ** p < 0.01 [148].
Females, carrying two B6-alleles at d3mit57 had 1.5-fold higher Vcam1 expression levels (p = 0.001) 
and developed 1.9-fold more atherosclerosis (p = 0.004). Since Vcam1 is a well-known regulator 
of atherogenesis [166] and high Vcam1 levels have been shown to promote atherosclerosis [167, 168], 
our data are consistent with the published literature and make Vcam1 a likely effector gene in 
cross B. 
Thus, from the analysis of cross A, Pla2g12a emerged as novel candidate atherosclerosis modifier 
[148].
3.1.8 Fine-mapping in cross A with SNP rs13464244
To improve eQTL mapping accuracy in cross A, we increased the marker coverage at the chromo-
somal location of Pla2g12a by genotyping SNP rs13464244, located only 0.24 Mb 5´ of the gene [148]. 
FIGURE 29: Chr3 LOD score plot for atherosclerosis and Pla2g12a mRNA expression in female F2 progeny of 
cross A after eQTL fine-mapping with SNP rs13464244 [148].
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This resulted in a sharp increase of the LOD score of atherosclerosis (from 3.2 to 3.7) as well as 
from the LOD score of Pla2g12a (from 3.6 to 5.01) and a co-localization for both traits. Homo- 
zygosity for the B6 allele at rs13464244 in F2 females from cross A was associated with enlarged 
atherosclerotic lesions (p = 0.0009) (Figure 29) and decreased mRNA abundance of Pla2g12a com-
pared to the FVB genotype at this position (p = 9.6 x 10-07) suggesting that high Pla2g12a expres-
sion was atheroprotective [148]. 
FIGURE 30: Genotypic effects for (A) lesion area and (B) Pla2g12a mRNA expression at SNP rs13464244. *	p	<	0.05;	
**	p	<	0.01;	*** p < 0.001 [148].
We also observed an inverse correlation of high Pla2g12a mRNA expression with smaller athero- 
sclerotic lesion sizes (r2 = 0.18, p = 0.002) further suggesting that Pla2g12a protects from athero-
sclerosis (Figure 31).
FIGURE 31: Correlation of Pla2g12a mRNA with atherosclerosis in female F2 mice of cross A [148].
Together, eQTL mapping in female F2 progeny from cross A identified Pla2g12a as an independent 
candidate gene for atherosclerosis susceptibility in this locus and indicated that low Pla2g12a 
expression in the arterial wall might promote atherosclerosis [148].
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3.1.9 Gender-dependence of eQTLs in F2 mice of cross A and B
Corroborating the known gender-dependence of this Chr3 QTL (Figure 32), eQTL fine-mapping 
with SNP rs13464244 in F2 males of cross A revealed LOD scores for Pla2g12a and atherosclerosis 
below the significance limit of 3 [148]. 
FIGURE 32: Chr3 LOD score plot for atherosclerosis and Pla2g12a mRNA expression in male F2 progeny of 
cross A after eQTL fine-mapping with SNP rs13464244 [148].
Consistently, no significant differences were observed regarding Pla2g12a mRNA expression and 
lesion area at SNP rs13464244.
FIGURE 33: Genotypic effects at SNP rs13464244 for (A) lesion area and (B) Pla2g12a mRNA expression in male 
mice of cross A. n.s. = not significant [148].
Furthermore, Pla2g12a mRNA levels in male mice of the F2 generation were not correlated with 
atherosclerosis lesions size (r2 = 0.00006, p	=	0.87) [148].
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FIGURE 34: Correlation of Pla2g12a mRNA expression with atherosclerosis in male mice of cross A. n.s. = not 
significant [148].
Similar to the results in male mice of the F2 generation in cross A we investigated the LOD scores 
of atherosclerosis and Vcam1 mRNA expression in 120 male mice of cross B at marker d3mit57. 
As in male mice of cross A, no significant LOD scores for atherosclerosis and Vcam1 mRNA ex-
pression were observed.
FIGURE 35: Chr3 LOD score plot for atherosclerosis and Vcam1 mRNA expression in male F2 progeny of cross 
B at marker d3mit57 [148].
Consistently, no significant differences were observed regarding Vcam1 mRNA expression and 
lesion area at marker d3mit57.
FIGURE 36: Genotypic effects at marker d3mit57 for (A) lesion area and (B) Vcam1 mRNA expression in male 
mice of cross B and correlation of Vcam1 [148].
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Additionally, Vcam1 mRNA levels in male mice of the F2 generation were not correlated with ath-
erosclerosis lesions size (r2 = 0.0002, p	=	0.87).
FIGURE 37: Correlation of Vcam1 mRNA expression with atherosclerosis in male mice of cross B [148].
Together, eQTL mapping in F2 mice indicated that downregulation of Pla2g12a and upregulation 
of Vcam1 might be causal for promoting atherosclerosis in female but not male F2 mice carrying 
the B6 alleles at the two atherosclerosis subloci of the Chr3 risk QTL [148].
3.1.10 Characterization of PLA2G12A
Whereas Vcam1 is an established atherosclerosis modifier gene [169], the potential role of Pla2g12a, 
which belongs to the secreted phospholipase A2 enzymes (sPLA2), in atherogenesis has not been 
investigated, yet. We thus focussed on PLA2G12A and performed qPCR analyses, immunohisto-
chemical stainings and western blots to prioritize which vascular cell type to study in subse-
quent functional analyses [148]. 
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3.1.10.1	Expression profiling of Pla2g12a in different tissues
In order to investigate the expression pattern of Pla2g12a, we first quantified its expression in 
different tissues from FVB mice (n = 3) with higher Pla2g12a expression. Pla2g12a mRNA expression 
was normalized to 106 copies of β-actin house-keeping gene.
FIGURE 38: Pla2g12a mRNA expression in different tissues of FVB mice (n = 3).
Pla2g12a is ubiquitous expressed and highest expression was detected in skeletal muscle, heart, 
brown fat and aorta. Consistent with our previous results, we observed significantly lower ex-
pression levels of Pla2g12a in the aortic tissue of B6 (n = 17) compared to FVB (n = 17) F0 mice [148]. 
FIGURE 39: Pla2g12a mRNA expression in aortic tissue of B6 and FVB F0 mice [148]. 
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3.1.10.2	Immunohistochemical stainings and co-stainings of PLA2G12A
To investigate which cells within atherosclerotic lesions expressed PLA2G12A, we performed 
immunohistochemical stainings in the aortic root of a C57BL/6 mouse co-stained with CD68 
positive macrophages, von Willebrand-factor (vWF) positive endothelial cells and alpha-smooth 
muscle actin (α-SMA) positive smooth muscle cells in consecutive sections in the aortic root of 
a C57BL/6 mouse (Figure 40) [148].
FIGURE 40: Immunohistochemical stainings of PLA2G12A, von Willebrand Factor positive endothelial cells 
(vWF), α-SMA positive smooth muscle cells and CD68 positive macrophages in the aortic root of a 
C57BL/6 mouse. Stainings were performed with Vector NovaRED so that PLA2G12A, CD68, vWF and 
α-SMA are stained red and hematoxylin was used to counterstain cell nuclei [148].
Immunohistochemical stainings showed that PLA2G12A was highly expressed in vascular endo- 
thelial cells (ECs) and to a lesser extent in macrophages [148].
3.1.10.3	Increased Pla2g12a mRNA and protein expression in ECs
Since immunohistochemical stainings demonstrated PLA2G12A expression in cells of atheroscle-
rotic plaques, we used qPCR and Western blotting in order to identify the cell type with highest 
gene expression. To this end, we performed RT-qPCR in MCEC mouse cardiac endothelial cells 
(ECs), bone marrow-derived macrophages (BMD MΦ) of a C57B/L6 mouse and MOVAS smooth 
muscle cells (SMCs).
FIGURE 41: Pla2g12a mRNA expression in mouse cardiac endothelial cells (EC), bone marrow-derived macro-
phages and vascular smooth muscle cells (MOVAS) [148].
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Pla2g12a was expressed most strongly in endothelial cells when compared to cultured macro- 
phages or vascular smooth muscle cells (Figure 41) [148].
Using Western blots, this finding was validated and we also observed highest PLA2G12A protein 
levels in mouse endothelial cells, whereas Glyceraldehyde-3-phosphate-Dehydrogenase (GAPDH) 
was unaltered.
FIGURE 42: PLA2G12A protein levels in mouse cardiac endothelial cells (EC), bone marrow-derived macro-
phages and vascular smooth muscle cells (MOVAS) [148].
3.1.11 Cell culture functional experiments
3.1.11.1	 Pla2g12a-deficiency promotes adhesion between endothelial cells and macrophages
Endothelial cell (EC) activation is one of the first cellular changes in the vasculature en route to 
atherosclerosis [170, 171]. During atherosclerosis development ECs control adhesion of circulating 
leukocytes to nascent atherosclerotic lesions [172]. Previous experiments showed a highly ex-
pression of Pla2g12a in endothelial cells, so we investigated if Pla2g12a was important for the 
adhesive capacity of ECs [148].
For the adhesion experiments, we used bone marrow-derived macrophages (BMDM) from ath-
eroprotective FVB mice, Chr3 congenic FVB.Chr3B6/B6 which contain the 80 Mb genomic DNA from 
Chr3 of C57BL/6 mice and atherosclerosis-sensitive C57BL/6 mice. Herewith, we wanted to explore, 
if genomic elements in the 80 Mb interval have an influence on adhesion.
For quantifying adhesion of BMDM to endothelial cells, two different experimental setups were 
investigated: first, Pla2g12a siRNA-treated endothelial cells (ECs) were preplated on uncoated 
96-well plates 24 hours before adhesion experiments. BMDMs were then allowed to adhere for 
45 min, washed twice and adherent cells were imaged with an IncuCyte Live Cell Analysis System 
(Essen Bioscience). 
Second, BMDM were treated with siRNA for 24 hours and subsequently were allowed to adhere 
to non-treated ECs. Adherent cells were quantified as described above. 
Additionally, cell adhesion assays with RAW264.7 macrophages were performed in 96-well plates 
coated with Matrigel or on uncoated dishes [148].
First, BMDM from FVB.Ldlr -/-, chromosome 3 congenic (FVB.Chr3B6/B6.Ldlr -/-) and C57BL/6.Ldlr -/- 
mice were seeded on mouse cardiac endothelial cells (MCEC) that were treated with siRNAs 
against Pla2g12a or with scrambled (SCR) siRNA control oligonucleotides (Figure 43).
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FIGURE 43: Adhesion of bone marrow-derived macrophages (BMDM) from FVB.Ldlr -/-, chromosome 3 congenic 
(FVB.Chr3B6/B6.Ldlr -/-) and C57BL/6.Ldlr -/- mice on mouse cardiac endothelial cells that were treated 
with siRNAs against Pla2g12a or with scrambled (SCR) siRNA control oligonucleotides. Quadru- 
plicate measurements per condition were performed. *	p	<	0.05;	** p < 0.01 [148].
Here, we found that BMDMs from B6 mice, as well as BMDMs derived from Chr3 congenic mice 
(both with lower Pla2g12a expression) were more adhesive than FVB BMDMs which have relatively 
higher Pla2g12a expression. 
Importantly, we found that depleting Pla2g12a from endothelial cells in this adhesion assay 
further increased adhesion of BMDMs to ECs, with a comparable relative increase in adhesion of 
both B6-derived and FVB-derived BMDMs (Figure 43 A, B). These results indicated that PLA2G12A 
was exhibiting parallel atheroprotective roles in macrophages and in ECs [148]. 
Parallel, we determined the mRNA levels of Pla2g12a and Vcam1 in the endothelial cells after 
Pla2g12a siRNA downregulation. 
FIGURE 44: qPCR analysis of (A) Pla2g12a and (B) Vcam1 mRNA expression in mouse cardiac endothelial cells 
(MCEC) after transfection with Pla2g12a siRNA or using scrambled (SCR) siRNA controls. mRNA 
expression was normalized to 106 copies of β-actin house-keeping gene. Statistical differences 
are depicted relative to SCR control. *** p < 0.001, n.s. = not significant [148].
In this adhesion assay, upon loss of Pla2g12a (Figure 44 A), mRNA levels of the integrin ligand 
Vcam1 did not change (Figure 44 B) suggesting that the change in adhesion was due to Pla2g12a- 
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dependent processes and independent of indirect transcriptional regulation of Vcam1. Pla2g12a 
mRNA expression was significantly reduced after Pla2g12a siRNA mediated knockdown. 
To ask if Pla2g12a levels were determining the adhesive capacity also in bone marrow-derived 
macrophages, we depleted Pla2g12a in BMDM that we derived from FVB, congenic FVB.Chr3B6/B6 
and C57BL/6 mice. After 24 hours BMDMs were let to adhere on untreated endothelial cells [148].
FIGURE 45: Adhesion of bone marrow-derived macrophages (BMDM) from FVB (n = 4), homozygous chromo- 
some 3 congenics (FVB.Chr3B6/B6 [n = 4]) or C57BL/6 (n = 4) mice that were treated with siRNAs against 
Pla2g12a or with scrambled (SCR) siRNA control on untreated mouse cardiac endothelial cells 
(MCEC). *	p	<	0.05;	** p < 0.01 [148].
Here again, we observed an increased adhesion after Pla2g12a knockdown in cells from all genetic 
backgrounds compared to cells treated with scrambled RNAi oligonucleotides (Figure 45).
Pla2g12a mRNA expression in BMDMs was significantly reduced after Pla2g12a siRNA knockdown 
(Figure 46 A) while Vcam1 was not induced during the adhesion experiment (Figure 46 B).
FIGURE 46: qPCR analysis of (A) Pla2g12a and (B) Vcam1 mRNA expression in FVB.Ldlr -/-, chromosome 3 con-
genic (FVB.Chr3B6/B6.Ldlr -/-) and C57BL/6.Ldlr -/- mice after transfection with Pla2g12a siRNA or using 
scrambled (SCR) siRNA controls. mRNA expression was normalized to 106 copies of β-actin house- 
keeping gene. Statistical differences are depicted relative to SCR control. *	p	<	0.05;	*** p < 0.001 
[148].
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To test whether Pla2g12a was, thus, a more general determinant of adhesion, we depleted Pla2g12a 
in a cultures macrophages cell line of independent genetic origin (RAW264.7 cells from BALB/C 
mice). 
While Pla2g12a siRNA mediated knockdown in RAW264.7 macrophages resulted in a significant 
decrease of the Pla2g12a mRNA expression (Figure 47 A), Vcam1 was barely expressed (Figure 47 B), 
and therefore had no influence on the adhesion results. 
FIGURE 47: qPCR analysis of (A) Pla2g12a and (B) Vcam1 mRNA expression in RAW264.7 macrophages after 
transfection with Pla2g12a siRNA or using scrambled (SCR) siRNA controls. mRNA expression was 
normalized to 106 copies of β-actin house-keeping gene. *** p < 0.001 [148].
Pla2g12a-depleted macrophages were seeded on uncoated and with matrigel-coated wells. 
Here again, we observed increased adhesion to both untreated culture plates as well as to 
matrigel-coated surfaces after Pla2g12a knockdown compared to cells treated with scrambled 
RNAi oligonucleotides [148]. 
FIGURE 48: Adhesion of RAW264.7 macrophages on uncoated (A) and matrigel coated (B) membranes after 
siRNA-mediated knockdown of Pla2g12a (n = 4) or using scrambled (n = 4) control olirgonucleo- 
tides. **	p	<	0.01;	*** p < 0.001 [148].
These data indicate that PLA2G12A is normally functioning as anti-adhesive factor irrespective 
of the genetic background which is consistent with the increased sensitivity to atherosclerosis 
when PLA2G12A levels are low [148].
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As the Pla2g12a expression was higher in endothelial cells we also examined the apoptotic be-
havior in mouse cardiac endothelial cells (MCEC) after Pla2g12a siRNA knockdown. Apoptosis in 
MCECs was stimulated with staurosporine (0.125 µM) and cycloheximide (10 ng/ml) (Figure 49).
FIGURE 49: Apoptosis assay in mouse cardiac endothelial cells (MCEC) after siRNA-mediated knockdown of 
Pla2g12a (n = 4) or using scrambled (SCR) oligonucleotide controls (n = 4). Apoptosis in MCECs was 
stimulated with staurosporine (0.125 µM) or cycloheximide (10 ng/ml) for 24 hours. Caspase activity 
is given as luminescence intensity (LI). n.s. = not significant [148].
Depletion of Pla2g12a did not alter any survival properties in MCECs. Therefore, we think that 
this role in curbing adhesion was a specific regulatory process, because depletion of Pla2g12a 
did, for example, not alter other cellular regulatory.
Summarizing, in vivo as well as in vitro data indicate a role for Pla2g12a in protecting from ath-
erosclerosis-relevant cellular functions and highlight Pla2g12a as novel atherosclerosis modifier 
in mice [148].
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Adam17-deficiency promotes atherosclerosis by 
enhanced TNFR2 signalling in mice
 
 
This work has been published in [130].
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3.2 Atherosclerosis locus on mouse chromosome 12
In the first part of this PhD thesis we focused on identifying novel candidate genes of athero-
sclerosis susceptibility in an atherosclerosis locus on mouse chromosome 3. In the same cross, 
the Adam17 gene was previously identified as the candidate gene underlying the atherosclerosis 
locus on mouse chromosome 12. Figure 50 presents the LOD score of atherosclerosis and Adam17 
mRNA expression on mouse chromosome 12. The colocalization of the peak LOD score of Adam17 
mRNA expression to the peak LOD score of atherosclerosis at proximal Chr12 suggested that 
both phenotypes might be related [105].
FIGURE 50: Atherosclerosis- and Adam17 mRNA LOD score on mouse chromosome 12 [105].
Expression QTL (eQTL) mapping in female mice of the F2 generation indicated that reduced ex-
pression of Adam17 mRNA and reduced ADAM17 activity was associated with increased athero-
sclerosis at the aortic root in female mice of the F2 generation [105]. This suggested that Adam17 
might confer atheroprotection, which at first seemed contradictory to its well-established 
role in promoting cell adhesion and inflammation [120, 131, 173-175]. Since Adam17 knockout 
(Adam17ΔZn/ΔZn) mice are not viable and die within several hours after birth having severe 
epithelial abnormalities [131], the direct effect of Adam17-deficiency on atherosclerosis devel-
opment has not been investigated so far. Only recently, hypomorphic Adam17 mice (Adam17 ex/ex) 
have been generated, which are partially deficient for Adam17 and have barely detectable levels 
of Adam17 in all tissues [132]. Until now, conditional knockout mice with Adam17 deletions in 
myeloid cells [133], thymic epithelial cells [134], osteochondroprogenitor cells [135], leucocytes 
[136], and endothelial cells [137, 138] were used to study inflammation (rheumatoid arthritis) and 
cancer. A mouse model overexpressing Adam17 showed no enhanced shedding activity in vivo 
despite higher Adam17 mRNA and protein expression [139]. To date, none of these mouse models 
have been used to study the effect of ADAM17 in atherosclerosis [130].
It was the aim of this thesis, to investigate the influence of partial Adam17-deficiency on athero- 
sclerosis development and elucidated potential mechanisms of atherogenesis. 
  86 / 154
Results – Chapter II –
3.2.1 Generation and characterization of Adam17 ex/ex.Ldlr -/- hypomorphic mice
Hypomorphic Adam17 mice (Adam17 ex/ex) were backcrossed onto the atherosclerosis-susceptible 
Ldl-receptor deficient (Ldlr -/-) background for 6 generations (Adam17 ex/ex.Ldlr -/-). Subsequently, 
heterozygous Adam17 wt/ex.Ldlr -/- mice were mated to generate male and female wild-type 
Adam17 wt/wt.Ldlr -/-, heterozygous mutant Adam17ex/wt.Ldlr -/- and homozygous mutant Adam17 ex/ex.Ldlr -/- 
mice. Homozygous Adam17 ex/ex.Ldlr -/- mice were born at a frequency clearly below the expected 
Mendelian distribution pattern [132], so we also mated male homozygous Adam17 ex/ex.Ldlr -/- mice 
with female heterozygous Adam17 wt/ex.Ldlr -/- mice. Female Adam17 ex/ex.Ldlr -/- mice had reduced milk 
duct development and were not suitable for matings [132]. The following shematic describes the 
matings and the generated mice used for the subsequent atherosclerosis experiments.
FIGURE 51: Shematic of the generation of male and female wild-type Adam17 wt/wt.Ldlr -/-, heterozygous 
Adam17 wt/ex.Ldlr -/- and homozygous mutant Adam17 ex/ex.Ldlr -/- mice. A total of 111 mice were generated. 
To induce atherosclerosis, male and female wild-type Adam17 wt/wt.Ldlr -/-, heterozygous Adam17 wt/ex.Ldlr -/- 
and homozygous Adam17 ex/ex.Ldlr -/- mice were fed a semisynthetic diet for 16 weeks, resulting 
in a moderate degree of hypercholesterolemia, which is more physiological than feeding on a 
high-fat, high-cholesterol diet [99, 130]. Mice were sacrificed at 20 weeks of age after they were 
weaned at 4 weeks of age by a standardized protocol. Total body weight and biochemical char-
acteristics and other clinical chemical parameters of male and female wild-type Adam17 wt/wt.Ldlr -/-, 
heterozygous Adam17 wt/ex.Ldlr -/- and homozygous Adam17 ex/ex.Ldlr -/- mice are indicated in Tables 
23 and 24. 
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Homozygous Adam17 ex/ex.Ldlr -/- mice developed eye, skin and hair defects compared to hetero- 
zygous and wild-type mice as previously described by Chalaris et al. [132]. In addition, 
Adam17 ex/ex.Ldlr -/- mice developed slightly enlarged hearts compared to wild-type Adam17 wt/wt.Ldlr -/- 
mice (4205 µm2/3772 µm2; 35/39 mice; p = 3.11 x 10-5) in accordance to TACEΔZn/ΔZn null mutants, which 
exhibit markedly enlarged fetal hearts and die at birth [176]. Plasma parameters were analyzed 
in an automated analyzer (Modular PPE, Roche) and lipoproteins were isolated by sequential 
ultracentrifugation.
Plasma total-, LDL-, and HDL-cholesterol levels were not significantly different in female 
Adam17 ex/ex.Ldlr -/- and Adam17 wt/wt.Ldlr -/- mice (Tables 23 and 24). In male Adam17 ex/ex.Ldlr -/- mice, 
LDL-cholesterol was even lower than in Adam17 wt/wt.Ldlr -/- controls. White blood cells were signifi- 
cantly elevated in whole blood of Adam17 ex/ex.Ldlr -/- mice. 
TABLE 23: Total body weight, biochemical characteristics and chemical clinical parameters of female 
Adam17 wt/wt.Ldlr -/-, Adam17 wt/ex.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice [130]. 
Measurement Adam17
 wt/
wt.Ldlr -/-
Adam17 wt/
ex.Ldlr -/- Adam17
 ex/ex.Ldlr -/- p-Value
n = 21 21 16 wt/ex* wt/het† het/ex‡
Body Weight [g] 19.5 ± 1.2 19 ± 0.9 19.5 ± 2.2 n.s. n.s. n.s.
Cholesterol [mg/dl] 521.7 ± 125.9 440.5 ± 90.4 577 ± 207 n.s. 0.01 0.009
LDL-Chol [mg/dl] 380.8 ± 85.1 303 ± 116.1 429.7 ± 117.7 n.s. 0.04 0.008
HDL-Chol [mg/dl] 69.7 ± 29.8 74.2 ± 37.2 62.9 ± 14.5 n.s. n.s. n.s.
Triglycerides [mg/dl] 137.5 ± 55.3 108 ± 46.8 240.5 ± 149.3 0.006 n.s. 0.0004
WBC [g/l] 1.44 ± 0.61 1.51 ± 0.53 2.97 ± 2.26 0.005 n.s. 0.006
ALT [U/l] 30 ± 18.9 27.6 ± 9.7 43.3 ± 18.8 0.04 n.s. 0.001
AST [U/l] 135.6 ± 64.5 158.8 ± 85.9 136.1 ± 40.2 n.s. n.s. n.s.
Cholinesterase [KU/l] 5.6 ± 1 6.1 ± 0.9 4.7 ± 1.2 0.005 n.s. 0.00001
GLDH [U/l] 14.8 ± 9.1 11.8 ± 4.9 45.4 ± 29.9 5.4	x	10-5 n.s. 4.5	x	10-6
Glucose [mg/dl] 278.8 ± 48.8 298 ± 53.6 249 ± 65 n.s. n.s. 0.006
Urea [mg/dl] 44.6 ± 10.2 45.2 ± 8.5 53.5 ± 14.7 0.014 n.s. 0.012
Total Protein [g/dl] 4.8 ± 0.4 4.4 ± 0.4 4.6 ± 1 n.s. 0.002 0.02
Data are given as mean ± SD. LDL-Chol, low-density lipoprotein cholesterol; HDL-Chol, high-density lipoprotein 
cholesterol; WBC, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLDH, Glutamate 
dehydrogenase. Comparison of multiple groups was done using ANOVA, and Tukey was performed as a post-test. 
*	Comparison of Adam17 wt/wt.Ldlr -/- (wt) and Adam17 ex/ex.Ldlr -/- (ex) mice;	† Comparison of Adam17 wt/wt.Ldlr -/- (wt) and 
Adam17 wt/ex.Ldlr -/- (het) mice;	‡ Comparison of Adam17 wt/ex.Ldlr -/- (het) and Adam17 ex/ex.Ldlr -/- (ex) mice.
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TABLE 24: Total body weight, biochemical characteristics and chemical clinical parameters of male 
Adam17 wt/wt.Ldlr -/-, Adam17 wt/ex.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice [130].
Measurement Adam17
 wt/
wt.Ldlr -/-
Adam17 wt/
ex.Ldlr -/- Adam17
 ex/ex.Ldlr -/- p-Value
n = 15 19 19 wt/ex* wt/het† het/ex‡
Body Weight [g] 25.2 ± 3.3 24.5 ± 1.2 24.9 ± 2 n.s. n.s. n.s.
Cholesterol [mg/dl] 394 ± 78 401 ± 61 379 ± 68 n.s. n.s. n.s.
LDL-Chol [mg/dl] 313.5 ± 56.8 285.4 ± 70.4 265 ± 39.5 0.009 n.s. n.s.
HDL-Chol [mg/dl] 91.7 ± 22.4 101.5 ± 39.4 82.9 ± 9.1 n.s. n.s. n.s.
Triglycerides [mg/dl] 127.5 ± 45.5 141.9 ± 43.5 181.6 ± 81.4 0.02 n.s. n.s.
WBC [g/l] 1.52 ± 0.68 1.46 ± 0.65 2.62 ± 2.48 n.s. n.s. 0.04
ALT [U/l] 30.1 ± 43.4 23.5 ± 5.6 44.7 ± 43.1 n.s. n.s. 0.03
AST [U/l] 115.2 ± 87.1 172.5 ± 79 125.1 ± 43.1 n.s. 0.04 0.048
Cholinesterase [KU/l] 4.1 ± 0.9 4.6 ± 0.4 3.2 ± 0.7 0.0001 0.02 4.9	x	10-14
GLDH [U/l] 16.7 ± 29.3 10.7 ± 4.1 35.4 ± 26.6 0.04 n.s. 0.0001
Glucose [mg/dl] 306.7 ± 74.2 322 ± 32.5 263 ± 62.5 0.027 n.s. 3.5	x	10-5
Urea [mg/dl] 49 ± 20 45 ± 4.3 61.5 ± 17.3 0.025 n.s. 6.8	x	10-7
Total Protein [g/dl] 4.9 ± 0.3 4.6 ± 0.2 4.6 ± 1 0.01 0.0005 n.s.
Data are given as mean ± SD. LDL-Chol, low-density lipoprotein cholesterol; HDL-Chol, high-density lipoprotein 
cholesterol; WBC, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLDH, Glutamate 
dehydrogenase. Comparison of multiple groups was done using ANOVA, and Tukey was performed as a post-test. 
*	Comparison of Adam17 wt/wt.Ldlr -/- (wt) and Adam17 ex/ex.Ldlr -/- (ex) mice;	† Comparison of Adam17 wt/wt.Ldlr -/- (wt) and 
Adam17 wt/ex.Ldlr -/- (het) mice;	‡ Comparison of Adam17 wt/ex.Ldlr -/- (het) and Adam17 ex/ex.Ldlr -/- (ex) mice.
3.2.2 Tissue expression profiling in Adam17 hypomorphic mice
We examined the Adam17 mRNA expression in different tissues and cells of wild-type Adam17 wt/wt.Ldlr -/- 
and homozygous Adam17 ex/ex.Ldlr  -/- mice using quantitative polymerase chain reaction (qPCR). 
Bone marrow cells were thawed and differentiated into macrophages (MΦ). Adam17 copies were 
normalized to µg RNA.
FIGURE 52: Adam17 mRNA expression in different tissues of Adam17 wt/wt.Ldlr  -/- (n = 6) and Adam17 ex/ex.Ldlr -/- (n = 6) 
mice. MΦ, Macrophages. *** p < 0.001 [130]
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We validated a consistent and ubiquitous decrease of Adam17 mRNA expression in cells and tissues 
of hypomorphic Adam17 ex/ex.Ldlr  -/- mice (Figure 52). The highest Adam17 mRNA expression was 
observed in bone marrow-derived macrophages (BMDM) [130]. 
3.2.3 Increased atherosclerosis in Adam17-deficient mice
To investigate the role of Adam17-deficiency in atherosclerosis we quantified atheroscle-
rotic lesions at oil red O-stained sections of the aortic root of male and female wild-type 
Adam17 wt/wt.Ldlr  -/- mice (n = 15/21), heterozygous Adam17 wt/ex.Ldlr  -/- (n = 19/21) and homozygous 
Adam17 ex/ex.Ldlr  -/- (n = 19/16) mice at 20 weeks of age.
In the aortic root, atherosclerosis was significantly increased in Adam17 ex/ex.Ldlr  -/- compared to 
Adam17 wt/wt.Ldlr  -/- mice, were male and female hypomorphic mice developed both approximately 
1.5 fold larger atherosclerotic lesions compared to wild-type controls [130]. 
FIGURE 53: Increased atherosclerosis in Adam17-deficient mice on the Ldlr  -/- background. Representative oil red 
O stainings of aortic roots of male and female (A/D) Adam17 wt/wt.Ldlr  -/- and (B/E) Adam17 ex/ex.Ldlr -/- 
mice, respectively. Quantification of atherosclerotic plaque area at the aortic root of male (C) and 
females (F) Adam17 wt/wt.Ldlr -/-(wt/wt), Adam17 wt/ex.Ldlr -/-(wt/ex) and Adam17 ex/ex.Ldlr -/- (ex/ex) mice. 
Animal numbers are given in the columns. Values are given as mean + SEM. * p	<	0.05; ** p < 0.01 [130].
These findings corresponded with the data from the previous study, demonstrating that reduced 
Adam17 expression and activity was associated with increased atherosclerosis at the aortic root 
in an F2 intercross of atherosclerosis susceptibility B6 and atherosclerosis resistance FVB mice 
[105]. 
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3.2.4 Immunohistochemical and immunofluorescence stainings
To examine the cellular composition of lesions in wild-type Adam17 wt/wt.Ldlr -/- and homo- 
zygous Adam17 ex/ex.Ldlr -/- mice we performed immunohistochemical stainings for CD68 positive 
macrophages, von Willebrand-factor (vWF) positive endothelial cells and alpha-smooth muscle 
actin (α-SMA) (Figure 54). Oil red O stainings of wild-type Adam17 wt/wt.Ldlr -/- and homozygous 
Adam17 ex/ex.Ldlr -/- mice are also shown.
FIGURE 54: Immunohistochemical staining (oil red O, CD68, vWF, α-SMA) of the aortic root of wild-type 
Adam17 wt/wt.Ldlr -/- and homozygous Adam17 ex/ex.Ldlr -/- mice.
No differences were observed at the cellular composition, but we observed significantly altered 
aortic valve morphology (thickening of the aortic valves) of male and female Adam17 ex/ex.Ldlr -/- 
mice compared to heterozygous and wild type littermate controls as previously described in 
mice (Tie2-Cre/+; Adam17Fl/ΔEx5) with endothelial cell-specific Adam17 ablation [138].
To investigate, which cells within atherosclerotic lesions expressed ADAM17, and to prioritize 
cells for subsequent functional studies, we performed immunofluorescence co-stainings in 
plaques of aortic roots of wild-type C57BL/6 mice with respect to the content of CD68 and Mac2 
positive macrophages, von Willebrand-factor (vWF) positive endothelial cells and alpha-smooth 
muscle actin (α-SMA) [130].
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FIGURE 55: Immunofluorescence co-stainings of ADAM17 protein with (A) CD68-positive macrophages, with 
(B) MAC2-positive macrophages, with (C) von Willebrand-factor (vWF)-positive vascular endothelial 
cells and with (D) Smooth muscle actin (α-SMA)-positive vascular smooth muscle cells in the 
plaque area of an aortic root of a C57BL/6 mouse [130].
We found that ADAM17 protein was expressed in CD68- and Mac2-positive macrophages, von 
Willebrand factor-positive endothelial cells, and α-SMA positive vascular smooth muscle cells 
demonstrating that all key cells involved in atherosclerosis development, expressed this gene [130].
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3.2.5 Adam17 mRNA expression and ADAM17 protein levels in different cell types
We next investigated the Adam17 mRNA expression and the ADAM17 protein levels in RAW264.7 
macrophages, mouse cardiac endothelial cells (MCEC) and MOVAS vascular smooth muscle 
cells. Copies of Adam17 mRNA were normalized to 106 copies of β-actin house-keeping gene and 
GAPDH protein levels was used as a control for the western blot analysis.
FIGURE 56: Quantification of (A) Adam17 mRNA expression and (B) western blot of ADAM17 protein in mouse 
cardiac endothelial cells (MCEC), vascular smooth muscle cells (MOVAS) and RAW264.7 macro-
phages [130]. 
Adam17 mRNA expression was higher in RAW264.7 cells, and in a less degree in vascular smooth 
muscle cells MOVAS cells and mouse cardiac endothelial cells MCEC cells. On the protein level, 
highest ADAM17 expression was observed in RAW264.7 macrophages compared to MCEC and 
MOVAS cells.
  93 / 154
Results – Chapter II –
3.2.6 Reduced release of TNFR1 and TNFR2 in plasma of Adam17 ex/ex.Ldlr -/- mice
ADAM17 is involved in several physiological and pathophysiological processes including ad- 
hesive and proteolytic properties and is also an important mediator of cell signaling which 
determine cellular fate, proliferation, and growth [121]. Until now, more than 70 substrates of 
ADAM17 have been identified [122]. The substrates of ADAM17 include membrane receptors, 
adhesion molecules, growth factors, cytokines and chemokines. Using multiplex technology, 
we systematically investigated the plasma concentrations of prototypical ADAM17 substrates 
in wild-type Adam17 wt/wt.Ldlr -/- (n = 12), heterozygous Adam17 wt/ex.Ldlr -/- (n = 10) and homozygous 
Adam17 ex/ex.Ldlr -/- (n = 12) mice such as soluble tumor necrosis factor receptor 1 (sTNFR1), soluble 
tumor necrosis factor receptor 2 (sTNFR2), soluble interleukin-6 receptor (sIL-6R), soluble tumor 
necrosis factor alpha (sTNFα), soluble fractalkine (sFractalkine), soluble interleukin-1 receptor 2 
(sIL1-R2), soluble vascular endothelial growth factor receptor 2 (sVEGFR2), soluble CD30 (sCD30) 
and soluble vascular cell adhesion protein 1 (sVCAM1) [130].
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FIGURE 57: Release of ADAM17 protein substrates in plasma. Soluble (s) (A), sTNFR1, (B), sTNFR2, (C), sIL-6R, 
(D), sTNFα, (E), sFractalkine, (F), sIL-1R2, (G), sVEGFR2, (H), CD30 and (I) sVCAM1 levels in plasma 
samples of Adam17 wt/wt.Ldlr -/- (wt; n = 12), Adam17 wt/ex.Ldlr -/- (wt/ex; n = 10) and Adam17 ex/ex.Ldlr -/- 
(ex; n = 12) male and female mice [130].
We detected significantly reduced plasma levels of sTNFR1, sTNFR2 and sIL-6R in male and female 
Adam17 ex/ex.Ldlr -/- mice compared to Adam17 wt/wt.Ldlr -/- controls (Figures 57 A-C). For soluble TNFα, 
we observed a trend toward decreased plasma levels in male and female mice, which did not 
reach significance (Figure 57 D). sIL1-R2 was significantly reduced only in female Adam17 ex/ex.Ldlr -/- 
mice (Figure  57  E). The release of other ADAM17 substrates (sFractalkine, sVEGFR2, CD30 and 
sVCAM1) was not significantly altered or inconsistent (Figure 57 E, G-I) [130]. 
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3.2.7 Plasma levels of ADAM17-independent inflammatory mediators 
We further tested plasma levels of a set of ADAM17-independent inflammatory mediators like 
soluble interferon-γ (IFN-γ), soluble interleukin-1 beta (IL-1β), soluble interleukin-6 (IL-6), soluble 
interleukin-10 (IL-10), soluble monocyte chemotactic protein 1 (MCP-1), soluble macrophage in-
flammatory protein 1α (MIP-1α) and soluble macrophage inflammatory protein 1β (MIP-1β) in 
wild-type Adam17 wt/wt.Ldlr -/- (n = 12), heterozygous Adam17 wt/ex.Ldlr -/- (n = 10) and homozygous 
Adam17 ex/ex.Ldlr -/- (n = 12) mice using the Luminex technology [130]. 
IL-1β and IL-6 are proinflammatory cytokines, IL-10 belongs to the anti-inflammatory cytokines, 
while MCP-1, MIP-1α, MIP-1β, and RANTES belong to the chemotactic proteins (chemokines) and 
IFN-γ is an immunoregulatory protein. 
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FIGURE 58: Cytokine release in plasma samples of Adam17 wt/wt.Ldlr -/-, Adam17 wt/ex.Ldlr -/- and Adam17 ex/ex.Ldlr -/- 
mice. (A) soluble IFN-γ (sIFN-γ), (B) sIL-1β, (C) sIL-6, (D) sIL-10, (E) sMCP-1, (F) sMIP-1α, (G) sMIP-1β, 
and (H) sRANTES levels in plasma samples of Adam17 wt/wt.Ldlr -/- (wt, n = 12), Adam17 wt/ex.Ldlr -/- (wt/ex, 
n = 10) and Adam17 ex/ex.Ldlr -/- (ex, n = 12) mice. * p	<	0.05; ** p < 0.01; *** p < 0.001 [130]. 
Proinflammatory cytokine IL-1β was significantly decreased in plasma samples of Adam17- 
deficient mice, while IL-6 and IL-10 were unchanged in Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- 
male and female mice (Figures 58 B-D). Chemokines MIP-1α (CCL3) and MIP-1β (CCL4) which are 
formed under pathological conditions and participate in the inflammatory response attracting 
immune cells to the site of inflammation were significantly less released especially in female 
mice (Figures  58  F, G). Released soluble MCP-1 and RANTES showed no differences between 
Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- male and female mice (Figures 58 E, H).
In summary, we observed no consistent trend between Adam17 wt/wt.Ldlr -/-, Adam17 wt/ex.Ldlr -/- and 
Adam17 ex/ex.Ldlr -/- male and female mice, indicating that Adam17-deficiency did not alter inflam-
matory signaling per se in our atherosclerosis model [130].
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3.2.8 ADAM17 substrate release in the supernatant of BMDM
For functional validation, we used in vitro cell culture of bone marrow-derived macrophages 
(BMDM) from Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice and quantified ADAM17 substrates, 
that were differentially released in plasma, in the supernatants with and without stimulation 
with phorbol 12-myristate 13-acetate (PMA), which is an activator of ADAM17 (Figures 59 A-D) [130]. 
FIGURE 59: Release of ADAM17 substrates in the supernatant of bone marrow derived macrophages. (A) sTNFR1, 
(B) sTNFR2, (C) sTNFα, and (D) sIL-6R levels in the supernatants of macrophages of Adam17 wt/wt.Ldlr -/- 
(wt) and Adam17 ex/ex.Ldlr -/- (ex) mice with and without stimulation with phorbol 12-myristate 
13-acetate (PMA). * p <	0.05; ** p < 0.01; *** p < 0.001 [130].
Bone marrow-derived macrophages of Adam17 ex/ex.Ldlr -/- mice released significantly less sTNFR1 
and sTNFR2 compared with macrophages from wild-type controls (Figures 59 A, B). Significant 
differences of sTNFα and sIL-6R release were only detected after stimulation with PMA, which in-
duced shedding in macrophages from wild-type but not from Adam17 ex/ex.Ldlr -/- mice (Figures 59 C, D). 
Taken together, these data indicated strongest effects of Adam17-deficiency on the shedding of 
TNF-receptors and of their ligand TNFα [130].
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3.2.9 TNFR1 and TNFR2 signaling in Adam17 ex/ex.Ldlr -/- Mice
To investigate whether differential shedding of TNFR1, TNFR2, and TNFα affected their cellular 
expression levels, we quantified these proteins in whole cell lysates and in the cellular mem-
brane fraction of bone marrow-derived macrophages (BMDM) of wild-type Adam17 wt/wt.Ldlr -/- and 
homozygous Adam17 ex/ex.Ldlr -/- mice. 
Here, we found that cellular protein levels of ADAM17 were barely detectable in hypomorphic 
Adam17 ex/ex.Ldlr -/- mice compared to wild-type Adam17 wt/wt.Ldlr -/- mice validating the hypomorphic 
Adam17 ex/ex.Ldlr -/- mice. Whereas TNFR1 levels were unchanged, cellular TNFα and TNFR2 protein 
levels were significantly elevated in homozygous Adam17 ex/ex.Ldlr -/- macrophages (Figure 60 A, B) 
[130]. 
FIGURE 60: (A) Western blot and (B) densitometric analysis of ADAM17, TNFα, TNFR1, TNFR2, and GAPDH control 
in whole cell lysates from BMDM of Adam17 wt/wt.Ldlr -/- (n = 3) and Adam17 ex/ex.Ldlr -/- (n = 3) mice [130].
Whereas TNFR1 is activated through both, membrane-bound TNFα (mTNFα) and soluble TNFα, 
TNFR2 becomes only activated by mTNFα [177]. To investigate this cell-membrane distribution, 
bone marrow-derived macrophages from wild-type Adam17 wt/wt.Ldlr -/- and homozygous 
Adam17 ex/ex.Ldlr -/- mice were labeled with the cell-impermeable EZ-Link Sulfo-NHS-SS-Biotin 
and isolated using Dynabeads MyOne Streptavidin C1. As a cell membrane marker we used the 
Na+/K+ ATPase. 
Consistently with the results from the whole cell lysates, we observed higher amounts of 
cell membrane-bound TNFα (mTNFα) as well as cell membrane-bound TNFR2 (mTNFR2) in 
Adam17 ex/ex.Ldlr/- macrophages compared to control macrophages (Figure 60) whereas TNFR1 
membrane distribution was not significantly altered [130].
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FIGURE 61: Western blots of ADAM17, TNFα, TNFR1, TNFR2, and Na+/K+ ATPase as a control in cell membrane 
fractions of primary BMDMs of Adam17 wt/wt.Ldlr -/- (n = 3) and Adam17 ex/ex.Ldlr -/- (n = 3) mice [130].
To investigate whether elevated amounts of mTNFα and mTNFR2, thus, resulted in an activation 
of TNFR2 signaling in Adam17-depleted cells, we quantified the phosphorylated form of bone 
marrow tyrosine kinase in chromosome X (pBMX), which is a downstream marker of TNFR2 but 
not TNFR1 activation. The endothelial/epithelial tyrosine kinase (Etk/Bmx) is a member of the 
Btk nonreceptor tyrosine kinase family. Etk and three other members of this family, (Btk, Itk, and Tec) 
participate in signal transduction stimulated by growth factor receptors, cytokine receptors, 
G-protein-coupled receptors, antigen receptors, and integrins [178]. This TNFR2-signaling path-
way has been shown to positively stimulate cell survival, proliferation, and adhesion [178-180] 
which is opposite to classical TNFR1 signaling that induces antiproliferative effects. We observed 
an increase of absolute and also of phosphorylated BMX protein in macrophages of Adam17 ex/ex.Ldlr -/- 
mice, indicating an activation of TNFR2 signaling in these cells [130].
FIGURE 62: (A) Western blots and (B) densitometric analysis of TNFR2 effector protein BMX and activated 
phosphorylated BMX (pBMX) in whole cell lysates primary BMDMs of Adam17 wt/wt.Ldlr -/- (n = 3) and 
Adam17 ex/ex.Ldlr -/- (n = 3) mice. GAPDH was used as control [130].
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3.2.10 Genome-wide expression profiling in mouse BMDM and aortas validated 
activation of TNF-signaling
Cytokines, such as TNFα, in concert with cytokine receptors, such as the ADAM17 substrates 
TNFR1, TNFR2 and IL-6R, control cellular functions through activating signaling cascades, which 
finally result in expression changes of gene networks. To investigate whether cell-specif-
ic TNFR2 activation is also observed in aortic tissue, and to test whether activation of TNFR2 
signaling was relevant for gene expression changes in Adam17 mutants, we performed trans- 
criptome-wide mRNA expression profiling using Illumina Ref-8 arrays microarrays in primary 
bone marrowderived macrophages (BMDMs) and aortas of female and male Adam17 wt/wt.Ldlr -/- and 
Adam17 ex/ex.Ldlr -/- mice (females n = 4/4; males n = 4/4) [130]. 
We performed an upstream regulator analysis using the Ingenuity Pathways Analysis (IPA/ 
www.ingenuity.com) and thereby calculated z-scores.The activation z-score makes predictions 
about potential regulators by using information about the direction of gene regulation [181]. Its 
purpose is two-fold: first, similar to the overlap p-value, the z-score can be used to determine 
likely regulators based on statistical significance of the pattern match Second, it can be used 
to infer the activation state of a putative regulator (i.e. whether the regulator is activated or in- 
hibited) [181]. Subsequently, we performed a gene set enrichment analysis to investigate which 
cell functions might be affected by Adam17-deficiency.
In Table 25, the top three pathways and TNFR2 of the combined upstream analysis in primary 
BMDM are shown.
TABLE 25: Combined upstream analysis of male and female Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice of 
bone marrow-derived macrophages (BMDM). Levels of significance and activation z-scores were 
calculated according to standard procedures of the software [130].
Macrophages
z-Score p-Value Molecules
TNFα 2.5 1.76 x 10-14 185
IL1β 2.4 2.63 x 10-14 149
IFNγ 1.8 2.73 x 10-09 157
TNFR2 2.2 3.76 x 10-03 166
In this analysis, we validated a significant induction of TNFα- and TNFR2-signaling pathways in 
Adam17 ex/ex.Ldlr -/- BMDMs (1.76 x 10-14 and 3.76 x10-03, respectively) (Table 25). 
Subsequently, we performed a combined upstream analysis of male and female Adam17 wt/wt.Ldlr -/- 
and Adam17 ex/ex.Ldlr -/- mice in the aortic tissue [130].
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TABLE 26: Combined upstream analysis of male and female Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice in 
aortas. Levels of significance and activation z-scores were calculated according to standard pro-
cedures of the software [130].
Aorta
z-Score p-Value Molecules
TNFα 5.6 2.08 x 10-46 467
IL1β 6.6 6.41 x 10-32 448
IFNγ 8.1 1.40 x 10-38 463
TNFR2 2.5 3.83 x 10-4 445
Here, we also detected a significant induction of TNFα and TNFR2 signaling (p = 2.08 x 10-46 and 
p = 3.83 x 10-4, respectively). 
With respect to TNFR1 signaling, we only observed a weak activation in macrophages (p = 1.09 x 10-02) 
and no significant activation in aortas. 
Together, data from the transcriptome-wide mRNA expression profiling in BMDMs and aortas 
indicated a stronger induction of TNFR2 by membrane-bound TNFα than TNFR1 signaling in 
Adam17-deficiency [130].
To determine metabolic, disease-related, and important cell function that might be affected 
by Adam17-deficiency, we performed pathway analysis using the Ingenuity Pathway Analysis 
(IPA) software. Genes with expression changes of < 0.7 and > 1.3, which were chosen as arbitrary 
biologically relevant cut off, in aorta and macrophages of wild-type Adam17 wt/wt.Ldlr -/- and 
hypomorphic Adam17 ex/ex.Ldlr -/- mice were used. In Table 27, pathways with significant enrich-
ment p < 10-6 are listed.
TABLE 27: Gene set enrichment analysis in aorta and bone marrow-derived macrophages (BMDM) of 
Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice. 
Function Aorta BMDM
Cellular growth and proliferation 2.20 x 10-37 2.62 x 10-24
Cellular development 2.20 x 10-37 4.73 x 10-13
Cellular movement/adhesion 5.11 x 10-36 8.60 x 10-15
Cell death and survival 1.14 x 10-19 2.58 x 10-16
Together, this analysis predicted that Adam17-deficiency controlled cellular growth and prolifer-
ation, cellular development, cellular movement/adhesion and cell death and survival which are 
key cell functions in the development of atherogenesis [1].
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3.2.11 Adam17-deficiency controls cell functions of atherosclerosis in macrophages, 
endothelial- and smooth muscle cells
3.2.11.1	Adam17-deficiency in primary macrophages
Apoptosis and proliferation are processes that are controlled through both TNF-receptor signalings. 
Whereas TNFR1 induces apoptosis and reduces proliferation, TNFR2 signalling has been associ-
ated with anti-apoptotic and proliferative cellular response [182]. Furthermore, TNFR2 signaling 
has been shown to increase cell adhesion by inducing the expression of intercellular cell ad- 
hesion molecule-1 (ICAM1) in different mouse models [183, 184]. 
qRT-PCR, immunofluorescence and western blot analysis revealed higher Adam17 expression in 
endothelial cells (ECs) as well as in macrophages (MΦ) and vascular smooth muscle cells (SMCs), 
therefore functional experiments were performed in all three cell types using primary cell lines.
To investigate whether Adam17-deficiency controlled cell functions through modulating 
TNFR2-signalling, we investigated apoptosis in bone marrow-derived macrophages (BMDM) of 
Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice. To this, BMDMs were stimulated with staurosporine 
(0.125 µM and 0.25 µM) and cycloheximide (10 ng/ml and 50 ng/ml). The main biological activity 
of staurosporine is the inhibition of protein kinases through the prevention of ATP binding to 
the kinase, thereby inducing apoptosis. Cycloheximid’s main biological activity is translation 
inhibition resulting in cell growth arrest and cell death by inhibiting protein biosynthesis at the 
ribosomes.
FIGURE 63: Apoptosis assay in bone marrow-derived macrophages of Adam17 wt/wt.Ldlr -/- (n = 4) and Adam17 ex/ex.Ldlr -/- 
(n = 4) mice in cell culture medium and after stimulation with staurosporine and cycloheximide. 
Caspase activity is given as luminescence intensity (LI) [130].
Apoptosis, as determined by caspase-3 activity, was significantly diminished in BMDM of 
Adam17 ex/ex.Ldlr -/- mice compared to Adam17 wt/wt.Ldlr -/- mice using different concentrations of 
staurosporine and cycloheximide (Figure 63). 
Furthermore, we tested the proliferation rate of bone marrow-derived macrophages of Adam17 ex/ex.Ldlr -/- 
and Adam17 wt/wt.Ldlr -/- mice. Here, we found that primary macrophages of Adam17 ex/ex.Ldlr -/- mice 
proliferated more than cells of Adam17 wt/wt.Ldlr -/- controls. Figure 64 shows the proliferation rate 
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over a time of 96 h in cultured primary BMDMs of Adam17 wt/wt.Ldlr -/- (n = 4) and Adam17 ex/ex.Ldlr -/- 
(n = 4) mice and at timepoint 96 h.
FIGURE 64: Cell proliferation in cultured primary BMDMs of Adam17 wt/wt.Ldlr−/− and Adam17 ex/ex.Ldlr−/− mice (A) over 
96 h and (B) at time point 96 h. *	p	<	0.05 [130].
Moreover, we performed adhesion experiments with primary macrophages of Adam17 ex/ex.Ldlr -/- 
and Adam17 wt/wt.Ldlr -/- mice. Adhesion experiments were performed in quadruplicates of 6 cell 
lines per genotype that were independently derived from 6 mice. We observed that bone marrow- 
derived macrophages of Adam17 ex/ex.Ldlr -/- mice adhered stronger to matrigel-coated wells than 
macrophages of control mice (Figure 65 A) [130]. 
To find out, whether the intercellular adhesion molecule 1 (ICAM1), a substrate of ADAM17, which 
is expressed by the vascular endothelium, macrophages, and lymphocytes plays a role in ad- 
hesion, we examined the protein levels of ICAM1 in whole cell lysates from a pool of primary 
BMDMs of Adam17 wt/wt.Ldlr -/- and a pool of primary BMDMs of Adam17 wt/wt.Ldlr -/- mice (Figure 65 B). 
FIGURE 65: (A) Adhesion of primary BMDMs of Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- to matrigel-coated 
wells. Adhesion experiments were performed in quadruplicates of 6 cell lines per genotype that 
were independently derived from 6 mice. 3 male and 3 female mice per genotype were used. 
(B) Western blot of ICAM1 and GAPDH control in whole cell lysates of a pool of primary BMDMs of 
Adam17 wt/wt.Ldlr -/- (n = 3) and Adam17 ex/ex.Ldlr -/- (n = 3) mice. *** p < 0.001 [130].
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By this, we could show that, primary macrophages of Adam17 ex/ex.Ldlr -/- mice induced higher ex-
pression levels of intercellular adhesion molecule 1 (ICAM1) compared to Adam17 wt/wt.Ldlr -/- mice 
(Figure 65 B), which is a plausible explanation for the enhanced adhesion of macrophages of 
Adam17 ex/ex.Ldlr -/- mice [130].
3.2.11.2	Adam17-deficiency affects apoptosis, proliferation and adhesion in mouse RAW264.7 
macrophages and mouse vascular smooth muscle cells MOVAS
To validate our previous findings in BMDMs with respect to apoptosis, proliferation and adhesion 
in an independent model, we knocked down Adam17 in RAW264.7 macrophages using small inter- 
fering RNA (siRNA). As a control, we used a scrambled (SCR) oligonucleotides. We obtained ~50 % 
knockdown efficiency of Adam17 in RAW264.7 macrophages (Figure 66).
FIGURE 66: Validation of Adam17 siRNA knockdown efficiency in RAW264.7 macrophages using qRT-PCR after 
48 hours. *** p < 0.001 [130].
The apoptosis assay in RAW264.7 macrophages after siRNA knock-down of Adam17 (n = 4) or after 
using scrambled siRNA control was stimulated with staurosporine (0.25 µmol/l) and cyclo- 
heximide (10 ng/ml) and validated that Adam17 knock-down reduced apoptosis at basal condi-
tions as well as after stimulation with staurosporine and cycloheximide (Figure 67). 
FIGURE 67: Apoptosis assay in RAW264.7 macrophages after siRNA knock-down of Adam17 and scrambled 
control siRNA in cell culture medium and after stimulation with staurosporine and cycloheximide 
(CHX). The caspase activity is given as luminescence intensity. *** p < 0.001 [130].
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We next examined the proliferation behavior of Adam17-depleted RAW264.7 macrophages over a 
period of 96 hours. We found an increased proliferation of Adam17 down-regulated macrophages 
compared to macrophages treated with SCR control siRNA oligonucleotide. Figure 68 A shows 
the proliferation performance over 96 hours and Figure 68 B at timepoint 96 hours. At time point 
96 hours we observed a significant difference between SCR and Adam17 siRNA treated RAW264.7 
macrophages.
FIGURE 68: Cell proliferation in RAW264.7 macrophages after Adam17 siRNA mediated (n = 4) knock-down or 
SCR RNAi (n = 4) control (A) over 96 h and (B) at timepoint 96 h. *	p	<	0.05;	*** p < 0.001 [130].
Adhesion experiments were performed with RAW264.7 macrophages on matrigel-coated wells. 
FIGURE 69: Adhesion of RAW264.7 macrophages after siRNA-mediated knockdown of Adam17 (n = 4) or in SCR 
RNAi control (n = 4) and with or without stimulation with PMA (100 pmol/ml). *** p < 0.001 [130].
RAW264.7 macrophages adhered strongly on matrigel-coated wells only after stimulation with 
phorbol 12-myristate 13-acetate (PMA), an ADAM17 activator. Adam17 knockdown in RAW264.7 
macrophages resulted in increased adhesion compared to macrophages treated with SCR siRNA, 
which was consistent with results from Adam17-deficient BMDMs.
To resemble an even more physiological situation, we used wild-type primary bone marrow- 
derived macrophages (BMDMs) and let them to adhere to wild-type mouse primary vascular 
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endothelial cells (EC). Either BMDMs or vascular ECs or both cell types were treated with siRNAs 
against Adam17 or with SCR siRNA control oligonucleotides [130]. 
FIGURE 70: Adhesion of wild-type primary bone marrow-derived macrophages (BMDMs) to a wild-type mouse 
primary vascular endothelial cell line (EC). All adhesion experiments were performed in quadru-
plicates. *	p	<	0.05;	** p < 0.01 [130].
Primary BMDMs treated with Adam17 siRNA showed stronger adhesion to primary vascular 
endothelial cells from C57BL/6 mice. Notably, RNAi mediated knockdown of Adam17 in these 
endothelial cells further increased adhesion of macrophages, and strongest adhesion was 
observed when both cell types were treated with siRNA against Adam17 (Figure 70) [130]. 
Since, immunofluorescence stainings had also revealed ADAM17 expression in VSMCs, we next 
depleted Adam17 in the vascular aortic smooth muscle cell line (MOVAS) using siRNA. We 
obtained ~50 % knockdown efficiency of Adam17 in MOVAS vascular smooth muscle cells com-
pared to the scrambled control (SCR).
FIGURE 71: Validation of Adam17 siRNA knockdown efficiency in vascular smooth muscle cells MOVAS using 
qRT-PCR after 48 hours. *** p < 0.001 [130].
We first examined the apoptosis behavior after siRNA-mediated knockdown with Adam17 siRNA 
and scrambled (SCR) control oligonucleotides. Apoptosis was stimulated with staurosporine 
(0.25 µM) and cycloheximide (10 ng/ml). 
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FIGURE 72: Apoptosis assay in vascular smooth muscle cells MOVAS after siRNA knock-down of Adam17 (n = 4) 
and scrambled control siRNA (n = 4) in cell culture medium and after stimulation with staurosporine 
(0.25 µM) and cycloheximide (10 ng/ml). Apoptosis was measured in luminescence intensity (LI). 
*** p < 0.001 [130].
Consistent with the results in BMDM and RAW264.7 cells, the knockdown of Adam17 resulted in a 
reduction of apoptosis primarily in transfected MOVAS cells after stimulation with staurosporine 
and cycloheximide. No major differences were observed in MOVAS cells without stimulation.
Furthermore, we examined also in MOVAS cells the proliferation rate after Adam17 depletion. 
Figure  73  A shows the proliferation performance over 96  hours and Figure  73  B at timepoint 
96 hours. 
FIGURE 73: Cell proliferation in MOVAS cells after Adam17 siRNA mediated (n = 4) knock-down or SCR RNAi 
(n = 4) (A) over 96 h and (B) at time point 96 h. *	p	<	0.05 [130].
Again, the Adam17 knockdown in vascular smooth muscle cells MOVAS also resulted in a slight 
increase in proliferation rates (Figure 73 A). At time point 96 hours we observed a significant 
difference between SCR and Adam17 siRNA treated MOVAS cells (Figure 73 B).
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3.2.11.3	Tnfr2 knockdown in Adam17-depleted cells restores cell functions
Because we had found that TNFR2 signaling was overactivated in the absence of Adam17, we 
next wanted to investigate whether changes of cell functions caused by Adam17 depletion were 
dependent on TNFR2. Thus, we performed double-knockdown experiments in RAW264.7 macro- 
phages and MOVAS vascular smooth muscle cells and investigated whether siRNA-mediated 
co-depletion of both Tnfr2 and Adam17 would restore cell functions back to normal. Experiments 
were performed in both, macrophages and vascular smooth muscle cells.
Figures 74 and 75 show the Adam17 and Tnfr2 mRNA expression in RAW264.7 macrophages and 
vascular smooth muscle cells MOVAS respectively, after transfection with Adam17 siRNAs, or 
Tnfr2 siRNAs, or after double knockdown using Adam17/Tnfr2 siRNAs or using scrambled (SCR) 
siRNA controls. mRNA expression of Adam17 and Tnfr2 was normalized to 106 copies of β-actin 
house-keeping gene. Statistical differences were calculated relative to SCR control [130].
FIGURE 74: Validation of (A) Adam17 and (B) Tnfr2 siRNA knockdown efficiencies in RAW264.7 macrophages 
used for proliferation and apoptosis experiments after 48 hours. **	p	<	0.01;	*** p < 0.001 [130].
Adam17 mRNA expression in RAW264.7 macrophages was significantly reduced after Adam17 siRNA 
mediated knockdown as well as after double knockdown with Tnfr2. We also observed a signifi-
cantly reduced Adam17 mRNA expression after Tnfr2 siRNA mediated knockdown. 
Tnfr2 mRNA expression in RAW264.7 macrophages was significantly reduced after Tnfr2 siRNA 
mediated knockdown as well after double knockdown with Adam17.
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FIGURE 75: Validation of (A) Adam17 and (B) Tnfr2 siRNA knockdown efficiencies in vascular smooth muscle 
cell line (MOVAS) for proliferation and apoptosis experiments after 48 hours. **	p	<	0.01;	*** p < 0.001 
[130].
In MOVAS cells Adam17 mRNA expression was significantly reduced after Adam17 siRNA mediated 
knockdown as well as after double knockdown with Tnfr2. No Adam17 mRNA differences were 
observed after Tnfr2 siRNA mediated knockdown. Tnfr2 mRNA expression in MOVAS was signifi-
cantly reduced only after Tnfr2 siRNA mediated knockdown as well after double knockdown with 
Adam17.
Figures 76 and 77 show the proliferation rate of RAW264.7 macrophages and MOVAS cells, respec-
tively after Adam17, Tnfr2, combined Adam17/Tnfr2 and control siRNA mediated knockdown over 
a period of 96 hours and at time point 96 hours.
FIGURE 76: Cell proliferation assay (A) over 96 h in RAW264.7 macrophages after Adam17,	Tnfr2,	Adam17/Tnfr2 
and scrambled siRNA mediated knockdown and (B) at time point 96 h. *	p	<	0.05	[130]. 
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FIGURE 77: Cell proliferation assay (A) over 96 h in MOVAS vascular smooth muscle cells after Adam17,	Tnfr2,	
Adam17/Tnfr2 and scrambled siRNA mediated knockdown and (B) at time point 96 h. *	p	<	0.05	[130].
Adam17-deficiency increased proliferation in both cell types, macrophages as well as smooth 
muscle cells, compared to the scrambled control.Tnfr2 deficiency led to decreased proliferation 
and knockdown of Tnfr2 in Adam17-depleted cells attenuated these effects.
Consistently with the results of the proliferation rates, Tnfr2 depletion also restored the levels 
of apoptosis in Adam17-depleted macrophages and also in vascular smooth muscle cells MOVAS 
[130].
FIGURE 78: Apoptosis in (A) RAW264.7 macrophages and (B) MOVAS vascular smooth muscle cells after siRNA 
mediated knock-down with Adam17, Tnfr2, Adam17/Tnfr2 and SCR control siRNA. *	p	<	0.05;	
**	p	<	0.01;	*** p < 0.001 [130].
Together, these data from the double knockdown experiments support that the proatherogenic 
cell-specific effects in Adam17-depleted cells may depend on TNFR2 signaling [130].
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3.2.12 Effects of Adam17-deficiency on apoptosis (TUNEL) in atherosclerotic lesions
To translate our in vitro findings into the atherosclerosis mouse model, we performed TUNEL 
(TdT-mediated dUTP Nick-End Labeling) stainings, which measures nuclear DNA fragmentation 
of apoptotic cells, in order to investigate the in vivo apoptotic behavior in the atherosclerotic 
lesions of the aortic root of wild-type Adam17 wt/wt.Ldlr -/- and homozygous Adam17 ex/ex.Ldlr -/- mice. 
Figure 79 shows a negative and a positive control for TUNEL staining of an aortic root. 
FIGURE 79: Controls for TUNEL staining. (A) Negative control for TUNEL staining; no recombinant Terminal 
Deoxynucleotidyl Transferase (TdT) enzyme was added to the TUNEL reaction. (B) Positive control 
for TUNEL staining; recombinant DNAse I was added prior to staining to cause DNA fragmentation 
and, thereby, experimentally-induced substrates for TUNEL labeling [130]. 
For TUNEL experiments, we used aortic roots of 6 wild-type Adam17 wt/wt.Ldlr -/- and 6 homo- 
zygous Adam17 ex/ex.Ldlr -/- male and female mice that were fed a semisynthetic diet for 16 weeks 
and were sacrificed at 20 weeks of age. Representative TUNEL stainings of Adam17 wt/wt.Ldlr -/- and 
Adam17 ex/ex.Ldlr -/- mice are shown in Figure 80. Quantification of TUNEL positive cells was per-
formed in relation to total cell number and plaque area respectively.
TUNEL stainings detected significantly less apoptotic cells (TUNEL+) in lesions of hypomorphic 
Adam17 ex/ex.Ldlr -/- mice in relation to total cell number and the plaque area, corroborating our 
in vitro results (Figure 80 C, D) [130]. 
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FIGURE 80: Apoptosis in atherosclerotic lesions of Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice. Representa-
tive TUNEL stainings for detecting apoptotic cells in the aortic root of (A) Adam17 wt/wt.Ldlr -/- (n = 6) 
and (B) Adam17 ex/ex.Ldlr -/- (n = 6) mice. Areas marked with white boxes in the top panels are depicted 
in the middle and bottom panels. Arrows indicate representative strongly TUNEL-positive nuclei. 
Curved white dashed line indicates the border of plaque tissue (left of the line) and arterial 
wall (right of the line). Apoptotic cells were quantified in (C) relation to total cell number and in 
(D) relation to the plaque area. Cell nuclei are marked by DAPI staining (blue). *** p < 0.001 [130].
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3.2.13 Effects of Adam17-deficiency on proliferation in atherosclerotic lesions 
through Ki67 stainings
To investigate the cellular proliferation in atherosclerotic lesions in vivo, we performed immuno- 
fluorescence stainings with Ki67 as proliferation marker and co-stainings with Mac2-positive 
macrophages (MΦ) (Figure 81) and α-SMA positive vascular smooth muscle cells (Figure 82) in 
aortic lesions of Adam17 wt/wt.Ldlr -/- (n = 6) and Adam17 ex/ex.Ldlr -/- (n = 6). 
FIGURE 81: Representative immunofluorescence stainings and co-stainings of Ki67-positive (Ki67+) proliferating 
cells (green) with Mac2-positive (Mac2+) macrophages (red) in the aortic roots of (A) Adam17 wt/wt.Ldlr -/- 
and (B) Adam17 ex/ex.Ldlr -/- mice. White arrows indicate proliferating Mac2-positive macrophages. 
Cell nuclei are marked by DAPI staining (blue) [130].
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FIGURE 82: Representative immunofluorescence stainings and co-staings of Ki67-positive (Ki67+) proliferating cells 
(green) with α-SMA-positive smooth muscle cells (red) in the aortic roots of (A) Adam17 wt/wt.Ldlr -/- and 
(B) Adam17 ex/ex.Ldlr -/- mice. White arrows indicate proliferating α-SMA-positive SMCs. Cell nuclei 
are marked by DAPI staining (blue) [130].
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FIGURE 83: Cellular proliferation in atherosclerotic lesions of Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice. 
(A) Quantification of Mac2+ macrophages and (B) SMA-positive (SMA+) vascular smooth muscle 
cells in aortic root plaque areas of Adam17 wt/wt.Ldlr -/- (wt/wt; n = 6) and Adam17 ex/ex.Ldlr -/- (ex/ex; n = 7) 
mice. (C) Ki67+/Mac2+ double-positive macrophages and (D) Ki67+/SMCs+ double-positive vascular 
smooth muscle cells in aortic root plaque areas of Adam17 wt/wt.Ldlr -/- (n = 5) and Adam17 ex/ex.Ldlr -/- 
(n = 7) mice. (E) Percentage of Ki67+/Mac2+ cells and (F) Ki67+/SMCs+ cells of Adam17 wt/wt.Ldlr -/- (n = 5) 
and Adam17 ex/ex.Ldlr -/- (n = 7) mice in relation to the total cell numbers of macrophages or of SMCs, 
respectively. * p	<	0.05; ** p < 0.01; *** p < 0.001, n.s. = not significant [130].
Here, we detected significantly more Mac2-positive macrophages (Figure 83 A) and α-SMA positive 
vascular smooth muscle cells (SMCs) (Figure 83 B) in lesions of Adam17-deficient mice corroborating 
our results from cultured cells. Ki67 staining revealed higher numbers of proliferating macro- 
phages per plaque area in atherosclerotic lesions of Adam17 ex/ex.Ldlr -/- mice (Figure 83 C) and a 
trend toward increased numbers of proliferating SMCs per plaque area (Figure 83 D) [130]. 
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Neither the ratio of proliferating Ki67-positive Mac2- nor of Ki67-positive SMA-cells in relation to 
the total number of the respective cell population was significantly different between wild-type 
Adam17 wt/wt.Ldlr -/- and homozygous Adam17 wt/wt.Ldlr -/- mice (Figures 83 E, F).
These data are confirmatory of our in vitro results, revealing however that the in vivo effects 
on proliferation were rather subtle (Figures 64 A, B; 68 A, B; 73 A, B) and suggested that the 
higher abundance of macrophages in plaques from Adam17-deficient mice (Figure 83 A) might 
be rather a consequence of resistance to apoptosis (Figures 63, 67) and increased adhesion 
(Figures 65 A, B; 69; 70). In summary, the histological cellular analysis validated our in vitro studies 
of the mechanisms of Adam17-deficiency, thereby establishing ADAM17 as a modulator of athero- 
sclerosis [130].
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The ADAM17 metalloprotease maintains arterial elasticity
 
This work has been published in [146].
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3.3 The role of ADAM17 in aneurysm formation
In the second part of this PhD thesis we identified an unexpected protective role of ADAM17 
against atherosclerosis. In the absence of Adam17, likely due to a deficit in tumour necrosis 
factor receptor 2 (TNFR2) shedding, the activity of membrane-tethered TNFR2 increased in macro- 
phages and vascular smooth muscle cells (VSMCs) leading to overproliferation, increased 
adhesive properties, and consequently, to increased atherosclerotic lesions. This atheroprotective 
function could be attributed to a specific role in cells of the myeloid lineage [185].
To date, Adam17 has also been studied in the context of other vascular diseases, such as 
aneurysms. Its role therein remained controversial, with one study reporting reduced ADAM17 
expression in aneurysms [140], and other studies showing a positive correlation of expression 
and aneurysm risk or occurrence [141-143]. In aneurysms the integrity of the arterial wall is com-
promised by inflammatory processes and other extracellular matrix (ECM)-degrading factors, 
impairing elastin lamellae that support and transmit mechanical load to the cellular cyto- 
skeleton [144, 145]. Whether and how ADAM17 links to these processes is unknown [146]. 
Here, we investigated whether mouse Adam17 was more generally involved in regulating arterial 
wall integrity. For this, we used the Adam17 hypomorphic mutant mice (Adam17 ex/ex) carrying an 
exon-induced translational stop codon leading to strongly decreased ADAM17 activity [132] and 
drawn comparisons with myeloid-specific or endothelial-specific conditional knockouts in an 
apolipoprotein E-deficient background (ApoE -/-.LysMCreADAM17fl/fl; ApoE -/-.BmxCreADAM17fl/fl) [185]. 
We determined the vascular size by quantifying intra-arterial lumen area in the aortic root, or, 
separately, arterial wall circumference and wall width in the brachiocephalic artery (BCA) of 
Adam17 ex/ex.Ldlr -/- and control mice. Arterial extracellular matrix (ECM) properties were deter-
mined by assessing elastic fibres with Verhoeff van Gieson staining and by quantifying total col-
lagen fibre content by PicroSirius Red imaging using polarized light [186]. Atherosclerotic plaque 
size was measured as the area of Oil Red-stained tissue in sagittal arterial tissue sections [146].
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3.3.1 Increased aortic root lumen area in Adam17-deficient mice
First, we quantified the aortic root lumen area in male and female mice of homozygous Adam17 ex/ex.Ldlr -/-, 
heterozygous Adam17 wt/ex.Ldlr -/- and wild-type Adam17 wt/wt.Ldlr -/- mice. 
FIGURE 84: (A) Representative Oil-Red O stainings of the aortic root of homozygous hypomorphic Adam17 
mutant mice (Adam17 ex/ex.Ldlr -/-) and Adam17 wild-type (Adam17 wt/wt.Ldlr -/-). (B-C) Quantification of 
the lumen area of the aortic root of (B) male and (C) female homozygous Adam17 ex/ex.Ldlr -/- (ex/ex), 
heterozygous Adam17 wt/ex.Ldlr -/- (wt/ex) and wild-type Adam17 wt/wt.Ldlr -/- (wt/wt) mice [146].
We found that the aortic root lumen area in hypomorphic Adam17 ex/ex.Ldlr -/- mutants was in-
creased by 30 % and 40 % in male and female mice compared to wild-type Adam17 wt/wt.Ldlr -/-, 
respectively (Figure 84 A-C). These results are in accordance to TACEΔZn/ΔZn null mutants, which 
exhibit markedly enlarged fetal hearts and die at birth [176].
In contrast, in a parallel study myeloid-specific Adam17 mouse knockouts (ApoE -/-BmxCreCreADAMfl/fl) 
showed only a trend toward dilation, which did not reach statistical significance, and endo- 
thelial-specific depletion (ApoE -/-LysMCreADAMfl/fl) did not show any dilation [185].
To test if Adam17-dependent cell wall control was a more general function, we analysed the 
dimensions of the BCA of Ldlr -/- mice [146].
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3.3.2 Atherosclerotic lesions and circumference in the branchiocephalic artery of 
Adam17-deficient and wild-type mice
The brachiocephalic artery is the first branch of the aortic arch and divides into the right common 
carotid artery and the right subclavian artery supplying blood to the right arm, the head and 
neck (Figure 85). 
FIGURE 85: Schematic of the quantification of the circumference of the brachiocephalic artery. Transverse 
cryosections of 10 µm were prepared at three positions (200 µm, 400 µm, and 600 µm proximal to the 
bifurcation of the BCA with the right common carotid artery and right subclavian artery [99, 146].
We measured the circumference of the brachiocephalic artery at a distance of 200 µm, 400 µm, 
and 600 µm proximal from the bifurcation of the BCA (1a, 2a, 3a).
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FIGURE 86: Quantification of the circumference of the brachiocephalic artery (BCA) at three different positions 
in (A) male and (B) female Adam17 wt/wt.Ldlr -/-, heterozygous Adam17 wt/ex.Ldlr -/- and homozygous 
Adam17 ex/ex.Ldlr -/- mice [146].
Quantification of the circumference of the brachiocephalic artery revealed a significant luminal 
widening at all three investigated positions in hypomorphic Adam17 ex/ex.Ldlr -/- mice in comparison 
to the heterozygous and the wild-type mice. We had an increase of 39 % and 24 % in female and 
male respectively, at position 3, 600 µm proximal from the bifurcation of the BCA. At position 2 
(400 µm) we observed an increase of 42 % and 15 %, respectively and at position 3 an increase of 
23 % and 16 % respectively.
We showed previously, that Adam17-deficiency is associated with increased atherosclerotic 
lesions at the aortic root in male and female mice. 
For this, we quantified atherosclerotic lesions in the brachiocephalic artery (BCA) of wild-type 
Adam17 wt/wt.Ldlr -/-, heterozygous Adam17 wt/ex.Ldlr -/- and homozygous Adam17 ex/ex.Ldlr -/- mice. For the 
quantification of atherosclerosis in the brachiocephalic artery, transverse cryosections of 10 µm 
were prepared in a proximal direction from the bifurcation with the right common carotid artery 
and right subclavian artery to the aortic arch at a distance of 200 µm, 400 µm, and 600 µm proximal 
from the bifurcation of the BCA (1A, 2A, 3A). For the atherosclerosis quantification we used male 
and female mice of wild-type Adam17 wt/wt.Ldlr -/- (n = 17; n = 19), heterozygous Adam17 wt/ex.Ldlr -/- 
(n = 18; n = 21) and homozygous Adam17 ex/ex.Ldlr -/- (n = 16; n = 14) mice, respectively (Figure 86) [146]. 
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FIGURE 87: Representative oil red O stainings of the brachiocephalic artery (BCA) of (A) Adam17 wt/wt.Ldlr -/- 
and (B) Adam17 ex/ex.Ldlr -/- mice. (C) Atherosclerotic lesion quantification in the BCA of wild-type 
Adam17 wt/wt.Ldlr -/- (wt/wt), heterozygous Adam17 wt/ex.Ldlr -/- (wt/ex) and homozygous Adam17 ex/ex.Ldlr -/- 
(ex/ex) in male and female mice [146].
Here, we observed no significant differences in the lesion sizes of wild-type Adam17 wt/wt.Ldlr -/-, 
heterozygous Adam17 wt/ex.Ldlr -/- and homozygous Adam17 ex/ex.Ldlr -/- male and female mice (Figure 87). 
This suggested that atherosclerotic plaque development and aneurysm onset were regulated 
independently by ADAM17, at least in the BCA of Ldlr -/- mice [146].
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3.3.3 Collagen staining in the brachiocephalic artery 
To explain the luminal widening in the BCAs of Adam17-deficient mice, we analyzed the extra- 
cellular matrix (ECM). Collagen is the main structural protein in the extracellular space in the various 
connective tissues in animal bodies. As the main component of connective tissue, it is the 
most abundant protein in mammals [187], making up from 25 % to 35 % of the whole-body protein 
content. To examine the collagen structure of wild-type Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- 
mice we used the Picrosirius Red (PSR) staining. The arterial wall is composed of a highly ordered 
structure of cells and extracellular matrix. The tunica media, the middle coat contains SMCs. The 
media is the thickest layer and provides structural support, vasoreactivity and elasticity. The 
outer coat, the tunica adventitia, contains mast cells, fibroblasts, nerve endings and micro- 
vessels [15]. The ECM makes up to 60 % of the intimal volume and consists of elastic lamellae, 
smooth muscle cells and three major protein components, including proteoglycans, collagen 
and multi-adhesive matrix proteins [16]. We examined the collagen structure in brachiocephalic 
arteries of 3 male and 3 female wild-type Adam17 wt/wt.Ldlr -/- and Adam17 ex/ex.Ldlr -/- mice. Quanti-
fication of the Picrosirius Red staining was imaged using polarized light [146].
FIGURE 88: (A) Representative PicroSirius Red stainings of the BCA of Adam17 ex/ex.Ldlr -/- and wild-type 
Adam17 wt/wt.Ldlr -/- mice for visualizing collagen density. (B) Quantification of PicroSirius Red intensity 
by polarization imaging in the intima and adventitia of homozygous Adam17 ex/ex.Ldlr -/- (n = 6) and 
wild-type Adam17 wt/wt.Ldlr -/- (n = 6) mice [146]. 
Based on Picrosirius Red imaging [186], and not distinguishing between different classes of fibres 
via birefringence colour discrimination [188], total collagen fibre content in the intima and in the 
adventitia was found to be unaffected in the dilated Adam17 mutant BCAs [146].
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Furthermore, we investigated the arterial wall thickness of BCA sections from Adam17 ex/ex.Ldlr -/- 
(n = 5) and wild-type Adam17 wt/wt.Ldlr -/- (n = 5) mice.
FIGURE 89: Quantification of the arterial wall thickness of BCA sections from Adam17 ex/ex.Ldlr -/- (n = 5) and 
wild-type Adam17 wt/wt.Ldlr -/- (n = 5) mice [146].
Here, we did not observe arterial wall thinning in the mutant BCA. 
3.3.4 Elastin staining in the brachiocephalic artery
In a parallel study, myeloid-specific and conditional endothelial-specific depletion of Adam17 
in ApoE -/-BmxCreCreADAMfl/fl or ApoE -/-LysMCreADAMfl/fl mice caused no significant differences in the 
lumen area of the BCAs [185]. This indicated that this phenotype might be driven by Adam17- 
deficiency in smooth muscle cells or fibroblasts rather than bone marrow-derived or endothelial 
cells. Elastic fibres are bundles of proteins (elastin) found in extracellular of connective tissue 
and produced by fibroblasts and smooth muscle cells in arteries [189]. To examine if elastin 
fibres hat a different morphology in wild-type and Adam17 ex/ex.Ldlr -/- mice we performed Ver-
hoeff’s Van Gieson stainings in brachiocephalic arteries of wild-type and Adam17-deficient mice 
(Figure 90).
FIGURE 90: (A) Representative Verhoeff-van Gieson staining visualizing elastin fibres in the brachiocephalic 
arteries in Adam17 wt/wt.Ldlr -/- (n = 3) und Adam17 ex/ex.Ldlr -/- (n = 3) mice. Elastic fibers and cell nuclei 
are stained black, while other structures are stained red. (B) Quantification of elastin fibre length 
of homozygous Adam17 ex/ex.Ldlr -/- (n = 3) and wild-type Adam17 wt/wt.Ldlr -/-(n = 3) mice. Three fibres 
were quantified of each animal [146]. 
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Here, we found in Adam17 wt/wt.Ldlr -/- mice as well as in Adam17 ex/ex.Ldlr -/- the same number of 
elastic fibres. However, elastin fibres were altered: The elastic fibers of the wild-type BCAs were 
arranged in wavy bundles, while the elastic fibres in Adam17 ex/ex.Ldlr -/- mice were stretched out 
and showed reduced ondulation. To quantify this phenotypic switch, we determined the length 
of individual elastic fibers within sub-segments of identical length (20 µm) in BCAs of mutants 
and wild-type mice [146].
To quantify this phenotypic switch, we determined the length of individual elastic fibres within 
subsegments of identical length (20 µm) in BCAs of mutants and wild-type mice (n = 3/3).
FIGURE 91: Quantification of fiber length of homozygous Adam17 ex/ex.Ldlr -/- (ex/ex) and wild-type Adam17 wt/wt.Ldlr -/- 
(wt/wt) mice. *** p < 0.001 [146].
We found a significantly reduced unit fibre length in homozygous Adam17 ex/ex.Ldlr -/- mice compared 
to wild-type Adam17 wt/wt.Ldlr -/-.
Thus, ADAM17 may protect the integrity of the arterial wall by regulating elastin fibre organization 
[146]. 
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3.3.5 Differentially expressed genes in aortic tissue of Adam17 wt/wt.Ldlr -/- and 
Adam17 ex/ex.Ldlr -/- mice.
To get first insights into how ADAM17 controlled arterial wall integrity, we investigated which 
genes were differentially expressed in aortic tissue of Adam17 ex/ex.Ldlr -/- hypomorphic mutants. 
mRNA microarray profiling revealed not only a set of bona-fide atherosclerosis regulators 
among the top differential abundant transcripts, but also a number of cytoskeletal contractility 
regulators and factors required for ECM elastogenesis. The latter included the elastin microfibril 
interfacer	Emilin2,	the elastin-binding laminin/fibronectin-interacting Fibulin	2,	matrix metallo- 
proteinases MMP3/12, the proteoglycan Syndecan 3, the adhesion molecule and sheer-stress 
mechanoresponsive Pecam1 (Figure 92) [146]. 
FIGURE 92: Volcano plot of mRNAs differentially abundant in aortas of wild-type Adam17 wt/wt.Ldlr -/- and homo- 
zygous Adam17 ex/ex.Ldlr -/-mice (transcriptome-wide expression profiling by microarrays). High-
lighted are genes with a fold change > 0.8 which are associated with atherosclerosis (purple; ex-
emplary: uncoupling protein Ucp1, Regulator of G Protein Signaling Rgs1, C-X-C Motif Chemokine 
Ligand Cxcl16, metalloproteinase Mmp3, C-C Motif Chemokine Ligand 5 Ccl5, Adipose Differen-
tiation-Related Protein Adfp) or with ECM/cytoskeletal regulation (yellow; exemplary: metallo- 
proteinase Mmp3 and Mmp12, Myosin Myo1f, Coronin Coro1a, Emilin2, Syndecan Sdc3, Pecam1, 
Fibulin Fbln2, Enah/Vasp-Like Evl, leupaxin Lpxn, melanoma inhibitory activity Mia1, Unc5c,	Fbxl22,	
Pip5k1b, Sarcolipin Sln). * p	<	0.05; ** p < 0.01; *** p < 0.001 [146]
Our combined data reveal a function of ADAM17 in arterial elastin network maintenance, which 
is separate from the previously known role in atherosclerotic lesion control [146].
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This PhD thesis aims to make a contribution in identifying new determinants of atherosclerosis 
by investigating two recently reported, yet still uncharacterized, atherosclerosis susceptibility 
loci on mouse chromosomes 3 and 12. These loci were identified in an intercross of athero- 
sclerosis-susceptible C57BL/6 (B6) and atherosclerosis-resistant FVB mice on the LDL-receptor 
deficient background (Ldlr -/-) [104].
As first major result, we identified and moleculary characterized the novel atherosclerosis modi-
fier Pla2g12a at the chromosome 3 locus. As second major result, using a hypomorphic genetic 
mouse model, we established that Adam17, located at chromosome 12, exhibited protective 
roles against both, atherosclerosis, as well as aneurysm formation. Both effector genes protect 
from the disesase by modulating central molecular mechanisms of atherosclerosis, such as ad-
hesion and proliferation of blood and vascular cells.
4.1 Mouse models for understanding human atherosclerosis
In this PhD thesis, we used different mouse models to identify novel candidate genes (Pla2g12a) 
for atherosclerosis susceptibility and to elucidate potential mechanisms of atherogenesis 
(ADAM17). Over the past 35-40 years, the mouse has become by far the most widely used animal 
model for atherosclerosis research. Mouse and human genomes are very similar with about 
95 % conservation of protein-coding genes. A recent study by Scheidt and colleagues confirmed 
that about 53-55 % of metabolic and cellular pathways overlapped between the study of mouse 
candidate CAD risk genes and the list of CAD risk genes from human GWAS, and that 45 of 46 
candidate CAD risk genes that were already studied in mouse CAD models showed a consistent 
role in modifiying disease [190]. With the results of this PhD thesis we show the principal suitability 
of mouse models in atherosclerosis research for the identification of novel effector genes and 
make a contribution to understanding different molecular pathways contributing to athero- 
sclerosis.
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4.2	 Identification	 of	 Pla2g12a	 as	 a	 novel	 candidate	 gene	 of	 atherosclerosis	
susceptibility on mouse chromosome 3
In the first part of this PhD thesis, we identified Pla2g12a as a novel atherosclerosis susceptibility 
gene that determined the risk executed by a genetic locus on mouse chromosome 3. Our study is 
the first to dissect two overlapping, yet independent female-specific QTL loci for atherosclerosis 
susceptibility by investigating inheritance patterns from the grandparental F0 generation to 
female F2 mice. Thereby, and supported by systematic expression QTL analyses, we identify 
Pla2g12a as novel atherosclerosis modifier gene in subcross A, where the atherosclerosis-sus-
ceptible B6 risk locus was introduced via B6.Ldlr -/- grandfathers. The prioritization of candi-
date genes in this locus was a multistep process, where gene expression profiling was initially 
performed in livers of congenic FVB.Chr3B6/B6 and FVB mice. Yet, subsequently we validated the 
results of the profiling in liver and aorta tissues as well as BMDMs of parental C57BL/6 and FVB 
F0 mice. So, 5 from 7 identified candidate genes that had been identified through liver profiling 
were, thereby, validated as expressed in aorta and/or BMDMs, and thus in sites that are likely 
more directly disease-relevant than liver (given the proposed molecular roles of our candidate 
genes and the absence of a relevant lipid phenotype). Further we found these 5 candidates were 
differentially expressed also in the aortas and BMDMs (with the same directionality of effects as 
in liver) in C57BL/6 compared to FVB mice. For eQTL analyses in mice of the F2-generation un-
likely only liver probes were at our disposal [104] and an eQTL analysis in vascular tissue could, 
thus, not performed in the segregating F2 population. 
To investigate if the B6-derived genetic variants that promoted atherosclerosis also regulated 
gene expression in cis, we used livers of female F2 mice that were derived from cross A or from 
cross B, and performed expression quantitative trait locus (eQTL) mapping for the remaining 
genes. We observed significantly LOD scores for Pla2g12a, Pklr and Cth in cross A and Vcam1 in 
cross B. As Pklr and Cth genes in cross A could be excluded, we concentrated on Pla2g12a which 
co-located with the atherosclerosis LOD score. In subcross B, a LOD score maximum of 4.4 for 
Vcam1 was detected and overlapped most closely the location of atherosclerosis-susceptibility. 
In female mice of the F2-generation, mice carrying two B6-alleles at d3mit57 had 1.5-fold higher 
Vcam1 expression levels and developed 1.9-fold more atherosclerosis. Vcam1 is a well-known 
regulator of atherogenesis [166] and increased Vcam1 levels have been shown to promote athero- 
sclerosis [167, 168]. So, our data are consistent with the published literature and make Vcam1 a 
likely effector gene in cross B [148]. 
From the analysis of cross A, Pla2g12a emerged as novel candidate atherosclerosis modifier. For 
better eQTL mapping accuracy in cross A fine-mapping with an additional SNP (rs13464244) led 
to an increased LOD score maximum for Pla2g12a expression of 5.01. Homozygosity for the B6 
allele at rs13464244 in F2 females from cross A was associated with decreased mRNA abundance 
of Pla2g12a compared to the FVB genotype at this position and with enlarged atherosclerotic 
lesions. Furthermore, we observed an inverse correlation of high Pla2g12a mRNA expression 
with smaller atherosclerotic lesion sizes indicating that Pla2g12a protects from atherosclerosis.
The Chr3 locus was correlated with atherosclerosis risk only in F2 female progeny of either cross, 
but not in male F2 mice and, consistently, we observed no eQTLs in male F2 mice for Pla2g12a 
or Vcam1. Given that the DNA sequence was identical in mice of the grandparents’ generation, 
an epigenetic regulation and sex-specific regulation of its transmission through the F1 and F2 
generations is likely. For example, although the DNA sequence may be the same, histone modifi-
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cations of nucleosome enwrapping this DNA, or DNA methylation patterns on regulatory regions 
could be set differentially on the region in the male and female germline [191, 192]. Also chro-
matin-based epigenetic patterns are known to be inherited over cell divisions and even over 
generations [193]. Whether such a mechanism occurs at the identified locus is still speculation. 
In any case, it might become an important factor in the experimental design for gene discovery 
in inbred mouse models to consider male or female germline transmission in QTL studies. 
Furthermore, future profiling of epigenetic imprints in such models may explain at least part of 
the missing causality of complex traits in existing studies [148, 194-197].
4.2.2 Pla2g12a-deficiency promotes adhesion between endothelial cells and 
macrophages
The potential role of Pla2g12a, which belongs to the secreted phospholipase A2 enzymes (sPLA2), 
has not been investigated in atherogenesis, yet. We thus focussed on PLA2G12A and through 
immunohistochemical stainings, qPCR analyses and western blots we showed that PLA2G12A 
was highly expressed in vascular endothelial cells (ECs) and to a lesser extent in macrophages. 
EC activation is one of the first cellular changes in the vasculature en route to atherosclerosis 
[170, 171] and during atherosclerosis development ECs control adhesion of circulating leukocytes 
to nascent atherosclerotic lesions [148, 172]. 
We found that BMDMs from B6 mice, as well as BMDMs derived from Chr3 congenic mice (both 
with lower Pla2g12a expression) were more adhesive than FVB BMDMs. Importantly, we found 
that depleting Pla2g12a from ECs in this adhesion assay further increased adhesion of (untreated) 
BMDMs to ECs, with a comparable relative increase in adhesion of both B6-derived and FVB- 
derived BMDMs. These adhesion results were validated in RNAi experiments in RAW264.7 macro- 
phages, to test whether Pla2g12a was, thus, a more general determinant of adhesion. These 
results indicated that PLA2G12A was exhibiting parallel athero-protective roles in macrophages 
and in ECs. In this adhesion assay upon loss of Pla2g12a, mRNA levels of the integrin ligand 
Vcam1 did not increase suggesting that the increase in adhesion was due to Pla2g12a-dependent 
processes and independent of indirect transcriptional regulation of Vcam1 [148].
Our analysis shows that PLA2G12A prevented leukocyte adhesion to endothelial cells in FVB 
mice, which is one of the earliest events in atherogenesis [166, 167, 198, 199], and establishes 
Pla2g12a as athero-protective factor in this mouse intercross [148]. 
4.2.3 Modulation of atherosclerosis through Pla2g12a and Vcam1
To identify the exact DNA position or epigenetic mark that causes Pla2g12a and Vcam1 mis- 
regulation through the female F2 risk alleles is difficult. This study establishes the possibility 
that VCAM1 and PLA2G12A may modulate atherosclerosis susceptibility by independently con-
trolling a common effector pathway: Induction of the immunoglobulin-superfamily adhesion 
molecule Vcam1 on endothelial cells [167] and binding of VCAM1 to integrin α4b1 [200] on homing 
blood mononuclear leukocytes [201] recruits monocytes to growing lesions [171], which is a key 
step in initiating and promoting atherosclerosis [199]. Consistently, blocking of VCAM1 by an anti- 
body [202] or in a hypomorphic mouse mutant in vivo [166] reduced monocyte adhesion on the 
early atherosclerotic endothelium and reduced lesion size [148]. 
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On the contrary, Pla2g12a has not been decisively functionally explored before [203] and no 
knockout data exist. PLAG12A belongs to the group of secreted phospholipase A2 enzymes [204]. 
The phospholipase A2 superfamily of enzymes are characterized by their ability to hydrolyze fatty 
acids at the sn-2 position of glycerophospholipids and generate multiple classes of bioactive 
lipids [205, 206]. There are five major families of phospholipases: the secretory phospholipases 
(sPLA2) where the phospholipase of the group 12A belongs (PLA2G12A), the cytosolic (cPLA2) 
that are Ca2+-dependent, the lysosomal A2 and two major Ca2+-independent groups (iPLA2) and 
platelet activating factor acetylhydrolase (PAF-AHs) [205]. Adipose-specific PLA2 also belong to 
the class of PLA2s. Cytosolic PLA2 enzymes are believed to play a major role in the metabolism 
of arachidonic acid, the iPLA2 family to membrane homeostasis and energy metabolism, and the 
sPLA2 family to various biological processes [207].
In the meanwhile, secretory PLA2 family consists of 12 isoforms with comparable molecular 
weights of 16 kDa and three-dimensional structures [205]. Likely due to the secretory nature of 
this family, existing mouse models of other sPLA2s have revealed diverse, tissue-specific and 
sometimes contradicting cellular functions [208-212]. Our data now indicate that PLA2G12A may 
dampen the onset of atherosclerosis via reducing cell-cell adhesive properties in the vascular 
endothelium. How adhesion changes upon alteration of PLA2G12A levels remain unknown, but 
we can at least exclude that Vcam1 expression itself is regulated by Pla2g12a. Interestingly, pre-
vious reports have shown that some soluble PLA2s (group IIA) can bind to selective integrin 
subtypes (avb3, α4b1), where they compete with the integrin ligand VCAM1 for binding [213, 
214]. Given that adhesion of macrophages to endothelial cells was increased when Pla2g12a was 
depleted in our own experiments, it is conceptually possible, that PLA2G12A impairs adhesion 
via impairing integrin signaling, by virtue of blocking the access of the integrin ligand VCAM1 to 
integrins. Supporting this integrin-binding hypothesis for altering adhesive properties, phos-
pholipase catalytic activity is not needed for this type of interaction of sPLA2’s with integrins 
[213]. This is relevant, because PLA2G12A’s phospholipase activity is known to be very weak com-
pared to other members of this family of secreted phospholipases [215, 216]. Together, Vcam1 
upregulation and Pla2g12a down-regulation may converge on activation of integrin-dependent 
adhesion [148]. 
4.2.4 Epistasis analysis
Epistasis analyses in the F2 generation of our intercrosses revealed no significant interaction 
between SNPs in the candidate interval on chromosome 3 [104], thus rather speaking against a 
coordinate regulatory function of Pla2g12a and Vcam1 in atherogenesis. Furthermore, despite 
the cell-proximal role of PLA2G12A in adhesion control (shown by the RNAi experiments) and the 
absence of relevant lipid changes, we can at this point not exclude that still unknown factors 
might change atherosclerosis onset by additional routes. Moreover, we have focused mainly on 
factors that changed their gene expression dependent on atherosclerosis risk genotype, but we 
want to note that a number of non-synonymous SNPs exist in the coding regions of the interval 
in genes that are not identical by descent. Bioinformatic predictions indicate that some may be 
detrimental to protein function, and Nes,	Gon4l,	Tchhl1,	Hsd3b2,	Pdlim5,	Erich3 and Tnni3k are 
potential candidates at this level of analysis. Nevertheless this does not necessarily affect our 
finding that the change in Pla2g12a mRNA abundance is an independent important factor, as 
demonstrated by functional RNAi experiments in different genetic backgrounds [148].
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4.2.5 Secretory phospholipases A2 as biomarkers
Supporting a broader relevance of our findings, sPLA2-IIA and -V genes are clustered in mouse 
and human in a syntenic region that has been attributed atherosclerosis-susceptible properties 
[217]. Supporting a broader relevance of our findings, increased secretory phospholipase A2 as 
well as lipoprotein-associated phospholipase A2 have already been identified as biomarkers of 
cardiovascular risk in population studies with patients with established coronary artery disease 
(CHD) [205]. This has to be qualified, however, as no SNPs within PLA2G12A itself have been 
associated with atherosclerosis in humans. Instead, other human SNPs contained in the mouse 
Chr3 syntenic regions are indeed associated with different endpoints of the disease and some 
of these associate with loci for atherosclerosis risk factors, such as blood pressure and relevant 
lipids. Since the orthologues of the relevant human genes were not differentially expressed in 
our mouse model, and since we found no co-localization of the Chr3 QTL, at least not with lipid 
phenotypes in mouse, it is thus, however, rather likely that the human genetic variants control 
atherosclerosis susceptibility through other molecular mechanisms. To date, pharmacological 
inhibition of conventional sPLA2s (not including PLA2G12A) have been clinically tested and failed 
in clinical phase III trials in cardiovascular patients and even increased myocardial infarction 
risk [218]. Therefore, to conclude, atheroprotective roles of some secreted phospholipases like 
Pla2g12a will have to be considered, and stimulation of Pla2g12a, not inhibition, might be medi-
cally relevant, but whether Pla2g12a or also other candidates from the mouse Chr3 interval have 
to be coordinately induced and repressed remains to be tested [148].
4.3 Mouse chromosome 12 and Adam17
In the second part of this PhD thesis we investigated the effect of Adam17-deficiency on athero-
sclerosis development. This work is the first functional study that describes a causal role of the 
metalloprotease ADAM17/TACE in atherosclerosis. Our data show that, contrary to what could 
have been expected from an enzyme that has been implicated mostly in releasing inflamma-
tory effectors from the membrane, ADAM17 exhibits an athero-protective effect in vivo. Based 
on the analysis of Adam17 hypomorphic knockout mice in vivo, and based on biochemical and 
genome-wide mRNA expression profiling, we describe pro-atherogenic aberrations of apoptosis, 
proliferation and cell adhesion in all three cell physiologically relevant vascular cell types, 
namely in macrophages, vascular smooth muscle cells and endothelial cells. We also demon-
strate how, mechanistically, ADAM17 executes its athero-protective function: we found that the 
release of TNFR2 and of TNFα from the cell membrane was impaired in Adam17-deficient cells. 
At the same time the pool of membrane-resident TNFR2 and membrane-resident TNFα were 
increased in Adam17-deficient cells, coinciding with increased TNFR2 pathway signaling and im-
paired apoptosis, increased proliferation rates of macrophages and vascular smooth muscle 
cells. Because knocking down Tnfr2 in Adam17-deficient macrophages or SMCs restored levels 
of apoptosis and cell proliferation back to wild-type levels, we conclude that the control of 
TNFR2 signaling is an important effector pathway for ADAM17 in protecting from atherosclerosis 
(Figure 93) [130].
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FIGURE 93: Role of ADAM17 in atherosclerosis development [130].
4.3.1 Adam17 and atherosclerosis
Since Adam17 knockout (Adam17ΔZn/ΔZn) mice are not viable and die within several hours after birth 
having severe epithelial abnormalities [131], the direct effect of Adam17-deficiency on athero- 
sclerosis development has not been investigated so far. To overcome the limitations of existing 
mouse models, Chalaris et al. generated hypomorphic Adam17 mice, which are partially defi-
cient for Adam17 (Adam17 ex/ex) and have barely detectable levels of ADAM17 in all tissues [132]. 
To induce atherosclerosis, we backcrossed hypomorphic Adam17 mice (Adam17 ex/ex) on the Ldl 
receptor deficient background.
Atherosclerosis studies revealed higher atherosclerotic lesions in both male and female hypo-
morphic Adam17 ex/ex.Ldlr -/- compared to wild-type Adam17 wt/wt.Ldl -/- mice. These findings corre-
sponded with the data from a previous study, demonstrating that reduced ADAM17 activity was 
associated with increased atherosclerosis at the aortic root in an F2 intercross of atherosclero-
sis-susceptible C57BL/6 and atherosclerosis resistant FVB mice [105]. Although several mouse 
models with tissue-specific Adam17-deficiency have been established [133-138], our study is the 
first to investigate the direct role of Adam17-deficiency in atherosclerosis giving evidence for 
an atheroprotective effect of ADAM17. The observed intense thickening of the aortic valves in 
Adam17 ex/ex.Ldlr -/- mice confirmed previous published data [138]. Additionally, the eye, skin and 
hair defects observed in Adam17-deficient mice, previously described by Chalaris et al., were 
likely caused due to the ADAM17 disturbed release of the heparin-binding epidermal growth 
factor (HB-EGF) and TGF-α shedding [131].
Until now, the direct effect of Adam17-deficiency in atherosclerosis and atherosclerosis devel-
opment has not been investigated yet. Canault et al. describe an increase of atherosclerotic 
lesions in an ApoE -/- mouse model, where the lesions contain ADAM17-positive cells. But given 
the fact that Adam17 is highly expressed in macrophages, and that macrophages are present 
in atherosclerotic lesions, this is not unexpected [219]. Beyond correlative evidence, the study 
by Caunault et al, however, did not investigate a causal role of Adam17 in atherosclerosis, for 
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example, by loss-of-function experiments. Satoh and colleagues demonstrated that both TACE 
and TNFα were highly expressed in patients with myocarditis [220] and also in peripheral blood 
mononuclear cells in patients with advanced congestive heart failure [221]. Furthermore, they 
showed in their studies evidence of increased ADAM17 and TNFα expression in areas of rup-
tured coronary plaques in patients with myocardial infarction [222]. Due to its well established 
molecular function in releasing proinflammatory TNFα [120, 131], a protective role of ADAM17 in 
atherosclerosis might at first seem counterintuitive and this atheroprotective effect seemed 
somehow to be contradictory to its well-established role in promoting inflammation and cell 
adhesion [120, 131, 173-175]. However, ADAM17 is also involved in potentially atheroprotective cell 
functions such as shedding of the receptors for TNFα and of cell adhesion molecules. Given this 
overall promiscuous nature, it was not obvious before our present study whether the depletion 
of Adam17 would push the balance toward a pro- or an antiatherogenic net effect. Our current 
study corroborates and extends our previous work where we have identified Adam17 as a candi-
date gene of atheroprotection using expression quantitative trait locus mapping in mice [105]. 
In this study, we elucidated the possible mode of action of Adam17-deficiency and we provide 
mechanistic insight into how ADAM17 executes this role [130].
4.3.2 Adam17-deficiency reduces TNFR1, TNFR2 and TNF-α release in plasma and 
cells of Adam17 ex/ex.Ldlr -/- mice
Adam17-deficiency resulted predominantly in a significant reduction of sTNFR1 and sTNFR2 re-
lease in plasma of mice and the supernatant of bone marrow-derived macrophages. Further-
more, the proinflammatory substrates sIL-6R and sTNF-α were also reduced in plasma of the 
atherosclerosis-prone Adam17-deficient mice whereas other ADAM17 substrates were not differ-
entially released. The EGFR- and TNFα pathways are 2 major signaling pathways that are under 
the control of ADAM17 [120, 131, 223]. Interestingly, in this mouse model, mainly the substrates 
(TNFR1, TNFR2 and TNFα) of the TNF-α pathway are in this mouse model significantly reduced 
released. Reduced shedding of TNFR1 and TNFR2 as well as TNFα hints to a role of TNFα signaling 
in atherogenesis in Adam17 ex/ex.Ldlr -/- mice. TNFR1 is ubiquitously expressed and primarily localized 
to the Golgi apparatus with little surface expression, whereas TNFR2 is predominantly expressed 
on the cell surface of endothelial and hematopoietic cells [224, 225]. Furthermore, TNFR1 is 
activated by membrane-bound as well as soluble TNFα, while TNFR2 becomes activated only 
through membrane-bound TNFα [177]. Protein studies reinforced the hypothesis of enhanced 
TNFR2 signaling, as higher amounts of TNFα and TNFR2 were detected in whole cell lysate and 
cell surface proteins of Adam17-deficient mice. The enhanced activation of Bmx/Etk, a signaling 
molecule of the TNFR2 pathway, confirmed this hypothesis even more. 
To investigate, if the differences in TNFR1 and TNFR2 levels were due to differential transcrip-
tional regulation, we quantified Tnfr1 and Tnfr2 mRNA abundance in Adam17-deficient primary 
macrophages using qPCRs. Since we detected no significant differences in receptor mRNA levels 
between wildtype and mutant, we conclude that the differences in TNFR1 vs TNFR2 protein levels 
are not controlled at the level of mRNA expression but might be post-transcriptionally regu-
lated. Given that the rates of TNFR1 and TNFR2 protein delivery to the cell membrane and the 
rates of TNFR1 and TNFR2 recycling and degradation (via the lysosome) have not been quanti-
fied in direct comparison to each other in the literature, we can only speculate about the exact 
underlying divergence between TNFR1 and TNFR2: It is known that membrane-availability of 
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TNFR1 is mainly controlled through internalization and subsequent degradation but not through 
shedding [226]. One can thus speculate that in the Adam17 hypomorphic mutants, the rate of 
new TNFR1 production meets equal rates of TNFR1 internalization/degradation, resulting in un-
changed net levels of cellular TNFR1 protein despite reduced ADAM17-dependent shedding of 
TNFR1. On the contrary, membrane-availability of TNFR2 is rather controlled through constitu- 
tive shedding [227], which is significantly down-regulated in our Adam17 hypomorphic mutants. 
Additionally, Fischer et al have shown that non-cleavable membrane-bound TNFα stabilized 
membrane protein expression of TNFR2 [227]. Since membrane-bound TNFα is increased in 
Adam17-depleted cells, it is likely that both, the reduced TNFR2 release in cells lacking ADAM17 
activity and stabilization through membrane TNFα, might result in increased net levels of TNFR2 
protein. Until today, the molecular mechanism of how membrane-bound TNFα stabilizes TNFR2 
is unknown and further work will be required to address this aspect.
How does our description of an antiatherogenic function of ADAM17 relate to the literature on 
the role of TNFα signaling in atherosclerosis? Overall, apart from the onset of atherosclerotic 
lesions, where TNFα is thought to delay lesion formation via impairing cholesterol accumulation 
in macrophages [228], the net effect of TNFα signaling seems to promote disease [229-233]. This 
conclusion based on the studies of atherosclerotic lesions sizes in TNFα-knockout mice and the 
observation of decreased vascular endothelial cell adhesiveness and decreased inflammatory 
factor expression in atherosclerotic plaques. In these earlier studies, proatherogenic effects of 
TNFα were, however, related mostly to the fact that soluble TNFα promotes classical inflamma-
tory TNFR1 signaling [130].
In our present work, we extend these earlier reports by focusing on the membrane-resident 
mTNFα and TNFR2, which were particularly increased in the absence of ADAM17, likely because 
of reduced shedding. Previous work had further suggested that mTNFα stabilized membrane 
protein expression of TNFR2 [227], thus potentially explaining why the levels of membrane TNFR2 
but not TNFR1 were higher in the Adam17 mutants. Because it is TNFR2 signaling and not TNFR1 
signaling, that is preferentially activated by mTNFα [177], an overactivation of TNFR2 signaling 
through both higher mTNFα and mTNFR2 protein might, thus, promote atherosclerosis. Consist-
ently, a study by Chandrasekharan et al [234] has shown that Tnfr2-deficient mice develop less 
atherosclerosis on the ApoE -/- background. Together, the activation of TNFR2 signaling seems to 
be a plausible effector mechanism promoting atherosclerosis in the Adam17 knockout mice [130].
4.3.3 Enhanced TNFR2 signaling in hypomorphic Adam17 ex/ex.Ldlr -/- mice
TNFR2 signaling has previously been associated with an anti-apoptotic and proliferative cellular 
response [182] as well as with increased adhesion via the induction of ICAM1 expression in different 
mouse models [183, 184]. It is those anti-apoptotic, proliferative and pro-adhesive responses 
that we also see in our in vitro and in vivo analysis of the Adam17 mutant: the direction of 
effects is identical in the Adam17 ex/ex knockout macrophages, and in the Adam17 siRNA-treated 
macrophages, vascular smooth muscle cells and endothelial cells.
Notably, all cell functions that we investigated were restored to normal when depleting TNFR2 
in Adam17-deficient cells, further supporting an important role of this receptor when Adam17 is 
depleted. On the contrary, the observed effects in our in vitro and in vivo experiments contrasted 
the functions classically associated with TNFR1 signaling, such as TNFR1-dependent induction 
of inflammation and apoptosis and reduction of proliferation [235-237], thus further speaking 
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against TNFR1 as a major effector in our Adam17 hypomorphic mouse model. Consistent with the 
results from this study, TNFα and TNFR2 deficiency also led to significantly decreased athero- 
sclerosis in other mouse models [229, 230, 232-234]. TNFα and TNFR2 signaling contribute to 
the development of atherosclerosis by enhancing cellular processes like proliferation and 
apoptosis, which are key regulators of atherogenesis [1]. Both processes are highly regulated 
in Adam17 ex/ex.Ldlr -/- mice as was already shown by gene set enrichment and pathway analysis. 
Increased TNFR2 signaling was already associated with increased cell proliferation [238, 239] and 
cell survival [130, 240, 241].
In this context, the function of ADAM17 in the vasculature is likely pleiotropic and cell context- 
dependent and its effect on TNF-signaling is only one of multiple facets of the protease: ADAM17 
enzyme activity and substrate specificity are selective and regulated. Similarly complex, the 
role of proliferation and apoptosis in atherosclerosis is multi-faceted, and inhibition of cellular 
proliferation and induction of apoptosis, such as ascribed here to ADAM17 function, is not neces-
sarily atheroprotective under all circumstances. For instance, apoptosis in macrophages might 
indeed attenuate early lesion progression, but can at later stages also induce secondary in- 
flammation and plaque rupture [13] and apoptosis in vascular endothelial cells may be pro- 
atherogenic [242]. Summarizing, the cell type-specific ADAM17 functions will have to be dissected 
one by one, and their individual effects integrated, to understand how the net atheroprotective 
output is achieved. It is likely that also other ADAM17 substrates will modulate atherosclerosis, 
including adhesion factors that are directly or indirectly shed by ADAM17. We do not claim 
that control of TNFR2 activity in macrophages and VSMCs is the single effector mechanism for 
ADAM17’s role in protection from atherosclerosis. We also do not claim that TNFR1 has no function 
at all for Adam17’s role in atherosclerosis. Reasons to be cautious are data from existing knock-
outs of other ADAM17 substrates, such as ICAM-1 [243], VCAM-1 [166], CX3CL1 (fractalkine) [153] or 
IL-1 [244] depletion, which show decreased atherosclerosis. While we did not see consistent 
changes in the shedding of these substrates, we do note that not all known substrates of ADAM17 
have been tested in our study. Thus, it is possible that overall small but coordinated changes in 
a variety of ADAM17 substrates, other than TNFR2, may add up to an atheroprotective function 
[130]. 
4.3.4 ADAM17 as a therapeutic target.
Over the past years, ADAM17 has become a therapeutic target in several cancers and inflamma-
tory diseases [245-251]. Here, therapeutic approaches aim to inhibit ADAM17 activity, and several 
agents are already used in different preclinical models and clinical trials [252]. Results of the 
current study now show that a general inhibition of ADAM17 may lead to an upregulation of 
atherosclerosis-associated cell functions by promoting TNFR2 signaling. Similarly, agonists 
of TNFR2 are considered for depleting insulin-specific autoreactive T cells in type 1 diabetes 
mellitus treatment [252-254], and our results suggest that an increased atherosclerosis risk 
might need to be considered as a side effect as well. Although a recent meta-analysis has shown 
that TNFα inhibition leads to a significant reduction of hard cardiovascular endpoints (relative 
risk 0.7; p	=	0.005) in patients with rheumatoid arthritis [255] the exact mechanisms of ADAM17 
in the vascular wall of humans and in the pathogenesis of human atherosclerosis remains to be 
determined [130].
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4.4 The ADAM17 metalloproteinase maintains arterial elasticity
In the second part of this PhD thesis we found that ADAM17, which is usually regarded as a proin-
flammatory enzyme, has disease-protective properties in atherosclerosis. In this role, ADAM17 
curbs the amount of membrane-bound (yet signaling-active) TNFR2 receptor, in order to avoid 
overactivation of pro-atherosclerotic TNFα/TNFR2-dependent adhesive and proliferative cellular 
properties. 
In the third part of this PhD thesis we investigated whether mouse Adam17 was generally in-
volved in regulating arterial wall integrity. Here, we report that ADAM17 exerts another role in 
vascular biology, namely by functioning as rheostat of arterial wall elasticity. We focused on the 
brachiocephalic artery (BCA), and we showed that the role in maintaining arterial wall integrity 
in the BCA is uncoupled from ADAM17-dependent atherosclerotic plaque development. We found 
no significant differences in plaque size formation between Adam17 mutants and controls in the 
brachiocephalic artery. 
Employing three complementary genetic mouse mutant models (the hypomorphic [Adam17 ex/ex.Ldlr -/-]
mutant, a conditional myeloid knockout [LysMCreADAM17fl/fl] and a conditional endothelial knock-
out [BmxCreADAM17fl/fl]), quantifying extracellular matrix (ECM) properties and transcriptionally 
profiling aortic tissue, we reveal arterial dilation and ECM changes in the absence of Adam17. 
This phenotypic switch was reminiscent of early-phase arterial aneurysm onset. Our data indicate 
a function of ADAM17 in maintaining a proper elastin network (but not collagen fiber integrity) 
in arteries.
In the parallel study, neither endothelial (LysMCreADAM17fl/fl) nor myeloid (BmxCreADAM17fl/fl) 
Adam17-depletion showed arterial wall dilation [146, 185]. Only hypomorphic Adam17-deficient 
mutant mice showed approximately up to 15 % increased aortic root mean circumference in male 
and female mice (Adam17 ex/ex.Ldlr -/-). Arteria dilated because Adam17 was required in cells other 
than macrophages or endothelial cells alone. So it is possible that ADAM17 executes its role in 
maintaining the elasticity of the arterial wall through vascular smooth muscle cells (SMCs) or 
fibroblasts. The elastin network in arteries is deposited largely by vascular smooth muscle cells, 
which accounts for arterial wall resilience and non-linear elasticity, protects the vessel from 
rupture and minimizes energy loss through elastic recoiling during cycles of arterial inflation 
and deflation [144, 146]. 
4.4.1 The protective effect of ADAM17 metalloproteinase in arterial elasticity 
The protective role of ADAM17 is corroborated by independent genetic work showing that in-
creased ADAM17 activity reduced coronary arteriole dilation [256] and that conditional deletion of 
Adam17 in cardiomyocytes increased left ventricular dilation in pressure-overload models [257]. 
How ADAM17 molecularly controls arterial elasticity remains open. Our analysis suggested a 
mixed extracellular matrix-elasticity phenotype, whereby elastin fiber straightened while fiber 
integrity, number and thickness were unaltered. Collagen fiber composition in the intima and the 
adventitia of the brachiocephalic artery was unaffected in Adam17 hypomorphic mice. An inter- 
pretation is that reduced fiber elasticity leads to radial dilation of the vessel coinciding with 
peripheral stretching of the arterial wall [145, 258].
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For controlling arterial wall elasticity, TNFα/TNFR signaling, which is an ADAM17 substrate and 
de-repressed in the Adam17 mutants (part two of this PhD thesis), could be one the many primary 
effectors. Indeed, TNFα was found to be anti-elastogenic by increasing the expression of 
metalloproteinases, which are elastolytic and more abundant and active in human aneurysms 
[259, 260]. Furthermore, TNFα was found to impair the expression of tropoelastin [261] and 
enzymes like lysyl oxidase, which cross-links elastin aggregates to mature fibers [262]. To get first 
insights into how ADAM17 controlled arterial wall integrity, we investigated which genes were 
differentially expressed in aortic tissue of Adam17 ex/ex.Ldlr -/- hypomorphic mutants. mRNA micro- 
array profiling revealed not only atherosclerosis regulators among the top differential abun-
dant transcripts, but also a number of cytoskeletal contractility regulators and factors required 
for ECM elastogenesis. We detected that the expression of selected metalloproteinases (MMP3/
MMP12) was increased while elastin abundance decreased. It will be important to dissect wheth-
er and how TNFα and other ADAM17 substrates impact the activity of elastin-regulating factors 
(such as emilins and fibulins) and of actomyosin-contractility regulators in smooth muscle cells, 
mutations in both of which are known genetic determinants also in human aneurysmal syn-
dromes [263, 264]. It has to be said, however, that these observations are only of correlative 
nature, and that we do not know whether any changes in these genes and ECM-regulators are 
causal for arterial widening or just the consequence of alterations in Adam17-dependent sign-
aling [146].
Nevertheless, our observations pertain to a specialized and less well-studied function of ADAM17. 
Given that previous correlative studies on ADAM17 in aneurysm development have been contra-
dictory [140, 141] we think that our findings are of relevance for a broad audience, including 
biomedical researchers of cardiovascular physiology and disease, as well as cellular and molecular 
biologists studying receptor-mediated signaling, ECM and cytoskeletal properties and their 
regulation by enzymes in the context of biomechanical forces. 
Although it goes beyond the scope of this study to identify the molecular effectors of how 
ADAM17 maintains arterial wall elasticity to withstand radial dilation and allow arterial recoil, 
our mouse model and our candidates stemming from transcriptional profiling may represent a 
valuable starting point for future mechanistic research. In particular, our experimental system 
for spontaneous aneurysm development in mouse (Adam17 ex/ex.Ldlr -/-) may be interesting for the 
community, as it does not require intravital operations or chemical inducers to trigger aneurysm 
onset.
In a medically relevant context, ADAM17 inhibitors have already been tested in clinical trials, 
but have so far failed to pass phase II for various reasons. If ADAM17 inhibitors are administered 
non-topically, in particular regarding the long-term treatment of cancers or other inflammatory 
diseases, our study indicates that one should be prepared to monitor side effects in form of 
artery wall destabilization and aneurysms [146].
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 Appendix
TABLE 28: Antibodies and their dilutions used for Western blot (WB) and immunohistochemistry (IHC).
Antibody Supplier Catalogue number
Primary/secondary 
antibody
Mono-/
polyclonal Host Dilution WB IHC
ADAM17 Abcam ab2051 primary p Rabbit 1 : 1000 +
TNF-α Abcam ab9739 primary p Rabbit 1 : 500 +
PLA2G12A Proteintech 160009-1-AP primary p Rabbit 1 : 500 + +
ELOVL6 BioCat AP6524a Primary p Rabbit 1 : 500 + +
Na+/K+-ATPase Cell Signaling #3010S primary p Rabbit 1 : 1000 +
TNFR1 Abcam ab64006 primary p Rabbit 1 : 3000 +
TNFR2 Novus Biologicals H7133-D01P primary p Rabbit 1 : 1000 +
BMX Santa Cruz sc-8874 primary p Goat 1 : 1000 +
pBMX Origene TA325277 primary p Rabbit 1.500 +
GAPDH Fitzgerald 10R-G109a primary m Mouse 1 : 10000 +
Peroxidase 
labeled Anti 
Mouse
Vector laboratories PI-2000 secondary p Horse 1 : 6000 +
Peroxidase 
labeled Anti 
Rabbit
Vector laboratories PI-1000 secondary p Goat 1 : 6000 +
α-SMA Abcam ab5694 primary p Rabbit 1 : 200 +
CD68 Serotec MCA1957 primary m Rat 1 : 10 +
vWF DakoCytomation A0082 primary p Rabbit 1 : 200 +
STAR72 Serotec - secondary p Goat 1 : 50 +
Anti-rabbit Ig Vector laboratories MP-7401 secondary - Rabbit undiluted +
Anti-mouse Ig Vector laboratories MP-7402 secondary - Mouse undiluted +
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TABLE 29: Primers and TaqMan probes used for the qRT-PCR (*: 6-FAM; # TAMRA).
Gene NM Number Primer Probes Sequence
5´- primer 5´-TGTAAGCCGCAAACATCTTG-3´
Fdps NM_134469.3 3´- primer 5´-CAATTTCTGGTTTCCCATTCATT-3´
probe 5´*-CCGGGAGAATCCGCGTTGAAGAACA-#3´
5´- primer 5´-GTGGAGGCTTCCTTCAAGTG-3´
Pklr NM_001099779 3´- primer 5´-AGGTCGGTAGCGAGACAGAA-3´
NM_013631 probe 5´*-TGTGCCGCAGCCATCATTGTGCT-#3´
5´- primer 5´-GAGGTAACATCTGTGCTCTCCTG-3´
Pmvk NM_026784 3´- primer 5´-GGAAGTCCAAGCCATGCTC-3´
NM_027348 probe 5´*-TCTCTGGTCCACTCAAGGAGGAGTATGCTCG-3´
5´- primer 5´-TGCTGAGAAACTGCGCTATG-3´
Them4 NM_029431 3´- primer 5´-GACTTTCTCAGAAGAAAATAACCTCCT-3´
probe 5´*-CCTGCGCACTCTTGGGGCCAC-#3´
5´- primer 5´-TCTCCAGGGTAATGGCAAAG-3´
Selenbp2 NM_019414 3´- primer 5´-GTAGCCCATTGGAGATGCAC-3´
probe 5´*-TGCTGCTGGATGGGGAGACCTTCG-#3´
5´- primer 5´-AGGTAGCCGGCACCAGAT-3´
Gm129 NM_001033302 3´- primer 5´-TTTGGCCCATCTTCTCTAGG-3´
probe 5´*-CAAGCACTTTCCCAGCCACCACGGT-#3´
5´- primer 5´-CTCTGGGAAGCTGGAACGAAG-3´
Vcam1 NM_011693.3 3´- primer 5´-CCAGGGGGCCACTGAATTGAATC-3´
probe 5´*-CCACGTGGACATCTACTCTTTCCCCAAGG-#3´
5´- primer 5´-AGCACAAGCTAGTCCCTTGG-3´
Abcd3 NM_008991 3´- primer 5´-TTGCTAAAGGAACATGATCAAACT-3´
probe 5´*-CCCTGGTGCTGGAGAAATCATCAATACAGACAC-#3´
5´- primer 5´-CAGCAAAGCACCCGAACTA-3´
Elovl6 NM_130450 3´- primer 5´-AGGAGCACAGTGATGTGGTG-3´
probe 5´*-CTGAGGAAACAGAAACTGATCTTCCTGCACTGG-#3´
5´- primer 5´-TGAGCTCTAGGAATGACGGGTTTAA-3´
Pla2g12a NM_023196 3´- primer 5´-TAGAAGATGGAAAACGGGGATGAG-3´
NM_183423 probe 5´*-CTGTGCGCTATCTGCTGCTGAGGTTGTG-#3´
5´- primer 5´-CAGCTCGGGCATGGAATA-3´
Agxt2l1 NM_027907 3´- primer 5´-AGCACAGCCAAGCCAACT-3´
NM_001163587 probe 5´*-TCAATACGTATGGAGGAAATCCAGTGTCTTGTGC-3´
5´- primer 5´-AGAAGACGTTCCTGTTTGCAG-3´
Adh7 NM_009626 3´- primer 5´-ACAGCCGCTTTGCACTTAAT-3´
probe 5´*-CACACACCCAGGAGAGGCAGGATGG-#3´
5´- primer 5´-ACAAACCTCTGTGGAAAACTCC-3´
Adh4 NM_011996 3´- primer 5´-AAATTGATCTTCCTTTGCAGGT-3´
probe 5´*-ACTATTGATCAGGAGCTCATGGAAGACAGAACCA-#3´
5´- primer 5´-TGGAGAGCGAAAAGGAGATG-3´
Gbp3 NM_018734 3´- primer 5´-TGAATCCTTCAATAAGCAGTTCTTC-3´
probe 5´*-AGGGAGCAGGAGAAGATGCTGGAGCAC-#3´
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Gene NM Number Primer Probes Sequence
5´- primer 5´-ATTCAAAAACGCCAAACGAA-3´
Ccbl2 NM_173763 3´- primer 5´-AGGATCCGCAGCCAACTTA-3´
probe 5´*-AGGCCTGGACAGCAATGTGTGGGTTG-#3´
5´- primer 5´-TGTCGAACACAACACTCGAAA-3´
Acadm NM_007382 3´- primer 5´-CTGCTGTTCCGTCAACTCAA-3´
probe 5´*-CTCACAAGCAGGAGCCCGGATTAGGGT-#3´
5´- primer 5´-GAGGATGAACAGGACCTTCTTG-3´
Cth NM_145953.2 3´- primer 5´-CAGCTTTGACTCGAACTTTTAAGG-3´
probe 5´*-ACCTGGATCGAGCTTTGAAGGCAGCG-#3´
5ʼ-primer 5ʼ-GGAAAGGGAAGCCATGTACAGTAG-3ʼ
Adam17 NM_009615.4 3ʼ-primer 5ʼ-CGCTCAATTACGTCCTGTACTCG-3ʼ
probe 5ʼF-GCGACATGAATGGCAAATGTGAGAAACG-3ʼT
5ʼ-primer 5ʼ-CCACCACGCTCTTCTGTCTACTG-3ʼ
TNF-α NM_013693 3ʼ-primer 5ʼ-TGGGCCATAGAACTGATGAGAGG-3ʼ
NM_001278601 probe 5ʼF-CGGTCCCCAAAGGGATGAGAAGTTCCC-3ʼT
5ʼ-primer 5ʼ-GCCCGAAGTCTACTCCATCATTTG-3ʼ
Tnfrsf1a NM_011609.4 3ʼ-primer 5ʼ-GCTGAAGGCTGGGGAGGG-3ʼ
probe 5ʼF-CGTGCCTGTCAAAGAGGAGAAGGCTGGA-3ʼT
5ʼ-primer 5ʼ-CAGTTTCGTACATGTTTGAGCTGC-3ʼ
Tnfrsf1b NM_011610.3 3ʼ-primer 5ʼ-CACACACTCGGTTCTGCTGTTTAG-3ʼ
probe 5ʼF-TACCACTGACCAGGTGGAGATCCGCG-3ʼT
5ʼ-primer 5ʼ-TGTCCGTCGTGGATCTGACG-3ʼ
Gapdh NM_001289726 3ʼ-primer 5ʼ-CCAAGATGCCCTTCAGTGGG-3ʼ
probe 5ʼF-GGCCTGGAGAAACCTGCCAAGTATGATGAC-3ʼT
5ʼ-primer 5ʼ-CCCACGCTACCTCTGCTC-3ʼ
Icam1 NM_010493 3ʼ-primer 5ʼ-GATGGATACCTGAGCATCACC-3ʼ
probe 5ʼ-TGGCCCTGGTCACCGTTGTGATCCCT-3ʼ
5ʼ-primer 5ʼ-CTCCTGGGAGTGGCACAG-3ʼ
Lox NM_010728.2 3ʼ-primer 5ʼ-CTTGCTTTGTGGCCTTCAGC-3ʼ
probe 5ʼ-CAGCCACTATGACCTGCTTGATGCCAACAC-3ʼ
5ʼ-primer 5ʼ-GAGAAGCTGTGCTATGTTGCTC-3ʼ
β-Actin 3ʼ-primer 5ʼ-AGGAAGAGGATGCGGCA-3ʼ
probe 5ʼ-AGACTTCGAGCAGGAGATGGCCA -3ʼ
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TABLE 30: SNPs, bp position, primers and probes used for genotyping (*: 6-FAM; # TAMRA).
SNP Mbp Primer/Probes Sequence
5´- primer 5´-CATTCCCTCTCAAGTGTTCCTCATGT-3´
rs4224041 87 3´- primer 5´-CCTCGAAAGAGTCTGAACATTGTGTTC-3´
probe 5´*-TTGGTGAACAGCCCCCA-#3´
5´- primer 5´-TGTCACTCTCAGAATTGCCTAGGCAG-3´
rs3683384 110 3´- primer 5´-ATCTGACACCTCCCCATCCCTATC-3´
probe 5´*-TAGGCACCCAAGACTTGAG-#3´
5´- primer 5´-CTGTCTAGCTGCTCCACCGTGC-3´
rs13459071 115 3´- primer 5´-TTGGTACCTGAGTTCAGCACAGCC-3´
probe 5´*-TGATCATTGTCCTGAGTGTCT-#3´
5´- primer 5´-GCACAAGTAGGCTTTTGGCTTCTGTT-3´
rs30132365 116 (Vcam1) 3´- primer 5´-TGTGGTCTCCATCATCCAAGGTCAT-3´
probe 5´*-TGGTTTGTGGCAAACACAG-#3´
5´- primer 5´-ATGTATTCACTTTGCAGCCCTAGGATG-3´
rs36523879 122 3´- primer 5´-ACGGTAGGACGGGAAGCTATTCTTTC-3´
probe 5´*-GATACAGAAGTCCCAAACCCA-#3´
5´- primer 5´-TCTTTGACTATTGGATTGCCTCAGTGTC-3´
rs13424644 129.3 (Elovl6) 3´- primer 5´-TTCTGGGCTGTCATCATGATCTCC-3´
probe 5´*-CGATCCTGCCAATGCAACT-#3´
5´- primer 5´-CAGGAAAAGCCTTGCTGAAGTGTGA-3´
rs30635946 129.6 (Pla2g12a) 3´- primer 5´-TCAGAAAGCTCAATACCCACCAACCA-3´
probe 5´*-CTCTTCACGGCACACCC-#3´
5´- primer 5´-CATTGGGAAAGTGTTAGCAGCAAACC-3´
rs31282710 130 3´- primer 5´-ACTTCTAAGCCCAACGCTCATTCCAT-3´
probe 5´*-ACAAATAAGATCGCATTGTCTGT-#3´
5´- primer 5´-AGAGACTTAGTAATTGCTCCTCATTCCTG-3´
rs30359806 140 3´- primer 5´-TAGTCAAGCTGTAATTCTGCCAGTTAATG-3´
probe 5´*-TATCACCAGGGTCCATACGA-#3´
5´- primer 5´-CTTGATATCATGCCAATTGCTCTGTCAT-3´
rs30102565 150 3´- primer 5´-TGTAGGAAATAGCAGGCTTCTCAAGGT-3´
probe 5´*-CATTATTTGGCACATTCTTCCT-#3´
5´- primer 5´-CTTCCTCATTTATCAAGGATACTCCCCTC-3´
rs31598641 160 3´- primer 5´-TATTCCTGTCTGACAATCATGGCTAATGA-3´
probe 5´*-GGAATTCATACAACAGGTTGAG-#3´
